membrane-aerated bioreactors for treatment a …

161
MEMBRANE-AERATED BIOREACTORS FOR TREATMENT OF WASTE WATER IN LONG-TERM SPACE FLIGHT by ERIC MCLAMORE, B.S. A THESIS IN CIVIL ENGINEERING Submitted to the Graduate Faculty of Texas Tech University in Partial Fulfillment of the Requirements for the Degree of MASTER OF SCIENCE IN CIVIL ENGINEERING Approved August, 2004

Upload: others

Post on 04-May-2022

3 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

MEMBRANE-AERATED BIOREACTORS FOR TREATMENT

OF WASTE WATER IN LONG-TERM SPACE FLIGHT by

ERIC MCLAMORE, B.S.

A THESIS

IN

CIVIL ENGINEERING

Submitted to the Graduate Faculty of Texas Tech University in

Partial Fulfillment of the Requirements for

the Degree of

MASTER OF SCIENCE

IN

CIVIL ENGINEERING

Approved

August, 2004

Page 2: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

ACKNOWLEDGMENTS

A thank you goes out to Dr. Andrew Jackson, Dr. Audra Morse, Dr. Dean

Muirhead, and Tony Rector for their guidance and support. A special thanks to the

Advanced Life Support Systems Water Team Unit at Johnson Space Center. Their

continuing help has been greatly appreciated over the last four years. In addition, the

authors would like to thank the student workers at Texas Tech University for their efforts.

u

Page 3: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

n

V

viii

xi

xii

TABLE OF CONTENTS

ACKNOWLEDGEMENTS

ABSTRACT

LIST OF TABLES

LIST OF FIGURES

LIST OF ACRONYMS AND SYMBOLS

CHAPTER

I. INTRODUCTION 1

II. BACKGROUND 3

2.1 Water Recovery in Space 3

2.2 Water Recovery at NASA 4

2.3 Water Recovery at TTU 9

2.4 Membrane-Aerated Biological Reactors 11

2.5 Processes Affecting Reactor Performance 13

2.5.1 Physiological Processes 13

2.5.2 Biological Processes 20

2.5.2.1 Water Quality Variations in Feed Tank 20

2.5.2.2 Urea Hydrolysis 25

2.5.3 Equivalent System Mass 26

III. MATERIALS AND METHODS 28

3.1 Water Recovery Systems at TTU 28

3.1.1 TTU-WRS 28

3.1.2 PB-AMR 30

3.1.3 Feed composition 34

3.2 Mass Transfer Experiments 37

3.3 Hydrodynamics Experiments 38

3.4 Biolchemical Characterization of Feed Tank Reactions 40

ui

Page 4: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

3.5 Analysis 42

3.5.1 Sample collection 42

3.5.2 Sample Analysis 43

3.5.2 Data Analysis 43

3.5.3.1 Nitrification 43

3.5.3.2 Denitrification 44

3.5.3.3 Determination of Organic Nitrogen 45

IV. RESULTS AND DISCUSSION 47

4.1 Water recovery systems at TTU 47

4.1.1 PB-AMR 47

4.1.1.1 Mass Transfer 47

4.1.1.2 Hydrodynamics 49

4.1.2 Biochemical characterization of feed tank reactions 54

4.1.2.1 Urease Activity 63

4.1.2.2 Determination of Useable DOC 65

4.1.3 Bioreactor System Comparison 71

4.1.4 Equivalent System Mass 81

IV. CONCLUSION 84

REFERENCES 86

APPENDIX

A PB-AMR PHYSIOLOGICAL DATA 90

B PB-AMR BIOLOGICAL DATA 99

C FEED TANK ANALYSIS DATA 135

D ESMDATA 142

IV

Page 5: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

ABSTRACT

In the future, long-duration space exploration will require the design of robust

advanced life support systems capable of supporting in-flight crews. The advanced life

support systems should be reliable while requiring little to no maintenance and

monitoring. Past systems onboard the National Aeronautics and Space Administration's

(NASA) SkyLab and Russia's MIR Space Station utilized an efficient but expensive

physio/chemical water recovery system. The past systems were not independent and

relied on shuttle resupply. Current NASA research is focused on water recovery systems

involving biological treatment. The objective of the biological treatment system in

combination with the physio/chemical system is to limit shuttle resupply and required

astronaut maintenance while meeting NASA's requirements for flight-ready water

recovery systems. Performance objectives based upon Finger et al. (1999) include a

microgravity compatible design, a minimum of 50% nitrification and a 365 day operation

life. Other performance objectives include an increase in reliability and a reduction in

astronaut maintenance time when compared to the current design.

One of the most extensively analyzed biological water recovery systems was buih

and operated at NASA's Johnson Space Center (JSC). A downscaled model (l/20'^) of

the water recovery system at JSC has been analyzed at Texas Tech University (TTU) for

the last four years. Although efficient, the current nitrifying bioreactor within the

biological system has experienced problems with excessive loss of biofilm and constant

required crew observation. In an attempt to increase the efficiency of the biological

Page 6: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

portion of the WRS, a gravity compatible membrane-aerated bioreactor (MABR) was

constructed and operated at TTU in August 2003.

The MABR at TTU operated as a plug-flow reactor where forced convection was

the major mode of transport. Substrate (carbon) limitations in the bioreactor feed

composition dominated the efficiency of the system, while electron acceptor transport

was not limiting. It is hypothesized that the MABR at TTU is oversized and ongoing

research will aid in sizing the bioreactor. The AMR required little to no maintenance,

was not subject to shock loading, did not experience excessive sloughing and was not

subject to significant failure to maintain treatment efficiency at any point during the

experiment. Large fiuctuations in alkalinity and ammonia loading rates did not shock the

AMR system. The presence of heterotrophic biofilms in the AMR did not decrease

reactor efficiency or increase maintenance requirements (McLamore et al , 2004).

Results from the MABR at TTU indicate that the MABR is a highly robust and versatile

gravity-compatible nitrifying reactor with little to no required crew maintenance.

Quantification of the transport and transformation processes within the MABR at

TTU indicated that the MABR is a likely candidate to replace the current nitrifying

reactor. Although ESM analysis indicated that the TR was more efficient than the

MABR, detailed analysis implied that the MABR was a much more versatile reactor than

the TR and over-sizing may have caused ESM analysis to be misleading. The use of an

MABR as a nitrifying bioprocessor could potentially reduce advanced life support

systems cost and required astronaut time which would be of great benefit to NASA.

VI

Page 7: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Future long-duration missions may reconfigure in-flight hardware due to the reduction in

payload weight and overall mission costs.

vu

Page 8: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

LIST OF TABLES

2.1 Average Waste Compound Concentrations 8

2.2 MABR Test Point Summary 13

2.3 Feed Tank Alterations at TTU 21

2.4 TC and COD Values For Compounds in Urine 23

2.5 Reaction Pathways ofCommon Compounds Found in Human Urine 25

3.1 TTU-WRS Design Details 29

3.2 PB-AMR Design Details 33

3.3. Simulated Humidity Condensate in Feed at TTU 35

3.4 Typical Surfactant Contribution in Raw Feed 36

3.5 Composition of Simulated Feed at TTU 37

4.1 AMR Mass Transfer 48

4.2 Hydrodynamic Results 53

4.3 Measured Hydrolytic Ammonia Production in Feed Tanks 58

4.4 Mature and Clean Feed Tank Comparison 58

4.5 Average Feed Tank Urea/Org-N Fraction 68

4.6 AMR BOD, COD and DOC Influent and Effluent Values 73

4.7 Nitrifying Reactor pH Decrease 78

4.8 Average Influent and Effluent values 79

4.9 ESM Analysis 82

A. 1. Mass Transfer Experiment # 1 Test Parameters 91

A.2. Mass Transfer Experiment #1 Test Results 91

A.3. Mass Transfer Experiment #2 Test Parameters 91

A.4. Mass Transfer Experiment #2 Test Results 92

A. 5. Mass Transfer Experiment #3 Test Parameters 92

A. 6. Mass Transfer Experiment #3 Test Results 92

A.7. Mass Transfer Reactor Characteristics 93

A.8. Mass Transfer Membrane Resistances 93

viu

Page 9: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

A.9. Mass Transfer Dimensionless Numbers 93

A. 10. PB-AMR RRO Tracer Study Experimental Resuhs 94

A.ll . PB-AMR Port Study Bromide Data 95

A.12. PB-AMR Port Study Nitrite Data 95

A. 13. PB-AMR Port Study Nitrate Data 95

A. 14. PB-AMR Port Study NOx Data 95

A. 15. PB-AMR Port Study TN Data 96

A. 16. PB-AMR Port Study Nitrification Data 96

A. 17. PB-AMR Port Study Denitrification Data 96

A. 18. PB-AMR Hydrodynamic Analysis 97

A. 19. PB-AMR Hydrodynamic Dimensionless Numbers 98

B.l. PB-AMR pH Data 100

B.2. PB-AMR TN Data 105

B.3. PB-AMR Alkalinity Data 110

B.4. PB-AMR TOC Data 115

B.5. PB-AMR TA Data 120

B.6. PB-AMR N02"-N Data 125

B.7. PB-AMR NO3-N Data 130

C I . Mature Feed Tank #1 Data 136

C.2. Mature Feed Tank #2 Data 137

C.3. Mature Feed Tank #3 Data 138

C.4. Clean Feed Tank #1 Data 139

C.5. Clean Feed Tank #2 Data 140

C.6. Clean Feed Tank #3 Data 141

D.l. AMR Reactor Description 143

D.2. AMR Porosity Design 143

D.3. AMR Volumes 144

D.4. AMR Reynold's Numbers (RR20) 144

D.5. AMR Reynold's Numbers (RRIO) 145

IX

Page 10: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

D.6. PB Reynold's Numbers (RR20) 145

D.7. PB Reynold's Numbers (RRIO) 145

D.8. PB-AMR and TTU-WRS HRT 145

D.9. AMR ESM 146

D.IO. TRESM 146

Page 11: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

LIST OF FIGURES

2.1 Aerobic Biofilm in Typical Attached Growth Systems 16

2.2 Typical Biofilm Formation on Silicon Membrane 17

2.3 Ideal Tracer Response Curves 20

3.1 Biological Portion of Water Recovery System at TTU 29

3.2 PB-AMR System Layout 31

3.3 AMR System 32

3.4 AMR Port Study Configuration 39

3.5 Urea Hydrolysis Test Schematic 41

4.1 AMR Hydrodynamic Experimental Results. 50

4.2 AMR Port Study Results 51

4.3 Mature and Clean DOC 55

4.4 Mature and Clean TA 55

4.5 Moles ofTA Produced Per Mole of DOC Consumed 57

4.6 Mature and Clean DO 59

4.7 Mature and Clean COD 60

4.8 (COD/ThCOD) Response Factor Ratio 62

4.9 Mature and Clean Feed Tank Average pH Values 64

4.10 Mature Feed Tank fu-N 66

4.11 Clean Feed Tank Urea/Org-N Fraction 67

4.12 Determination ofUseable DOC Methods 70

4.13 PB-AMR pH Data 72

4.14 PB-AMR DOC Data 74

4.15 PB-AMR TN Data 75

4.16 PB-AMR NOx-N Data 76

4.17 PB-AMR Effluent Nitrogen Distribution 77

4.18 PB-AMR vs. TTU-WRS System Performance 80

D.l. AMR Porosity Design 143

XI

Page 12: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

LIST OF ACRONYMS AND SYMBOLS

AMR = Advanced Membrane Reactor

C(TN)initiai = Feed TN concentration

C/Co - normalized tracer response

CM = Complete Mixed Reactor

CTSD = Crew and Thermal Systems Division

D = coefficient of axial dispersion

dC(NOx)/dt = Mass increase in NOx due to nitrification

dC(TN)/dt = Mass decrease in N due to denitrification

DDI = Deionized-Disfilled Water

DO = Dissolved Oxygen

DOC = Dissolved Organic Carbon

DOCf = Final dissolved organic carbon concentration

DOCi = Initial dissolved organic carbon concentration

ECLSS = Environmental Control and Advanced Life Support Systems

EPS = Extracellular Polysacharides

ESM = Equivalent-System Mass

fu-N = Fraction of organic nitrogen as urea

AG° = Gibbs Free Energy at Standard Temperature and Pressure

GLS = Gas-Liquid Separator

H = Henry's Constant

HC= Humidity Condensate

IC = Ion Chromatography

IE = Ion Exchange

ISS = International Space Station

J = Flux

JSC = Johnson Space Center

kooc m = DOC Reaction Rate in Mature Feed Tank

xi i

Page 13: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

koocc = DOC Reaction Rate in Clean Feed Tank

ko = Gas mass transfer resistance

kt = Liquid mass transfer resistance

km = Membrane mass transfer resistance

ko = Overall mass transfer resistance

kjA.m = Ammonia Reaction Rate in Mature Feed Tank

kTA.m = Ammonia Reaction Rate in Clean Feed Tank

L = reactor length [cm],

LCMS = Liquid Chromatography-Mass Spectrometry

MN/C = Ratio of moles of ammonia produced per mole of DOC degraded

MABR = Membrane-Aerated Bioreactor

MDL = Minimum Detection Limit

MWD = Molecular Weight Distribution

NASA = National Aeronautics and Space Administration

PB = Anaerobic Packed Bed

Pe # = Peclet number

PF = Plug-Flow Reactor

PPKm®= Pert Plus for Kids "minus"

PPS= Post-Processing System

RO = Reverse Osmosis

Re # = Reynold's Number

RFR = Response factor ratio

RR = Recycle Ratio

Sh # = Sherwood Number

9 = normalized time

T = theoretical detention time

Xe = Membrane Thickness

t = time

TAf = Initial ammonia concentration

xiu

Page 14: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

TAi = Final ammonia concentration

TC = Total Carbon

TDS = Total Dissolved Solids

ThCOD = Theoretical Chemical Oxygen Demand

Th.Org-N = Theoretical Organic Nitrogen

TN = Total Nitrogen

TOC = Total Organic Carbon

TR = Tubular Reactor

TTU = Texas Tech University

u = fluid velocity

Um = Measured Urea Concentration

UV = Ulfraviolet Disinfection

WRS = Water Recovery System

XIV

Page 15: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

CHAPTER I

INTRODUCTION

Long-duration space exploration requires environmental control and advanced life

support systems (ECLSS) capable of providing potable water and oxygen for a typical

crew of asfronauts. Considerations in the design of water reclamations systems in space

include shelf life, resupply-retum logistics, crew time needed for maintenance, power

needs to operate the system, launch weight and stowage volume (National Academy

Press, 2000). The high cost of transporting the large amount of water required for long-

duration missions is impracticable and research is currently under way by ECLSS to

improve the efficiency of environmental systems in space.

One of the systems under consideration for long-term water reclamation in space

includes a biological system upstream from a physio/chemical system. The biological

portion of the system contains an anaerobic packed bed (PB) designed to reduce organic

carbon via denitrification and a tubular reactor (TR) designed to oxidize inorganic

nitrogen species (via nitrification) prior to physio/chemical treatment. Current research is

being conducted at TTU on a downscaled model (1/20*) of the biological system at

NASA-JSC. Although the nitrifying bioreactor at JSC and TTU was highly efficient in

terms of launch weight and stowage volume, the system was unpredictable and required

constant crew observation and maintenance. Various alternative nitrifying bioreactors

have been constructed and operated in an attempt to avoid the required maintenance and

high unpredictability of the original nifrifying reactor.

Page 16: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

A novel alternative nitrifying bioreactor designed and operated at TTU is a

membrane-aerated bioreactor (MABR) known as the advanced membrane reactor

(AMR). The considerations listed above and the physiological and biological processes

occurring within the AMR were analyzed and compared to the TR in an attempt to verify

the assumption that the AMR is a highly robust gravity compatible nitrifying reactor that

could possibly be a potential replacement for the TR. Should the AMR maintain steady

state treatment levels equal to or greater than the TR in the TTU system, the initial

assertion could be made that the AMR is a possible candidate to replace the TR following

observations that the AMR has less maintenance requirements than the TR.

Page 17: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

CHAPTER II

BACKGROUND

2.1 Water Recoverv in Space

Recently, global trends such as increased population growth, severe drought, and

environmental concerns have increased the worldwide importance of water reclamation.

Additionally, the United State's re-commitment to a long-term human space exploration

program in 2004 highlights the importance of water reclamation systems (WRS). Current

long-term manned missions, such as the International Space Station (ISS), are not self

sufficient, requiring shuttle missions for resupply. Depending on the future mission

scenario, water reclamation for space applications can be viewed as either a potential

long-term efficiency measure or as a requirement in the case of very long-duration

missions (e.g., extended moon expeditions or missions to Mars). Researchers at NASA

and elsewhere have conducted significant research on biological pretreatment and/or

physio/chemical water reclamation processes.

Water reclamation systems have been used in space travel for the last 30 years.

One of the first WRS to be used in space was NASA's Sky Lab system, which was

launched in 1973 and returned in 1979; the longest manned occupation of SkyLab was 84

days. Water has been recovered from humidity condensate wastestreams since the era of

Russia's Salyut WRS in the 1970s. Russia's MIR water recovery system was launched

after SkyLab and has been in operation since 1989. The WRS aboard MIR freated three

separate wastestreams: urine, humidity condensate and hygiene wastewater. Each system

Page 18: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

receives supplemental fuel cell-generated water supply to compensate for system losses,;

thus significantly increasing mission costs. Water recovered from the urine stream was

used to generate oxygen by a water electrolysis system. Potable water for drinking,

hygiene, cooking, etc. was recovered from the other wastestreams. The most recent WRS

in space is onboard the International Space Station (ISS). The water processor onboard

the ISS Alpha treats a single combined wastestream. The ISS and MIR systems utilize

multifiltration as a means of primary treatment and require pretreatment by one of several

distillation/evaporation processes. These pretreatment phase change processes are very

costly as the latent heat of vaporization must be supplied. Long-term space missions

require a self-reliant WRS that can maintain near 100% water reclamation efficiency

under zero gravity conditions for long periods of time at minimum payload weight to

significantly reduce mission costs.

2.2 Water Recoverv at NASA

NASA has currently been investigating the potential of a combined biological-

physical water recovery system (WRS) to reclaim wastewater for potable water uses.

The physical portion of the WRS, known as the post-processing system (PPS) consists of

reverse osmosis (RO), ion exchange (IE) and ultraviolet (UV) disinfection. The purpose

of the biological system is to reduce cost and required astronaut maintenance time by

replacing the current phase-change pretreatment process and improving water quality

upstream of the PPS. This paper focuses on optimizing bioreactor performance and

increasing the versatility of the biological portion of the WRS. The WRS would not

Page 19: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

replace disinfection agents as disinfection is a requirement for all water supplies in space

to maintain flight crew health.

To investigate the potential of a biological WRS in space, an immobilized cell

bioreactor (ICB) was designed and extensively analyzed at Johnson Space Center (JSC)

during the Lunar-Mars Life Support Phase 111 Test (Pickering et al., 1998). Following

the Phase III Test, researchers in the Advanced Life Support unit at JSC have

successfully developed a biological and physio/chemical treatment train capable of

treating wastewater typical of extraterrestrial waste streams known as the Advanced

Water Recovery System (AWRS). The AWRS was operated at NASA's JSC by the

Crew and Thermal Systems Division (CTSD) from 1998 to 2001. The system consisted

of a biological carbon-nitrogen removal system followed by a post-processing system

consisting of reverse osmosis, ion exchange, and UV treatment. The biological

component of the WRS is the focus of this research; details concerning the operation of

the post-processing system at JSC can be found in Verostko et al. (2000). The goal of the

CTSD was to design a robust system capable of treating all of the waste streams

produced during long-term space missions to drinking water standards. The applications

of such a system include long-term missions in space such as the International Space

Station and extended lunar expeditions. A robust WRS that requires little or no astronaut

maintenance time and zero resupply of potable water would be of great value to the space

industry.

The compounds to be removed within the biological portion of the WRS are

carbonaceous and nitrogenous material. The typical processes of concern in the removal

Page 20: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

of carbon and nitrogen from wastewaters are nitrification and denitrification.

Nitrification is the process by which autotrophic microorganisms oxidize ammonia (NH4-

N) to nifrite (NOi'-N) and/or nifrate (NOs'-N) by utilizing oxygen as the terminal electron

acceptor (see Equation 2.1).

NH4 -^ NH2OH -> ? -^ NO2" -^ NOB" Equation 2.1.

The initial monooxygenation of NH4 to NH2OH (hydroxylamine) requires oxygen as a

direct reactant and is the first step in the nitrification process; this step is usually

neglected as oxidation from hydroxylamine to nitrite is considered to take place

instantaneously. The intermediate between hydroxylamine and nitrite is not known

(Henze et al., 2002). The oxidation of NH4-N to N02'-N is normally attributed to being

carried out by the nitrosomonas bacteria; however, nitrosopira has gained recognition in

recent years for a large percentage of the oxidation. Ammonium oxidation by

nitrosomonas/nitrosopira is more energetically favorable (with AG =-45.79 kJ per e" eq)

than nitrite oxidation carried out by the nitrobacter/nitrospira genus (AG =-37.07 kJ per

e' equivalent) (Rittman et al., 1994). The term incomplete nitrification refers to the

presence of NOi'-N within the bulk liquid, while the term complete nitrification refers to

the conversion of NH4-N to NOa'-N. Incomplete nitrification takes place when the

ammonium ion concentration is excessively high causing the ammonium oxidation rate to

be higher than the nitrite oxidation rate, and is not necessarily an indication of poor

system performance. Incomplete nitrification can, however, reduce the efficiency of

Page 21: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

heterotrophic denitrifying organisms downstream as fewer electrons are available from

nitrite than nitrate.

The denitrification process follows the nitrification process and is the

mineralization of organic carbon by heterotrophic bacteria utilizing nitrite/nitrate as the

terminal electron acceptor. Denitrifying organisms are facultative aerobes that can shift

between organic and inorganic electron donors; for the research herein, only the organic

electron donor is considered due to the nature of the waste. Although the denitrification

process is the second step in the biological removal of organic carbon and NH4-N from

wastestreams, the denitrification process is typically located upstream of the nitrification

process in small scale systems so that removal of organic carbon takes place prior to the

wastestream entering the nitrifying reactor. This is done to ensure that the slow-growing

autotrophic nitrifying bacteria are not out-competed by heterotrophic bacteria within the

nitrifying reactor. A recycle line from the effluent of the nitrifying reactor back to the

head of the denitrifying reactor is typically included to supply the electron acceptor for

the denitrification process. The majority of the organic carbon removal within biological

systems of this type takes place within the anaerobic region but some aerobic carbon

oxidation can take place within the nitrifying bioreactor. Denitrification is a four-step

process that involves the sequential reduction of NO3" to NO2", nitric oxide (NO), nitrous

oxide (N2O) and finally nitrogen gas (N2) (see Equation 2.2).

NOa"^ NO2" -^ NO ^ N2O -^ N2 (gas) Equation 2.2.

Page 22: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

The AWRS at JSC contained a waste collection system (WCS) consisting of a shower,

urinal and sink to accurately simulate wastesfreams produced on board a typical space

flight. The average compound concentrations collected in the WCS are presented in

Table 2.1 (Campbell et al., 2003; Thomas et al., 1991; Verostko et al., 1989; Wydeven et

al., 1990).

Table 2.1. Average Waste Compound Concentrations

Compound

Shower water

Soap for shower

(guideline)

Handwash water

Soap for handwash

(guideline)

Urinal flush water

Urine

Simulated humidity

condensate

Oral hygiene water

Total volume per day

5.44 L/d

0.012 kg/d

8.16 L/d

0.032 kg/d

1.0 L/d

3.0 L/d

4.54 L/d

0.72 L/d

The AWRS at JSC was designed to process a 2-person load typical of wastewater

onboard the ISS (Campbell et al , 2003). The microgravity compatible biological portion

of the WRS is composed of an anaerobic packed bed (PB) upstream from a gravity

independent nitrifying tubular reactor (TR) (Ungar et al., 1998). The PB is designed to

remove nitrogen and organic carbon through the process of denitrification. The system

Page 23: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

has an internal recycle to allow nifrite/nitrate ions (NOx) produced during nitrification to

be used during denifrification. Although the biological portion of the JSC-WRS achieved

acceptable levels of carbon and nitrogen removal, the nitrifying TR at JSC required

continual maintenance and regulation of excessive biomass buildup to avoid decreases in

nitrification efficiency and total system performance. For more details on the operation

and performance of the WRS at JSC, see Campbell et al. (2003). The excessive buildup

of biomass in the JSC-TR caused shedding events which occasionally reduced the

efficiency of the JSC-WRS to unacceptable levels and the system was placed on recycle

to recover system performance. The term shedding refers to excessive biomass buildup

within the 3.2 mm (0.125 in.) inside diameter tubing, causing an increase in shear forces

on the biofilm and resulting in sloughing of nearly all biomass downstream from the

shed. To control excessive biofilm growth and reductions in treatment efficiency, the

JSC-TR required continual maintenance and removal of sloughed biofilm.

2.3 Water Recoverv at TTU

In order to increase the versatility of the data collected on the WRS system, TTU

has been conducting research on a downscaled model (l/20') of the JSC-WRS for the

past three years (Jackson et al., 2002). Operation of the TTU-WRS was designed to be

similar to the JSC-WRS so the two systems could be compared. Organic carbon is

removed within the PB by denitrification, and NOx"-N is oxidized to N2 (gas) to be

removed by a downstream gas-liquid separator (GLS). The summation of N02'-N and

NO3-N is taken as NOx-N throughout this paper. The TR is designed to remove

Page 24: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

inorganic carbon and oxidize NH4^-N to NOx-N (the electron acceptor used during the

denitrification process). Muirhead et al. (2003) reported 50% removal of ammonia and

80% removal of influent organic carbon within the TTU-WRS for a recycle ratio (RR) of

1:20 (expressed as raw feed to TR recycled effluent). Operation of the TTU-WRS has

since been conducted at numerous recycle ratios to determine the effect of various

recycle ratios on system efficiency (Jackson et al., 2004). Test points varying from RR2

to RR20 were completed on the TTU-WRS and it was noted that recycle ratio has no

significant effect on treatment efficiency, but operational issues (such as excessive

clogging at low recycle ratios) did occur (Jackson et al., 2004). The recycle ratios

analyzed in this paper were RRIO and RR20. The fate of various pharmaceuticals

(mainly amoxicillin) within the TTU-WRS was examined between 2001 and 2003

(Morse et al., 2004).

As occurred in the JSC-TR, the TR at TTU, while effective at nitrification,

suffered in efficiency due to biomass sloughing. The sloughing events caused loss of

biofilm downstream of the events and required an excessive amount of manpower to

monitor and control events. In an attempt to avoid temporary system failure, the TR at

TTU was equipped with biofilm traps and forced to shed when tube pressures exceeded

75.8 kPa (11.0 psi) by drastically increasing the air and liquid fiowrate. Due to the lack

of a solid-liquid separation process, suspended cells leaving the PB may have increased

the frequency of shedding events by augmenting the buildup of biofilm on the walls of

the tubes. NASA engineers require onboard spaceflight systems that need little or no

astronaut maintenance time. Due to the sporadic shedding events that resulted in poor

10

Page 25: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

performance and large maintenance requirements, the current TR design was not deemed

to be a technology that would be used in future manned space missions. Data from both

the JSC and TTU-WRS indicated that it could be significantly advantageous to replace

the TR with a more robust, low maintenance reactor. As such, researchers at TTU

designed and built a membrane-aerated bioreactor as a potential replacement for the

tubular reactor (Morse et al., 2003).

2.4 Membrane-Aerated Biological Reactors

Application of membrane-aerated bioreactors to long-term space flight is

appealing due to the ease of operation and microgravity-compatible nature. Preliminary

work at TTU indicated that MABR systems have less biomass management issues than

the current nitrifying reactor at TTU (McLamore et al., 2004). In addition, MABR's have

the advantage of providing an electron acceptor (in this case O2) on the lumen side of the

biofilm and wastewater on the bulk liquid side; other attached growth systems rely on

electron acceptor and substrate diffusion from the bulk liquid side. A test phase MABR

constructed and operated at JSC by Finger et al. (1999) reported 50% conversion of

influent organic nitrogen to N2 (gas) and 93% dissolved organic carbon (DOC) reduction;

the DOC being removed in the anoxic zone upstream of the membrane-aerated nitrifying

reactor. The DOC values noted herein refer to samples which were filtered in a 0.4 | m

filter before being analyzed for TOC. This method is used to avoid any TOC degradation

within sample bottles following sample collection.

11

Page 26: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

A preliminary membrane-aerated bioreactor known as the preliminary advanced

membrane reactor (preliminary AMR) was constructed at TTU and designed as a possible

candidate to replace the TR as a simple, robust, space efficient nitrifying reactor

(McLamore et al , 2004; Morse et al., 2003; Morse et al., 2002). Data from the

preliminary AMR indicated that the AMR was a highly efficient microgravity compatible

nitrifying reactor. The preliminary AMR was not downstream of an anoxic zone

promoting denitrification. The percent nitrification for the preliminary AMR (60.7%)

was above the minimum accepted value reported for membrane-aerated bioreactors by

Finger et al. (1999) during RRIO. The percent denitrification within the preliminary

AMR (91%)) was due to a combination of aerobic organic carbon oxidation and

denitrification due to the formation of anoxic zones within the reactor (McLamore et al.,

2004). The amount of aerobic DOC oxidation {3%) was comparable to values reported

by Finger et al , (1999); the values of percent DOC reduction during denitrification

reported herein are corrected for aerobic DOC oxidation taking place within the

membrane reactor. Additionally, the preliminary AMR provided a foundation of

experience in operation and maintenance of the MABR systems. Following the

indication that the preliminary AMR was a highly robust, self-sufficient nitrifying

reactor, a second AMR was built and operated at TTU so that a comparison could be

made between the TR and AMR as microgravity compatible nitrifying reactors for long-

term space applications (see Table 2.2).

12

Page 27: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table 2.2. MABR Test Point Summary

System

Preliminary

AMR

PB-AMR

PB-AMR

PB-AMR

Test

Point

RR2, RR5, RR10,RR20

Startup

RR20

RRIO

Start

Date

6/5/2002

7/28/2003

9/19/2003

1/17/2004

End

Date

5/14/2003

9/18/2003

1/16/2004

4/2/2004

Duration

[days]

343

52

125

73

The second WRS (PB-AMR) constructed at TTU consists of an AMR

downstream of an anaerobic packed bed. This system mimics the TTU-WRS and all data

collected from the two systems can be directly compared (following normalization for

hydraulic retention time). The systems each receive the same waste stream and are

maintained in the same fashion. The PB-AMR system was operated at identical TTU-

WRS test points to allow for direct comparison of data.

2.5 Processes Affecting Reactor Performance

2.5.1 Physiological Processes

Transport processes including hydrodynamics and mass transfer were investigated

in order to analyze and fully understand the AMR system. Interphase transport refers to

processes such as the mass transfer of oxygen and adsorption while intraphase transport

refers to processes such as molecular transport due to advection. Mass transfer in

bioreactors and the type of flow regime occur sequentially and a complete analysis

depends on examination of both parameters as changes in either parameter will alter

13

Page 28: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

system performance. Election acceptor mass fransfer is controlled via the transmembrane

pressure delivered to the system and the local biofilm thickness, while substrate mass

transfer is controlled by the fluid specific velocity and local biofilm thickness.

Depending on the type and concentration of the influent substrate, transport properties

can be the rate limiting step in bioreactor design. Characklis et al. (1990) stated that the

transport processes are the main distinguishing factors between biofilm systems and

traditional attached growth systems. Experimental determination of reactor transport is

particularly significant in MABR's due to the complexity of the system. A brief

discussion of biofilm configuration and structure is necessary in order to fully understand

the common fransport processes occurring in attached growth bioreactors. Significant

increases in biofihn thickness confribute to fluid frictional resistance and the formation of

microchannels, possibly creating preferential flow patterns. Mass transfer and

hydrodynamic properties should be evaluated before and after biofilm formation to

account for fransport alterations due to the growth of the biofilm.

In biological systems mass transfer in biofilms can limit microbial reactions and

overall system performance. In a typical biofilm, extracellular polymers (EPS) are

considered to act as the "cement" holding groups of microbial clusters together, while

liquid is allowed to flow through the void spaces. The specific type of EPS depends on,

amongst other things, the type of microbial population but all EPS act as diffusion

barriers, molecular sieves and adsorbents, regardless of their charge density or acidic

natiare (Characklis et al., 1990). MasS transfer in biofilms is a direct function of the EPS-

free void spacing where electron donor, electron acceptor and nutrient transport takes

14

Page 29: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

place by diffusion, advection, or a combination of the two; it is generally accepted that

diffusion is the major type of transport in biofilms but analysis of mass transfer and

hydrodynamics is required to accurately model the biofilm within the system. Characklis

et al. (1990) noted an increase in active biofilm thickness with an increase in substrate

concenfration to a maximum point when the active biofilm thickness exceeds the depth of

subsfrate penefration into the biofilm.

The active biofilm layer is typically described by zero order kinetics. The

thickness of the active layer is a function of bacteria type, mass transfer, hydrodynamics

and subsfrate type/concenfration. Henze et al. (2002) noted a required time of 14 days

for an active biofilm to form on a clean surface and a required time of 2 days for a

biofilm to re-form on a svurface after sloughing occurred. One of the concerns when

dealing with microgravity-compatible bioreactors is the occurrence of bubbles within

aerobic biofilms which can result in biofilm detachment (see Figure 2.1). In typical

aerobic attached growth systems, such as trickling filters, bubble formation can form on

the surface-bound side if anaerobic layers exist because oxygen diffusion may not occur

throughout the entire biofilm. This surface-bound bubble formation can significantly

increase sloughing of the biofilm.

15

Page 30: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

aerobic anoxic aiueroliic

Electron Acceptor

Substrate (C/N)

Siir&ce Film

Base Film

"'-'"A

Figure 2.1. Aerobic Biofilm in Typical Attached Growth Systems

Mass fransfer within membrane-boimd biofilms is more complicated than the

typical attached grov^^h systems described above (see Figure 2.2). Substrate diffusion

and electron acceptor diffiision must occur from opposing sides of the biofilm. This

"dual substrate limitation" increases the complexity of the transport processes and

depends on both interphase and infraphase transport processes. Mass transfer refers to

oxygen transport from the lumen side of the membrane, while hydrodynamics refers to

substrate transport through forced convection (Cussler, 1997). Following biofilm

formation, the two properties are not independent and both are a function of biofilm

cliaracteristics (density, thiclmess and type of bacteria). Complete diffusion of both

16

Page 31: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

subsfrates and electron acceptor must occur from opposing sides of the biofilm to have a

fully active biofilm layer. Not only does bulk transport influence biofilm formation, and

therefore freatment efficiency, but the accumulation of biofilm influences bulk liquid

processes (i.e., hydrodynamics). An extreme increase or decrease in mass transfer or

hydrodynamics within the system could possibly shock the microbial population. It is

hypothesized that excess dissolved oxygen concenfrations within the biofilm could

reduce the Van der Walls adhesive forces at the membrane-bound side of the biofilm;

however it is unknown if this reduction is significant.

Elfcti-oii Acceptor

Oxvaen

Sub,s'li-afe

.Aininoiua

Figure 2.2. Typical Biofilm Formation on Silicon Membrane

Mass transfer in attached grov^h systems takes place in the EPS-free void spaces

within biofilms. Molecular diffiision through EPS-free void spaces occurs in any

direction within the biofilm, as advection transports liquid to the clusters themselves.

Cussler (1997) noted that mass transfer is quantified by two common methods of

analysis: Fick's first law of diffiision (using diffusion coefficients) and the "no name"

17

Page 32: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

method using mass fransfer coefficients. Cussler (1997) stated that "neither the equation

using the mass fransfer coefficient nor that using the diffiision coefficient D is always

successfiil." The AMR was analyzed using both methods but the results using mass

fransfer coefficients were much more accurate than those from Fick's Law. Mass transfer

coefficients are considered applicable to the analysis of the system as they are generally

considered to be a combination of diffusion and dispersion.

The overall resistance to mass transfer (ko) within membrane reactors of this type

is composed of three separate resistances, i.e.,

1/ko = l/ko + [Te/(km*H)] + (l/kO Equation 2.3.

where:

1/ko = overall mass fransfer resistance [L/T],

l/ko = gas mass transfer resistance [L/T],

[Te/(km'''H)] = membrane transfer resistance [L/T] and

(1/kL) = liquid mass transfer resistance [L/T].

where the value of each resistance is represented by its respective mass transfer

coefficient. The gas mass fransfer resistance (ko) is usually much less than the liquid and

membrane resistance, and thus can be considered negligible in mass fransfer analyses of

this type (Cussler, 1997). The unitless Sherwood's number is generally used to define the

relative worth between the individual mass fransfer resistances; the Sherwood number is

the ratio of overall mass transfer to diffusional mass transfer (Cussler, 1997).

18

Page 33: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Cote et al. (1989) noted that the majority of the resistance was from the bulk-

liquid interface for silicon membranes similar to those used in the AMR. The liquid film

resistance is a fimction of fransmembrane pressure, biofilm thickness and hydrodynamic

properties, to name a few. Research has indicated that the liquid-film resistance can be

decreased by many methods; including increases in forced convection and rotation of the

reactor vessel (Rector et al., 2004; Casey et al., 2000) but these measures were not

included due to the extent of mass fransfer in the AMR. The membrane resistance is a

function of membrane type and membrane thickness.

Throughout this paper, the terms advection and forced convection are used

synonymously, where the fransport is due to fluid velocity from pumping. The modeling

of the hydrodynamic behavior within a bioreactor is vitally important in understanding

system performance. A typical tracer response for a completely mixed (CM) reactor and

a plug-flow (PF) reactor is presented below. Reactor performance is expected to be

arbifrary (non-ideal), but the closer the flow regime lies to being ideal, the simpler the

hydrodynamic modeling becomes. Experiments to quantify both mass transfer and

hydrodynamics allowed determination of the major mode of transport in the AMR both

before and after biofilm formation. Generally if forced convection (fiowrate) is increased

transport, and therefore treatment efficiency, increases in attached growth systems

(Characklis et al., 1990). Research has indicated that extremely large increases in forced

convection would be required to increase overall fransport within the AMR designed at

TTU (Weisner, 2004). Tracer studies were conducted at each system operating point to

ensure that the dominant form of transport and flow regime were accounted for when

19

Page 34: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

analyzing the system. A detailed description of the fracer studies and their resuhs

presented in Chapters III and IV, respectively. are

o o c o

c V u c o o 0)

.N

E

1.0

0.8

0.6

0,4 -

0,2 -

0,0 -

Ideal Plug-flow

2 3 4

Normalized time (t/x)

Figure 2.3. Ideal Tracer Response Curves

2.5.2 Biological Processes

2.5.2.1 Water Quality Variations in Feed Tank

Before discussing the efficiency of the nifrifying and denitrifying bioreactors, it is

important to consider feed tank activity. It was initially assumed, followdng current

literature, that all hydrolysis reactions would be complete within a matter of minutes and

that significant biological activity within the feed tank would be negligible (Fidaleo et al.,

2003). The purpose of the biochemical feed tank analysis was to investigate ammonia

and organic carbon loading rate assumptions for the biological reactors at TTU during

normal operation, aiding in sizing and mass balances for the biological reactors within the

20

Page 35: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

WRS. The experiment specifically aids in designing optimum wastestream holding times

prior to delivery to the biological system. Some of the problems encountered during the

operation of the biological portion of the TTU systems include inaccurate NH4^ and DOC

concenfrations; the average fraction of "useable DOC" being the main concern. Useable

DOC refers to the organic carbon that can be utilized by heterotrophic bacteria within the

biological system. During initial operation of the TTU-WRS, urine was collected and

used to make fresh bioreactor feed daily, with feed tanks being regularly cleaned to

minimize activity within the feed tank. In an attempt to reduce the large variations of

feed concentrations associated with the raw feed tanks the biological feed preparation

methods were altered at TTU (see Table 2.3). However, the high variability of ammonia

(from 120 mg-N/L to 630 mg-N/L) and DOC (from 105 mg-DOC/L to 805 mg-DOC/L)

persisted in the feed tank foUovidng these alterations.

Table 2.3 Feed Tank Afterations at TTU

Alteration

Feed tank cleaning ceased

Urine refrigerated for 24-hours

Urine stored for 24

hours at room temperature

No decant of excess feed

Desired Effect

Increase hydrolytic activity

Allow hydrolysis to occur

before feed solution formulated

Increase hydrolysis

reaction rate

Increase hydrolytic activity

Alteration

Continued

yes

no

yes

yes

21

Page 36: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Daily urine compound concentrations vary drastically with things such as

individual diet, use of medications, exercise and sex of donor. Urine is composed of

elecfrolytes, small molecular weight proteins and various nutrient metabolites. Some

typical compounds found in urine are iron salts, sodium, potassium, magnesium, calcium,

chlorides, phosphates, citrates, oxalates, sulfates, hormones and vitamins (National

Academy Press, 2000). Research has been conducted to examine some of the compounds

in female vu-ine and their effect on system performance (Morse et al., 2004). Although

the urine in the ground-based systems will have a slightly different chemical composition

than that in space, the WRS is designed to be a robust system capable of handling large

daily fluctuations in wastesfream composition. It is the high daily variability in

individual urine concentrations that causes the relatively high standard deviation in all of

the carbon and nitrogen data concerned with biological systems. Preliminary feed tank

studies indicated a pH increase of 2.1, a decrease of 40 mg-DOC/L and an increase of

110 mg-N/L over a 60 hour period. Theoretical chemical oxygen demand (ThCOD)

values were calculated following Equation 2.4 taken from Metcalf and Eddy (2002).

CnHaObNc + dCr207^- + (8d + c)!!^ -^ nCOz + (a+8d-3c)/2 + cNH4^ + 2dCr^^

Equation 2.4.

where:

d=(2n/3) + (a/6)-(b/3)-(c/2)

The relative concentrations of typical compounds found in urine are presented in Table

2.4 and were taken from Altman et al (1989), Diem and Lentiier (1989), Hawk et al

22

Page 37: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

(1989), Long (1989), Putiiam et al (1989), Smith et al (1989) and Webb et al (1989). The

values are based on average urine concenfrations and do not necessarily accurately

represent the daily compound concenfrations. Not all of the compounds listed in Table

2.4 can be utilized by heterotrophic bacteria as organic carbon sources for cell synthesis

and some of the compounds following hippuric acid are amino acids that can be directly

assimilated for direct cell utilization. The compounds of interest in this research were

urea, creatinine and hippuric acid. The TC/ThCOD values in Table 2.4 indicate the

theoretical approximate freatability of each of the compounds found in typical urine; this

is a relative value and does not necessarily represent the specific biodegradability of each

compound. It was estimated from values in Metcalf and Eddy (2002) tiiat TC/ThCOD

values below approximately 0.5 indicate compounds which are not easily degradable by

biological means and TC/ThCOD values above 0.5 indicate that the compound may have

some toxic components at high concentrations or acclimated microorganisms may be

required for degradation; the reference to 0.5 is a "rough" adapted number that does not

Table 2.4. TC and COD Values for Compounds in Urine

Compound

Urea

Creatinine

Hippuric Acid

L-Histidine

Range

[mg/]

9550-23900

675-2000

240-1560

40-335

Assumed

Concentration

[mg/L]

13400

1790

900

190

TC/ThCOD

[mg-TC/mg-

ThCOD]

0.00

0.00

0.71

0.29

23

Page 38: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table 2.4. Continued

Compound

a-D-Glucose

Cifric Acid

Taurine

Uric Acid

L-Glutamic Acid

L-Lactic Acid

Glycine

Phenol

Formic Acid

Oxalic Acid

Reinge

[mg/]

50-300

95-1000

5-295

210-870

1-485

50-600

90-360

300-320

30-140

1-50

Assumed

Concentration

[mg/L]

175

550

150

540

240

325

225

310

85

25

TC/ThCOD

[mg-TC/mg-

ThCOD]

0.39

0.35

0.26

0.69

1.43

0.41

0.46

1.20

0.11

0.77

specifically define biodegradability. The 0.5 mg-TC/mg-ThCOD value is an estimation

based on BOD and ThCOD values in Metcalf and Eddy (2002) and is not an

experimental value obtained at TTU. Compounds such as lactic acid and glycine are

highly degradable. The only compound with a TC/ThCOD ratio greater than 0.5 that has

a significant typical concentration is hippuric acid.

Nearly all of the individual compounds found in urine are subject to hydrolysis

reactions in the presence of specific hydrolytic enzymes. Most of these enzymes are

either found in human urine, produced by bacterial cells within the biological system, or

24

Page 39: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

both. Bitton (1999) noted that non-protein groups may also be involved in catalytic

activity of the subsfrate-specific enzyme. In order to quantitatively define the

concenfration of useable DOC within the raw feed, a general overview of the reaction

pathways for the major compounds in urine is necessary. Table 2.5 presents one of the

reaction pathways and required enzyme for hydrolysis of the three major compounds in

urine.

Table 2.5 Reaction Pathways ofCommon Compounds Found in Human Urine

Compoimd

Urea

Creatinine

Hippuric

Acid

Hydrolytic

Enzyme

Urease

Creatinine

Deiminase

Histozyme

Product

NH3, CO2

C4H9N3O2

CeHsCOOH

Product

Concenfration

[mg-N/L]

8026

2070

90

Product

Concentration

[mg-C/L]

2675

190

120

2.5.2.2 Urea hydrolysis

Urea is the most prevalent compound found within human urine, and it can be

seen in Table 2.5 that the nitrogenous and carbonaceous contribution of urea to the

biological system is the most abundant of all the compounds in urine. The products of

urea hydrolysis are NH3 and CO2; the hydrolysis is described in Equation 2.5.

(OC(NH2)2) + 2H2O -^ 2NH3 + H2CO3 + H2O -^ 2NH4 + 20H Equation 2.5.

25

Page 40: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

It is generally accepted that hydrolysis to ammonia does not occur in the absence of the

urease enzyme. Although urea is an organic compound, the carbonaceous product of

urea hydrolysis is inorganic by nature, and therefore may not be utilized by heterotrophic

bacteria for cell growth.

Fidaleo et al. (2003) developed an enzymatic kinetic expression describing urea

hydrolysis in the 4-9 pH range. Although jack bean urease and synthetic urea were used

in the analysis, as opposed to raw urine, the simplified model gives a rough indication of

the average reaction rates in the urea-urease system. It was assumed that the model

developed by Fidaleo could not be directly utilized when analyzing the raw feed at TTU

due to non-competitive enzyme inhibition by compounds found within the feed solution.

The objectives of the feed tank analysis were to determine:

(1) If a mature feed tank is more biologically active than a clean feed tank,

(2) The effect of a pH buffer and head-space oxygen on hydrolysis rates,

(3) If ammonia stripping takes place within a feed tank,

(4) The fraction of organic nitrogen that exists as urea,

(5) The extent of hydrolytic activity within feed tank and

(6) The average percentage of total TOC available for heterotrophic bacteria.

2.5.3 Equivalent System Mass

An equivalent systems mass (ESM) analysis was conducted following the

procedures outiined in (Levri et al., 2003). The purpose of the ESM is to quantitatively

26

Page 41: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

compare two systems designed for space flight in terms of mass, power requirements,

stowage volume requirements and any other parameter which may be used to select the

best overall design scheme. A simplified ESM analysis was conducted for both the TR in

the TTU-WRS and the AMR in the PB-AMR system. The ESM is not the final

parameter in choosing the best flight-ready system, but is a straightforward way to

conduct an overall system comparison.

The purpose of this research was to determine the applicability of a membrane-

aerated bioreactor as a gravity-compatible nitrifying reactor for long-term (duration)

space missions. The major physiological processes and biological processes of concem

were experimentally analyzed at TTU. The biological water recovery system was

compared to similar systems at both TTU and JSC.

27

Page 42: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

CHAPTER III

MATERIALS AND METHODS

The physiological and biological processes affecting bioreactor transport and

fransformation were investigated by conducting a series of experiments outlined in

common bioreactor literature. Bioreactor transport was investigated via hydrodynamic

and mass fransfer experiments, while the biological processes within the reactor were

monitored for a 280 day period during normal operation.

3.1 Water Recoverv Systems at TTU

3.1.1 TTU-WRS

The anaerobic packed bed in the TTU-WRS is a plexiglass column with a

working volume of 2.2 Liters (0.58 gal) and contains 10 mm (0.34 in) Intalox ceramic

saddles as media, providing a void space of 0.58 (see Table 3.1). The ceramic saddles

provide for the attachment of denifrifying heterofrophic biofilms. Gravity dependent gas-

liquid separators (GLS) were constructed to allow gaseous N2 and CO2 to be released

from the wastestream before entering the downstream reactor. The nitrifying TR in the

TTU-WRS consists of two 15.5 m (50 ft) long Tygon ttibes 3.16 mm (0.12 in) internal

diameter, and acts as a plug-flow reactor with a very short per-pass hydraulic retention

time (2.6 minutes for 31 m of ttibing) (Muirhead et al., 2003).

28

Page 43: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table 3.1. TTU-WRS Design Details

Description

Anaerobic PB Reactor Vessel

Ceramic Saddles

GLS

Tubular Reactor

Dimensions

10cmODX45cm

10 mm

4 cm OD X 20 cm

3.16 mm ODX 15.5 m

Total Volume

3.5 L

2 mL/saddle (660 saddles)

0.25 L

0.12 L

Working Volume

2.2 L

-

-

0.10 L

The TTU-TR was equipped with traps to prevent sheds downstream of the point

where the biomass enters the frap; a mass-flow confroller and an operating system to

maintain air/liquid equilibrium within the tubes was also required. A simplified

schematic of a replica of the biological portion of the TTU-WRS may be seen in Figure

3.1.

High Pressui« Ismatec

Piston Pump C Programmable

lubsterflex Peristalic Pump

fTP PB Denitrification

1 Pacl<ed Bed Bioreactor

(PB5

Tubular

Nitrifying

Reactor

(TR)

Gas-Liquid Separator

Figure 3.1. Biological Portion of Water Recovery System at TTU

29

Page 44: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

3.1.2 PB-AMR

The PB-AMR system was designed in the same manner as the TTU-WRS with

the AMR replacing the TR as a nifrifying reactor. The PB-AMR system contains a

gravity dependent gas-liquid separator (GLS) upstream of each reactor to avoid gas

bubbles in the liquid influent. The reactors were inoculated separately and allowed to

operate until the appropriate microbial populations were established. Bacteria taken from

the reactors within the TTU-WRS and JSC-WRS were used as inoculum for each reactor.

During inoculation, alkalinity, pH and trace element concentrations were controlled. The

start up period referred to throughout is the acclimation period following inoculation

when the TTU-WRS feed solution was used and the reactors began operating in series.

The raw feed fiowrate delivered to the system throughout the experiment is 1.0

mL/min producing 1.44 L (0.38 gal) of processed waste per day. The lines between

reactors were cleaned/replaced every 15 days to ensure that biofilm growth in the system

only occurred within reactor vessels. Figure 3.2 gives a simplified layout of the PB-

AMR system.

30

Page 45: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Ram Feed Tanl

(RFT)

Cas-Uquld i Separator b L^S CN2 off-gas] T 3

y . -^ Programmable ( Ivbaerfiex ^ - l j Peristalis

Pump

i k - O

Effiuent Tank Control Volume

Figure 3.2. PB-AMR System Layout

The anaerobic packed bed (PB) in the PB-AMR system consists of a 43.8 cm

(17.25 in) long clear PVC column with a 7.6 cm (3.0 in) inside diameter and is

downstream of an Ismatec high pressure piston pump. The total volume of the PB is 2.5

L (0.66 gal), while the working volume is 1.1 L (0.29 gal). The media in the PB selected

was lava rock (Twin Moimtain Rock Co., Des Moines, NM) to provide a higher surface

area for biofilm attachment compared to the ceramic saddles (Rector et al., 2003). The

packing ratio for the PB is 0.69. To insure by-product gases remained in solution

(following the TTU-WRS design) the PB was pressurized to 172.3 kPa (25 psi).

The AMR consists of 150 non-porous silastic® brand silicon hollow fiber

membranes (Dow Coming Co., Midland, MI) which allow oxygen to diffuse from the

lumen side of the membrane and act as support media for nifrifymg biofilm growth (See

Figure 3.3). Facility air is delivered to the membranes via air cavities located at opposing

ends of the reactor (see Figure 3.3).

31

Page 46: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Facil i ty Air Flow E f f l u e n t

Air Cavity

Liquid Flow E f f l u e n t

Liquid Flow I n f l u e n t

Air Cavit

J a s e Plate

Mei^brane Sheet

Menbrane Plate

Facil i ty Air Flow In f l uen t

Figure 3.3. AMR System

The silicone membranes have an outside diameter of 0.17 cm (0.065 in), an inside

diameter of 0.08 cm (0.030 in), resulting in a membrane thickness of .09 cm (0.035 in).

The gas pressure throughout each test point was 20.7 kPa (3.0 psi). The membranes are

approximately 2.3 times longer than the length of the reactor, increasing the surface area

32

Page 47: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

available for oxygen fransfer and providing a increased random packing (surface area) for

biofilm growth. The total specific surface area for oxygen fransfer in the AMR is

approximately 0.83 m /m . Some specific membrane surface area will be lost due to the

contact of membranes in random packing, but this was determined to be negligible. As

with other MABR systems tiie depth of oxygen penetration into the biofilm layer can be

directiy confroUed via the fransmembrane pressure. Several researchers have

investigated mass fransfer of O2 in MABR's and a detailed discussion of mass transfer

may be found in Cussler (1997).

The total volume and working volume of the AMR system are 4295 mL (1.13 gal)

and 3865 mL (1.02 gal), respectively giving a packing ratio of 0.83 (see Table 3.2 for

AMR design details). The length of the AMR is 54.7 cm (21.5 in) and the diameter is

10.2 cm (4.0 in). The bottom air chamber is pressurized witii facility air which flows

through the silicone tubing to the air chamber located at the opposite side of the reactor.

The silicone tubing is attached to stainless steel pressure taps (Scanivalve Corp., Liberty

Lake, WA) that pass through a rubber plate and connect the silicone hollow fiber

membranes to the pressurized air cavities. Although the AMR was not operated under

microgravity conditions (the AMR was not pressurized), the system is microgravity

compatible.

Table 3.2. PB-AMR Design Details

Description

Anaerobic PB Reactor Vessel

Dimensions

8.5 cm OD X 44 cm

Total Volume

2.5 L

Working Volume

1.9 L

33

Page 48: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table 3.2. Continued

Description

Lava Rock AMR

Reactor Vessel Silicon

Membranes

GLS

Dimensions

3 cm

54.7cm X 10 cm OD

0.17 cm ODX 125 cm (150 hollow fibers)

3.2 mm ODX 15.5 m

Total Volume

0.6 L

4.3 L

430 mL

0.2 L

Working Volume

0.6 L

3.8 L

430 mL

0.2 L

An ESM analysis was conducted on the TR and the AMR to analyze the two

systems as possible long-term bioreactors in space. The pumps, pressure gages and gas

liquid separators used for each system at TTU were identical, and were therefore

neglected m the ESM analysis. For the purposes of this paper, the only important

fimction of the PB is that the TOC removal efficiency is high enough to limit significant

heterofrophic growth wdthin the nifrifying reactors; thus, the anaerobic packed bed within

each system was not ESM analyzed. To conduct the ESM analysis, each reactor was

weighed before and after filling the reactor. The stainless steel pressure taps, membranes

and rubber mats were weighed separately to account for possible future design

alterations. The mass of the accumulated biofilm was considered to be negligible for the

ESM analysis.

3.1.3 Feed Composition

The feed for the biological systems at TTU simulates tiie urine-based wastewater

solution used at JSC for the analysis of the WRS so that data may be dfrectly compared

34

Page 49: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

(Campbell et a l , 2003). The PB-AMR feed solution consists of a modified version of

Pert Plus® for Kids "minus" (PPKm), deionized-distilled water (DDI) as make-up water

and non pre-freated urine (see Table 3.3). The degradation potential of the two main

surfactants in PPKm has been previously investigated (Rector et al., 2003). PPKm is a

solution NASA is currently considering for space flight. Currentiy, the TTU-WRS

contains a mixture simvdating humidity condensate (see Table 3.3) produced by the ISS

air ventilation system (Campbell et al., 2003; Verostko et al., 2004).

Table 3.3. Simulated Humidity Condensate in Feed at TTU

Compound

Ethanol

2-Propanol

1-2, Propanediol

Caprolactam

2(2-butoxyethoxy)

4-ethylmorpholine

Methanol

Formaldehyde

Formic Acid

Propionic Acid

Zinc Acetate Dihydrate

Ammonium Bicarbonate

Ammonium Carbonate

Concentration

[mg-compound/L]

260

70

143

52

8

9

15

31

44

14

88

66

65

35

Page 50: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

The humidity condensate was not added to the feed solution in the TTU-WRS

until after recycle ratio 20 was completed. The feed for the PB-AMR system, therefore,

did not include tiie humidity condensate. It was assumed that the low concentration of

humidity condensates (A, B and C) did not significantly contribute to TC (0.44 mg-

TC/mg-compound), COD (1.50 mg-COD/mg-compound) or TN (0.05 mg-N/mg-

compound). The humidity condensate and surfactant concentration does not vary with

each fresh batch of feed. The contribution of the two major surfactants in PPK® minus

can be seen in Table 3.4.

Table 3.4. Typical surfactant contribution in raw feed

Surfactant

Sodium

Laureth Sulfate

Cocoamphodiacetate

Surfactant

Concenfration

[mg/L]

81.11 mg/L

71.11 mg/L

Theoretical

TC

[mg-TOC/L]

40 mg-C/L

45 mg-C/L

Theoretical

TN

[mg-TN/L]

0

6 mg-N/L

TC/COD

[-]

12.31

20.64

A summary of the average type and amount of wastewater produced per day for a

2-person crew can be foimd in Campbell et al. (2003). Feed was prepared daily, and

samples were collected and analyzed daily at various points within the system. The

concentrations of each individual compound added to the system is presented below.

36

Page 51: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table 3.5. Composition of Simulated Feed at TTU

Ingredient

DDI

URINE

SURFACTANT

HUMIDITY

CONDENSATE

Amount (TTU-WRS)

RR20 RRIO

[mg] [mg]

1000

245

1.28

*PPKm

1000

245

1.28

IGEPON

0.60

Amount

(PB-AMR)

[mg]

1000

245

1.28

*PPKm

-

* * PPK minus consists of sodium laureth sulfate and cocoamphodiacetate

3.2 Mass Transfer Experiments

Aeration experiments were conducted to analyze the mass transfer characteristics

of the AMR within the PB-AMR system. Deionized-DistiUed (DDI) water was boiled

and sparged with nifrogen gas until the dissolved oxygen (DO) concentration was below

1.0 mg-DO/L. The DO was measured using a ThermoOrion DO probe and a DO-

compatible Orion pH meter. The reactor was immediately filled with the de-aerated

water with the transmembrane pressure initially being set to zero. At time zero, both the

feed water and the reactor were sampled and analyzed for DO concentration and the

transmembrane pressure was increased to the pressure for each respective test point; test

number one used a transmembrane pressure of 2.6 psi while test number two used a

pressure of 3.6 psi. Transmembrane pressure was supplied by pressurized local facility

air in the Environmental Science Laboratory (ESL) at TTU. Bulk liquid samples were

collected every 6 hours and measured for DO; aeration experiments were conducted for 8

37

Page 52: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

hours to ensure tiiat saturation was reached. DDI water was not de-aerated by chemical

means to avoid interference witii the instruments used to experimentally determine the

DO. Values obtained from the aeration experiments were plotted and mass transfer

coefficients were obtained following common practices outiined in Cussler (1997) and

Metcalf and Eddy (2002).

3.3 Hydrodynamic Experiments

A conservative, non-colored substance was desired for the tracer study

experiments so that the biological system could continue to operate normally during the

three-day study. Phenol-red was considered for the experiment so that any charmeling or

radial mixing could be observed visually, but the continuing performance of each reactor

was too important to risk any corruption by outside sources. The fracer selected for use

in the experiment was sodium bromide. It was assumed for the duration of the

experiment that at concentrations below 50 mg-NaBr/L, the sodium ion would not

interfere with reactor performance, as the average concentration of sodium in human

urine is 550 mg-Na/L. The theoretical hydraulic retention time in the AMR is

approximately 64 hours; experiments were conducted for 75 hours to ensure the bulk

liquid reached the feed tank concenfration.

Values from AMR hydrodynamic experiments are reported as (mg-Br'/L).

Samples from the reactor and feed solution were analyzed for bromide prior to

conducting the experiment to measure background concentration of bromide in the

reactor. Upon verification of negligible bromide within the feed tank and reactor, a

38

Page 53: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

typical feed solution was prepared with an additional 40 mg-Br/L and stirred for

approximately 20 minutes. The feed was then continuously injected into the system at a

fiowrate of 1.0 mL/min and influent and effluent samples were collected every two hours.

Feed tank samples were collected to ensure that no cross-contamination had taken place

within the feed tank during the experiment.

Two separate sets of fracer studies were conducted on the AMR. The first set of

fracer studies was conducted before biofilm formation and is referred to as the tracer

study experiments. The second set of experiments was conducted following biofilm

formation and is referred to as the port study. The port study followed the same

procedures as the "clean" fracer study, but 40 mg-Br/L of sodium bromide was added to a

fresh feed solution and samples were collected from sampling ports along the reactor (see

Figure 3.4). Samples were collected from the uifluent tank, effluent tank and each port

for a period of 70 hours and analyzed for NOx-N, TN, DOC, pH and bromide.

3SD Port #3

38D Port (¥2

3gD Portal

Figure 3.4. AMR Port Study Configuration

39

Page 54: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

3.4 Biochemical Characterization of Feed Tank Reactions

Six experiments were simultaneously conducted on 3 clean feed tanks and 3

established feed tanks (see Figure 3.5). The feed was formulated by preparing 12.0 L of

feed and adding 2.0 L of feed to the respective tanks; this was done in an attempt to

decrease inaccuracy due to the variable nature of urine. Treatments included the sparging

of head-space oxygen within nifrogen gas, the addition of a phosphate buffer and a

confrol. The effect of pH was investigated following the assumption that non­

competitive pH inhibition could possibly temporarily reduce enzymatic activity within

the feed tanks.

The addition of phosphate buffer and nitrogen sparging to the corresponding feed

tank was then conducted and the feed tanks were covered with foil and sealed to

minimize interference of microbial reactions or any contamination from outside sources.

The feed tank analysis was conducted over a 140-hour period to guarantee completion of

the major biological activity within the tank. Samples were collected every 6 hours,

filtered, tested for total dissolved solids (TDS), pH, total nitrogen (TN as mg-N/L), NOx-

N, NH4-N, DO, chemical oxygen demand (COD) and dissolved organic carbon (DOC).

The feed tank is not expected to be in operation for longer than 24 hours, but preliminary

experiments indicated that the maximum time required for complete urea hydrolysis

within the feed tank was approximately 60 hours.

40

Page 55: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

C'leain Fee<l

Taiilc#l Buffer

Clean Feed

Taiilv#2 No Buffer

Clenn Feed

Taiil£#3 N2 Sparge

Dirty Feed

Tanlc#l Buffer

Dirty Feed

Taii l i#2

ITo Buffer

Dirty Feed

Taiilv # 3

N2 Sparge

Figure 3.5. Urea Hydrolysis Test Schematic

The mature feed tank herein refers to a feed tank that is decanted to 500 mL daily

before adding fresh raw feed. It was assumed from preliminary studies that a mature feed

tank would be more biologically active than a clean feed tank. The effect of phosphate

buffer addition (0.5 g-KHP04/L) and sparging of head-space oxygen with nitrogen gas on

hydrolytic activity were not primary objectives for the analysis. The concentration of

phosphate buffer added to the feed tanks was determined by formulating DDI solutions

containing various buffer concenfrations and adding known amounts of sulfuric acid.

The assumption that ammonia stripping is negligible in the feed tank was observed

during the experiment by preparing gas traps (pH=2.0) containing sulfuric acid; gases

escaping the feed tanks entered gas fraps where samples were analyzed for NH4

(pK{NH4}= 9.1). The fraction of organic nitrogen that exists as urea was determined by

dividing the theoretical organic nitrogen concentration by the urea concentration

41

Page 56: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

determined by molecular weight disfribution (MWD) on a liquid chromatography-mass

specfromefry (LC/MS) analyzer at JSC (see Equation 3.1), i.e.,

fu-N = Th.Org-N [mg-N/L] / Um-N [mg-N/L] Equation 3.1.

where:

fu-N = Fraction of organic nitrogen the exists as urea [mg-N/L],

Th.Org-N =(TN-N) - (NH4-N) - (N02'-N) - (NO3-N), and

Um-N = Measured urea concentration (by MWD)

and the average time required to complete urea hydrolysis for a typical feed solution was

assumed to be complete when the TN concentration equaled the inorganic nitrogen (NH4

+ NOx) concentration (implying negligible organic nitrogen exists).

3.5 Analysis

3.5.1 Sample Collection

Reactor influent and effluent samples were collected daily, fihered (< 0.45

micron) and analyzed for DOC, pH, N02"-N, NOa'-N and conductivity (TDS); while tests

for NH4"-N and TN-N were conducted three times a week. All nifrogen measurements

are reported as mg-N/L, and all carbon measurements are reported as mg- DOC /L.

42

Page 57: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

3.5.2 Sample Analysis

The NH4'', pH, total dissolved solids (TDS) and temperature samples were

analyzed at TTU using a ROSS probe (Thermo Orion model 8102-BN) and Thermo

Orion pH meter (model 250A). DO samples were analyzed using an O2 electrode DO

probe (Thermo Orion model 9708) and pH/ORP meter (IQ Scientific). COD samples

were analyzed using high range HACH COD vials and a HACH spectrophotometer

(HACH DR/2010 Loveland, CO). N02"-N, and NO3-N samples were analyzed using ion

chromatography at TTU (DX-600 Dionex, USA) and continuous count blank and spikes

(standards) were used every 20 samples to ensure proper functioning of the IC as outlined

withm Standard Methods. The TN and DOC samples were analyzed using a Shimadzu

analyzer (Non-Purgeable Organic Method).

3.5.3 Data analysis

3.5.3.1 Nifrification

It was originally assumed that the rate of urea hydrolysis would not affect

nitrification rate due to the extent of urease activity v^thin the system, and total ammonia

removal rates would be an accurate indication of nitrification rates. Feed tank analysis

indicated that ammonia loading rates vary drastically within the system over time.

Therefore, ammonia removal rates would not be accurate in analysis of the TTU-WRS

and PB-AMR systems. Thus, the percent nifrification was calculated using Equation 3.2

(below)

43

Page 58: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

% Nifrification = (dC(NOx)/dt - dC(TN/dt)/C(TO)initiai Equation 3.2.

where:

dC(NOx)/dt = Mass increase in NOx due to nitrification [mg-N/L],

dC(TN)/dt = Mass decrease in N due to denitrification [mg-N/L], and

C(TN)initiai = Feed TN concenfration [mg-N/L].

as opposed to mass ammonia removal commonly used; Equation 3.2 is a nitrogen mass

balance on the entire system, and not the AMR alone. The loss of NOx due to

denifrification was taken into account when reporting the nifrification rate; it was

assumed that the mass decrease in TN equaled the mass production of N2 (g). Ammonia

sfripping was found to be negligible at pH= 8.27 (%NH3= 0.095), which is the maximum

pH detected in the AMR to verify this assumption. The loading rate of each system was

considered so that the percent change values would reflect the true performance of each

biological system. To calculate the true system performance, percent change in each

constituent was divided by hydraulic retention time, allowing a direct comparison of

system performance to be made.

3.5.3.2 Denifrification

Following the assumption that NH4* loss to biomass and ammonia stripping are

negligible, the mass TN loss can be directly calculated by subtracting the effluent TN

from the influent TN. The percent denitrification is then equal to the percent TN loss.

The only point witiiin the system where ammonia stripping could occur is in the effluent

44

Page 59: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

of the packed bed, where high pH values can cause the NH4'' to be transformed to

aqueous NH3. Ammonia stripping in the WRS at TTU was assumed to be negligible

because of tiie short retention time in the TR, the low pH (6.0 ± 0.7), and the closed

water-loop operation of the WRS. Ammonia stripping in the AMR was considered to be

negligible because tiie bulk pH was slightly acidic throughout the 120 days (6.0-6.3).

The mass loss of DOC witiiin tiie system can be calculated in the same manner as the TN.

The DOC loss represents the loss of DOC to heterotrophic bacteria.

3.5.3.3 Determination of Organic Nitrogen

The total organic nifrogen concentration will be calculated by subtracting the

summation of measured inorganic nifrogen species (NH4 + NOx) from the measured TN

(see Equation 3.3). The fraction of total organic nifrogen as urea can then be directly

(total organic nifrogen-N) = (total nitrogen-N)-{(NH4-N) + (N02"-N) + (NO3-N)}

(Urea-N) / (total organic nitrogen-N) = fu,o (urea fraction) Equation 3.3.

calculated and will aid in understanding whether the organic nitrogen in the feed tank is

easily degradable organic nitrogen (urea) or other forms of organic nitrogen (see below).

Following the calculation of urea within each sample for a given period of time, tiie rate

of urea hydrolysis within a typical feed solution at TTU can be determined. The rate of

ammonium production should tiieoretically equal tiie rate of urea degradation by

45

Page 60: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

hydrolysis. The assumption tiiat arnmonia sfripping in the feed tank is negligible

(5.9<pH<8.6) will be investigated by observing tiie NH3 values collected in the gas traps.

46

Page 61: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

CHAPTER IV

RESULTS AND DISCUSSION

The objective of tiiis research was to design and analyze a gravity compatible

nifrifying bioreactor capable of operating in typical space conditions. A detailed

physiological and biological analysis of the MABR constructed and operated at TTU is

presented below.

4.1 Watbi: recovery Systems at TTU t I

An analysis of both the physiological and biological properties of the AMR is

required to fully vmderstand optimurh operatirig conditions and possible bioreactor j '

limitations. The analysis consisted' of fransport phenomenon affecting reactor

performance, including mass transfer and hydrodynamics. The analysis evaluated

fransformation phenomenon affecting reactor (performance, including an overall system

analysis of treatment efficiency and a biological characterization of feed tank reactions.

4.1.1 PB-AMR

4.1.1.1 Mass Transfer

Three separate sets of massijransfer experiments were conducted on the AMR

within tiie PB-AMR system. The first experiment was conducted at what was considered

tiien a high transmembrane pressure (3.6 psi) |and low liquid velocity (2 mL/min) where

mass transfer was expected to be limiting under these conditions. Following the resuhs

47

Page 62: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

more of tiie first experiment, indicating a relatively large mass fransfer coefficient, two

aeration experiments were conductdd at a relatively low transmembrane pressure and

high feed fiowrate to determine tiie conditions required for mass transfer to inhibit

biofilm growtii. The second set of experiments was conducted at the same liquid

fiowrate (24 mL/min) and operating fransmemlirane pressure (2.6 psi). The resuhs of the

mass fransfer experiment are presented in Table 4.1. In both experiments, the major mass

fransfer resistance in tiie AMR was in the membrane. The membrane resistance in the

first experiment, which represents normal AMR operating conditions, was 17.5 times

higher tiian tiie liquid boundary layer resistance (see Appendix A for detailed calculations

of mass fransfer and hydrodynamic! values). This result could be significant in future

AMR design, where bulk DO concenfration can be manipulated by altering the

membrane thickness, as opposed to alternative methods investigated by others (Rector et

al., 2004; Casey et al., 2002) whichli are more energy intensive.

Table 4.1.

1/km

[min/m]

2.1E+05

2.1E+05

AMR Mass Transfer ,

I/kL

[min/m] j

1.2E+04

6.4E+03±1.2E-04:i i

1 L J

ko

[m/min]

7.7E-05

1J5E-04±3.7E-12

Sh#

[-]

35

71

Flux (J)

[mol-DO/sec*m^]

1.9E-07

3.6E-07 ±

The mass transfer referred to throughout this paper refers to electron acceptor

(oxygen) fransport by diffusion through the membrane, while hydrodynamics refers to the

fransport of substrates by forced convection. Although it was initially assumed that mass

48

Page 63: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

fransfer would be the limiting factor in AMR transport processes, the data indicate that

mass fransfer is not limiting bioreactor fransport. jEven at the high fiowrate (24 mL/min)

and low fransmembrane pressure (2.6 psi) used during the second experiment, mass

fransfer did not limit fransport processes. The relatively high Sherwood numbers in Table

4.1 and the bulk liquid DO concenfrktidn of 5.0 n^g-DO/L indicate that only very large

changes in hydrodynamic effects will significantly increase the overall mass transport in

the system and that forced convection is the major form of transport; implying the AMR

is not limited by election acceptor diffusion. It is generally assumed that a bulk DO I

II concenfration above 3.0 is an indication that mas^ transfer is not limiting aerobic growth

within membrane aerated bioreactors.

Although the data does not seem to indicj.te a lack of mass transfer from either the

bulk or membrane side, Characklis et al. (1990) rioted that significantly thick mass

boundary layers are formed at low fluid velocitiels that can at times decrease the substrate

concentration at the local fluid-biofilm interface. The substrate removal rate within the

biofilm and high bulk liquid DO concentration wfere indications that neither the laminar

fiow conditions nor the heightened thickness of the mass boundary layer appeared to

significantly affect substrate transport.

I 4.1.1.2 Hydrodynamics 'j

The results for botii the "clean" and "dirty" tracer stiidies are presented below.

The clean tracer studies refer to AMR tracer st^cjies conducted before biofilm formation

and are concerned with general reactor hydrodyiiamic properties while the dirty tracer

49

Page 64: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

stiidies refers to experiments conducted after biofilm formation and the addition of an

internal system recycle. The results of the clean flow through (RRO) hydrodynamic

analysis are presented in Figure 4.1. Continuous The data indicate that preferential flow

(channeling) within the AMR was negligible, butj further studies are required to

quantitatively define the amount of preferential flow. The data indicate that the reactor

may be modeled by a plug-flow regime, which is [evident by the nine hour lag in the i

tracer response (see Figure 2.3). Although the trdcer response does not indicate an ideal

plug-flow regime, experimental bioijeactors are ejcpected to operate as non-ideal, or

arbifrary, flow reactors.

mg-

Br/

L]

hmmM

C/C

o

1,0 -

0,8 •

0,6

0,4 -

0,2 -

0,0 i

9

mt9 99 r-

tv: K

• • ^

• • • J M ^ • ^ ^ ^

0,0 0.2 0,4 0,6 : 0,8 1,0 1,2 1,4

Time [hpurs]

Figure 4.1. AMR Hydrodynamic Experimental Resuhs

The port study (dirty tracer study) was conducted in the AMR following biofilm

formation in an attempt to understand ihe effec^ of biofilm formation and internal recycle

50

Page 65: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

on bioreactor hydrodynamics. A fracer profile alpng the reactor is presented below. The

data from a port study of tiiis type on a completel ' mixed (CM) reactor would indicate no

change in freafrnent along tiie lengtii of tiie reactor, as CM reactors assume that the

concenfration at any point within tiie reactor is the same. It can be seen in Figure 4.2 that

a CM profile exists, but detailed dimensionless analysis indicates that the bioreactor still

behaves in a P-F manner.

m 1 O) E k

ca J£ C n 1-c 0) 3

E lU a: S <

i?n

inn 80

60

40

20

- J

CQ

D)

f-t..

m CM

4t:

ort

Q.

01

s <

140

120

ion

80

60

40

20

i

I •

i

u

L . OQ JC c |2 •o

ili 11.

o: F <

140 1

120 •

100 •

80 •

60 •

40 -

20 •

0 -

C

' ) 1

' 2

Time [hours]

Figure 4.2. AMR Por Study Resuhs

CO

120 i,

100 £

80 m

60 8 40 C

20 "•

140 =J

1?0

100

80

60

40

20

0

OQ

O)

F

ffi ^ %

ort

Q.

tt s

51

Page 66: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

At first glance, tiie low Reynold's number (from 0.001 to 0.035 ) seems to be an

indication of possible mass fransfer limitation, but the results indicate that the dominant

factor in mass fransport is advection, which support resuhs of the mass transfer

experiments (Sherwood number= 35). To ensure the validity of the hydrodynamic

dominance of tiie system, tiie dimensionless Peclet number and coefficient of axial

dispersion were determined using Equation 4.1 ta!ken from Metcalf and Eddy (2002), i.e.,

C/Co=l/[2(7t(D/ML)] exp [-{\-Qf/^{D/uL)] Equation 4.1. I

where: i

C/Co= normalized tracer response [unitiess],

D = coefficient of axial dispersion [cm^/sec],

u = fluid velocity [cm/sec],

L = reactor length [cm],

9 = normalized time (t/t) [unitless], |

t = time [sec], and i

T = theoretical detention time [sec].

and compared to values in current literature. The Peclet number (ML/D) is the ratio of i

flow velocity to diffusional velocity, where Peclet numbers greater than 1 indicate that

the majority of the transport is due to forced convection. Table 4.2 suggests that the

majority of the fransport is due to forced convection, as indicated by the large values of

the Peclet number (greater than one) for each recjycle ratio. The axial Reynolds's number

52

Page 67: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

(Re<3.0) and unitless dispersion numl^er (d) indie ite that the AMR operates under plug-

flow conditions (d<0.01). Ideal plug-flow reaci;ol s with no dispersion have unitless

dispersion numbers of zero, while unitless disppr^ion numbers above 0.05 have slight

dispersion. Significant dispersion does not tak^ jjlace below unitless dispersion numbers

I 1 of 0.25 (Metcalf and Eddy, 2002). Altiiough tiie major form of transport in the AMR is

due to forced convection, tiie unities^ dispersion numbers indicate that axial dispersion

witiiin the membrane reactor is considered to he bw; verifying assumptions made based I '•

on the Reynold's number. All of the physiologiciil studies indicate that hydrodynamics

(specifically advection) dominate mass transport

having a Peclet number significantly greater than

I within the system, which is verified by

Table 4.2. Hydrodynamic Results

one.

Fiowrate

[mL/min]

1.0 (RRO)

11.0 (RRIO)

21.0 (RR20)

Coefficient of

axial dispqrsion

[cm^2/sbc]

9.01E-04

1.02E-03

7.51E-04

! Ujfiitless dispersion

number

[-]

0.0776

0.0876

0.0647

Peclet

number

12

11

15

The results of the mass transfer and hyjdn

can be accurately modeled as a plug flow reactor

advection and axial dispersion is coiisidered to bs low.

•|)dynamic analysis indicate that the AMR

where transport is dominated by

53

Page 68: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

4.1.2 Biochemical characterization i f feed tank i

The overall objective of the ieed tank analysis was to quantify the significance

and average rate of enzymatic/hydrclytic activity

reactions

(change and were constant at

sub-objective of the feed tank reactiim characterization was to determine if a significant

difference exists between the enzymlatic activity! within a mature feed tank and a clean i

feed tank. To accomplish this, the data from each feed tank was compared by averaging

all of the clean feed tanks and all of the mature ^eed tanks. Temperature values

throughout the experiment did not s ignificantly <

nature and ctlean feed tank DOC concentrations (mg-j

DOC/L) are presented below. Tabl(; Curve'''"'* yvjas used to approximate rate constants for

each set of feed tanks. average ratd <

(kDOC,m = 0:

approximately 23° C. The average

Figure 4.3 indicates that the

hydrolysis, in the mature feed tanks

rate m the clean feed tanks (koocc T -0025 houi' ). It is not fully understood at tiiis time

why the initial DOC value (0 hours) was lower

analyzed. The vertical line in the p

within the feed tanks at TTU. The first

;han the value at 10 hours for all samples

ots below represents the maximum holding time (24

hours) for a fresh batch of feed at TTU (excluding the 500 mL residual following decant)

54

11

of DOC degradation, and therefore urea

0050 hour"^) was higher than the average

Page 69: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

p-i 500

o o Q

I

£ c o n O

c M O)

T3 0) _> o M OT

400

300 -

200

100 -

S t ^ J

• Mature Feed T inks O Clean Feed Ta iks

20 60 SO

Figure 4 Time [hburs]

3. Mature aid Clean DOC

The average ammonia formation

is presented below. The average region

feed tanks (kTA,m = 0.151 hour'')

rate (kTA,c = .00034 hour"'). No si

clean feed tanks during the first 24

(mmol-

rate

much higlji

ghificant

lours of the

was

600

500

g) 400

i 300 E E

< 200

100

• Mature Fee( O Clean Feed

Tanks ranks

gCD iOO

20 40

Figure

100 120 140 160

N/L) for the mature and clean feed tanks

estimated by Table Curve' ' for the mature

er than the average clean tank reaction

amrHioma production took place within the

experiment.

I 60

Time

4.4. Mature

55

to 100 120 140 160

[jliours]

and Clean TA

Page 70: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

According to the urea hydrolysis stoichiobetry

ammonia are produced for every mole of urea hy^rolyzed

compounds in urine hydrolyze to CO2, the total

hydrolytic activity in the feed tank isj equal to the

in the feed. Although every reaction pathway of each

unknown, one of the compounds which can hydrblyze

acid but it was assumed that this wojild be insignificant

acid concenfration (4%) in urine. Thus, the numper

mole of urea (DOC degraded) was calculated by

in Equation 2.5, two moles of

Assuming no other organic

(jhange in DOC (mmol-DOC/L) due to

number of moles of urea (mmol-urea/L)

individual compound in urine is

to ammonia and CO2 is hippuric

due to the low average hippuric

of moles of ammonia produced per

the following equation:

MN/C = dTA/dDOC = (TAf- TAi) / (DOd - DOCf)

where:

MN/C = Ratio of moles of arti|monia

TAf = Initial ammonia concenfration

TAi = Final ammonia concentration

DOCi = Initial dissolved org

DOCf = Final dissolved organic carbon cjoncentration [mmol-DOC/L].

Figure 4.5 presents the average

values for the mature and clean feec,

that approximately 2 moles of

hydrolyzed. The deviation between

tanks. The

the six tanks

56

Equation 4.2.

prodiiced per mole of DOC degraded,

[mriol-N/L],

[mmol-N/L],

anic carbon concentration [mmol-DOC/L], and

calculate^ urea values and the measured ammonia

molar ratios comply with Equation 2.5 in

ammonia were prjoduced for every mole of urea

is due to the varying amount and rate of

Page 71: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

enzymatic activity within the tanks,

the same manner, as each mature tai|ik

due to its relative "age". It was assumed

because they did not contain significant

o

E

E E

1 -

0 -LT Mature Feed Tanks

The measured urea values were

to ensure that the feed tank reactions

mole ammonia are produced for every

the mature feed tanks produced resiilts

the clean feed tanks produced value|s

is hypothesized that this was due to

in The mature tanks were not expected to respond

contained a different amount of biological activity

that the clean feed tanks would behave similarly

microbes prior to the test.

Average= 1.77 mmoi-N/mmol-C St. Dev.= 0.68 mmol-N/mmol-C

Clean Feed Tanks

2 3 4

Feed Tank No.

Figure 4.5. Moles of TA Produced Per Mole of DOC Consumed

then compared to the measured ammonia values

followed Equation 2.5 (where two moles of

of urea hydrolyzed). As occurred in Figure 4.5,

near expected values based on Equation 2.5, while

near 1.0 mol-NILi produced/mol-urea consumed. It

the lack of enzymatic activity within the clean feed

57

Page 72: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

tanks and it was assumed tiiat inhibition of hydrolysis by pH, product, subsfrate and

temperature was not significant in the clean feed tanks.

Table 4.3. Measured Hydrolytic Ammonia Production in Feed Tanks

Tank No.

Mature #1 Mature #2 Mature #3 Clean #1 Clean #2 Clean #3

Moles of Urea Hydrolyzed

[mmol-urea/L] 9.92 15.73 14.48 16.63 8.93 10.33

Moles of N H / Produced

[mmol- NILt"" /L] 25.14 25.79 26.50 10.57 8.93 10.71

N H / Production Ratio

[moles- NH4" /mole-urea] 2.53 1.64 1.83 0.64 1.00 1.04

Table 4.3 is a comparison of the average pH, TA and DOC change during the feed

tank analysis. The results from the experiment outiined in Table 4.4 verify the

assumption that a mature feed tank is more enzymatically active than a clean feed tank.

Table 4.4. Matvire and Clean Feed Tank Comparison

Feed Tanks

Mature

Clean

Average pH

Increase

[-]

2.32 ±0.18

1.95 + 0.36

Average TA

Increase

[mg-N/L]

360 ±10

140 ±15

Average DOC

Decrease

[mg-DOC/L]

143 ±32

100 ±28

The DO degradation rate did not significantly vary between the matiire and clean

feed tanks. Figure 4.6 indicates that the feed tank tiims anoxic within the normal 24 hour

holding time. The sparging of nitrogen did not reduce the initial DO value in tiie mature

58

Page 73: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

or clean feed tanks because only the head space was sparged with nitrogen in an attempt

to examine tiie effect of head-space oxygen on hydrolytic activity. It was assumed that

head space oxygen could possibly increase tiie aerobic heterotrophic activity within the

feed tank.

o -

: ^ 5 -^ *-' o 9 D) 4 . E, c 0 O) 3 -i

> X 0 • 0 2 fl) '^ > 0 (A 5 1

0 -

2

I

( T 6 • 1

5 s do Ti T It

1 1 1

f i • ; »

-0—1

-0—1

• Mature Feed Tanks 0 Clean Feed Tanks

-p

0

H-C

H

20 40 60 80 100

Time [hours] 120 140 160

Figure 4.6. Mature and Clean DO

The average COD in the mature and clean feed tanks is presented below. The

NOx-N concentration within each feed tank was consistently below detection limit

(MDL=1.0 mg-N/L) throughout the 140 hour test. Tests indicated that urea and ammonia

do not exert a COD, agreeing with theoretical calculations. Therefore, the COD

concentration was not expected to change during tiie feed tank analysis. The 140 hour

change in COD for the mature and clean tanks were 18 ± 13 mg-COD/L and 35 ± 25 mg-

COD/L, respectively. Although the change in COD within tiie clean feed tanks appeared

59

Page 74: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

to be larger tiian the COD change in the mature tanks, it was assumed that neither

decrease in COD was significant. Possible interferences with the accuracy of the COD

test include high chloride concenfrations (300 ±80 mg-Cl/L) and intermediate compounds

formed during urea hydrolysis. It is unlikely that these intermediate compounds would

exert a COD, but little research has been conducted concerning this matter.

r-j. 1400

Q 2 1200

I

o .§. 1000

E 0) Q c fl) O) >« O 400

800

600

i

(Q U

200 E fl)

O 0

• Mature Feed Tanks O Clean Feed Tanks

20 — I —

40 — I —

80 60 80 100

Time [hours] 120 140 160

Figure 4.7. Mature and Clean COD

A response factor ratio (RFR) was calculated to ensure that DOC and COD data

correlate. The ThCOD concenfration was calculated for each sample as a function of

DOC, and matiire and clean values were averaged. The ratio of DOC/COD (2.25 ± 0.3)

was taken from average values for all of tiie compounds found in urine and was used to

calculate the ThCOD. Calculation of the ThCOD by customary methods requires an

60

Page 75: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

accurate chemical formula describing the compound(s) of interest. Due to the extreme

variability of urine, the approximate DOC/COD was calculated to estimate the ThCOD.

The response factor ratio is the ratio of the measured COD to the calculated ThCOD

(Equation 4.3), i.e.,

RFR = COD/ThCOD-f{COD} Equation 4.3.

where:

RFR = Response factor ratio [mg-COD/mg-ThCOD],

COD = Measured COD value [mg-COD/L] and

ThCOD-f{COD}= Theoretical COD value [mg-COD/L] (approximately 2.2).

a value of 1.0 would indicate a high correlation between DOC and COD data. When

compared to the mature feed tanks, the clean feed tanks did not show significant RFR

deviation from 1.0, due to the minimal biological activity in the clean tanks (see Figure

4.8). The clean feed tank values in Figure 4.8 signify a random RFR, implying that the

variation in the clean feed tank ThCOD and COD values are due to random noise in the

data. A decreasing trend, however, can be seen in the mature feed tank RFR. The noted

decrease in the average mature tank RFR (from 1.2 to 0.78) is an indication of relatively

high biological activity and DOC reduction, verifying data presented above.

61

Page 76: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

o o o Q O O

re a:

0) (A C

o Q. (A O

1.6

1.4

1,2 -ft

1,0 -I-

0,8

0,6

0,4 H

0,2

0.0

i

• Mature Feed Tanks O Clean Feed Tanks

20 40 120 140 60 80 100

Time [hours]

Figure 4.8. (COD/ThCOD) Response Factor Ratio

160

No sigiuficant effect of pH or nitrogen sparging was observed in any of the feed

tanks. Tests should be fiirther conducted to investigate the optimum, minimum and

maximum pH and phosphate buffer ranges for urea hydrolysis to occur in a fresh feed

solution at TTU. It was assumed that oxygen concentration would not affect urea

hydrolysis rates in the feed tank, and results supported this hypothesis. Ammonia

sfripping within the feed tanks was verified to be negligible. The maximum ammonia

concentration in the clean and dirty gas fraps was 1.32 mg-N/L and 1.57 mg-N/L,

respectively, which is below the MDL for the TA test. In addition, the TN concentration

did not significantly change in any of tiie feed tanks (ATN= 19.5 ± 8.0 mg-N/L). This

was expected due the value of the Henry's constant (5.6 X 10'^ or 0.75 atm) for ammonia

and the lack of mixing in tiie feed tanks (Metcalf and Eddy, 2002).

62

Page 77: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

The required time for complete urea hydrolysis was investigated upon completion

of the experiment. Urea hydrolysis was assumed to be complete when the TN-N

concenfration equaled the NH4-N concenfration because at this point relatively no org-N

exists. The clean tanks did not reach this condition during the 140 hour duration due to

the lack of enzymatic activity within the clean feed tanks. The time required to complete

urea hydrolysis in the mature feed tanks was 58 hours, 64 hours and 62 hours. Thus, it

can be assumed that any urea that does not break down within the 24 hour holding time

under normal operating conditions but will hydrolyze within the anaerobic packed bed

(HRT = 36.5 hours) where urease activity is assumed to be relatively high.

4.1.2.1 Urease Activity

Research concerning urea hydrolysis usually reports required times of completion

on the order of seconds (Fidaleo et al., 2003). Non-competitive inhibition refers to a

reduction m enzymatic activity which can be recovered if the vmdesired effect is reversed

(ie. addition of a acid to an alkaline feed tank). Fidaleo et al. (2003) analyzed the effect

of phosphate buffering and noted that pH has a significant effect on reaction rate, but a

limited effect on the Michaelis constant; implying that the effect of pH on urea hydrolysis

may be non-competitive. The hydrolytic activity in the feed tanks, however, was on the

order of days. The inhibition of enzymatic activity within each feed tank is due to a

combination of parameters (pH being among the most important) and the kinetics, which

are very complex, are outside the scope of this work. Webb (1966) and others noted pH-

dependent non-competitive urease inhibition by intermediates formed during urea

63

Page 78: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

hydrolysis; namely metiiylurea and oxyurea (NH2CONH2OH). Shaw and Raval (1961)

noted competitive urease inhibition below a pH of 6.5 and above a pH of 8.9, while

noncompetitive inhibition took place between pH values of 7.0 and 8.9. Webb (1966)

also noted significant pH-dependent thiourea effects on urease activity. Competitive

inhibition took place below a pH of 6.0 and small concentrations of thiourea

(approximately 5niM) were found to stimulate urease activity. Thiourea inhibhion is

prevented in the presence of cysteine, which is a non-essential amino acid in human

development. It can be seen from this brief discussion that fiirther research is required to

fiiUy understand the hydrolytic activity of the compounds in urine. To simplify the

analysis, it was assumed that only pH inhibition took place within the feed tanks (see

Figure 4.9).

10

9

8 -

7 -

6

5

4

3

2 -

1 •

0

V ^

Competitive Inhibition

P^on-Competidve Inhibition

Conyfetitive Inhibition

20 40

— I —

60 80 100 120 140 160 180

Time [hours]

Figure 4.9. Matiire and Clean Feed Tank Average pH Values

64

Page 79: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

It is hypotiiesized that the excessive time required (60 hours) to complete the

majority of tiie hydrolytic activity in the feed tanks was due to a combination of non­

competitive pH inhibition and enzyme concentration. Further research to understand this

hydrolytic activity is currently imder way at TTU.

4.1.2.2 Determination ofUseable DOC

The calculated urea concenfration was formulated by observing DOC and NH4

data. A brief explanation of the TOC analysis method is required to fully understand the

method of calculating the theoretical urea concentration. The TOC method of analysis

used at TTU is conducted on a Shimadzu TOC analyzer. Following sample collection,

samples are acidified with concentrated sulfuric acid to strip any inorganic carbon

(mamly HCO3 and CO3) remaining in solution. The Shimadzu analyzer then combusts

the sample and measures the remaining total carbon (TC) as CO2. The inorganic carbon

is assumed to be negligible following acidification/volatilization and the TC (as CO2)

measured is assumed to be equal to the TOC. The theoretical urea concentration in each

feed tank can be calculated by noting that one mole of CO2 is produced for every mole of

urea that is combusted within the Shimadzu TOC Analyzer (see Equation 2.5). The total

change in DOC (mmol-DOC/L) during the feed tank analysis is equal to the initial urea

concentration (mmol-N/L); assuming that only hydrolytic activity occurs within the feed

tank. Thus, tiie useable DOC is the difference between the measured DOC (mmol-C/L)

and the initial urea concenfration (mmol-C/L). The orgaruc nitrogen was calculated by

subtracting the summation of inorganic species (NH4-N + NOx-N) from the TN-N. The

65

Page 80: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

average fraction of organic nifrogen as urea (urea/org-N) was then calculated. This

parameter is exfremely important in determining the concentration of DOC within the

feed tank that can be utilized by heterofrophic bacteria within the system. The calculated

and measured fraction of urea/org-N for the mature feed tanks is presented below. The

plots represent average values taken from each feed tank. A complete determination of

all of the hydrolytic activity within the feed tank is outside the scope of this paper.

Compounds other than urea in the raw feed of potential interest are creatinine and

hippuric acid. It is assumed that the majority of the hydrolytic reactions in the feed tank

are due to urease activity.

1,0

0,9

0,8

0,7

0,6 -

0.5 -^

0.4 -

0,3

0,2

0,1

0,0

I • Calculated Urea/Org-N o Measured Urea/Org-N

-^T «

I

20 — I —

40 60 80 100 120 140

Time [hours]

160 180

Figure 4.10. Mature Feed Tank fu-N

Figure 4.10 indicates that the calculated fraction of organic nitrogen as urea (0.80)

is much higher tiian the measured value of fraction of organic nitrogen as urea (0.45).

66

Page 81: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

The final org-N value for each of the mature feed tanks was estimated to be

approximately zero, implying that after 140 hours the TN-N consisted only of NH4-N.

The average fraction of organic nifrogen as urea for the clean feed tanks is presented in

Figure 4.11. This value cannot be compared to tiie mature feed tanks due to the

heightened reduction of DOC v^thin tiie mature feed tanks. The mature feed tanks were

more enzymatically active than the clean feed tanks and it is possible that some aerobic

organic carbon oxidation took place in the mature feed tanks.

1.0

0,9

- , 0 , 8

0) 0,7

<8 0,6 I abi S

O) 0,5 -

o * . 0,4

o

.1 0-3 '•is

u 2 0,2 u.

0,1

0,0

• Calculated Urea/Org-N o Measured Urea/Org-N

0 20 40 60 80 100 120 140 160

Time [hours]

Figure 4.11. Clean Feed Tank Urea/Org-N Fraction

180

In the clean feed tanks the calculated fraction of organic nitrogen as urea (0.52)

and the measured value of fraction of organic nifrogen as urea (0.55) did not vary

significantly. The average fraction of organic nifrogen as urea for each of the feed tanks

is presented below.

67

Page 82: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table 4.5. Average Feed Tank Urea/Org-N Fraction

Tank

Dirty Tank #1

Dirty Tank #2

Dirty Tank #3

Clean Tank #1

Clean Tank #2

Clean Tank #3

Calculated fu-N

[-]

0.76 + 0.16

0.78 + 0.07

0.81+0.14

0.44 + 0.06

0.60 + 0.07

0.55 + 0.12

Measured fu-N

[-]

0.37 + 0.03

0.54 + 0.09

0.40 + 0.11

0.59 + 0.13

0.59 + 0.12

0.55 + 0.10

Table 4.5 indicates that further research should be conducted to accurately

estimate the average fraction of organic nifrogen as urea, aiding in determining the

average fraction of useable DOC in the raw feed. Further studies may include

investigation of hydrolytic activity inhibition by surfactant and/or humidity condensate

concentrations. The urine within the feed solution compromises an average of 75% of

the useable DOC, with the remaining 25% being contributed from the surfactant; the

urine and soap confributed an average of 233 mg-DOC/L and 78 mg-DOC/L,

respectively.

Three methods were used to determine the average concentration of useable DOC

witiiin a typical batch of raw feed. The amount of useable DOC was estimated based on

the observation that one mole of urea is equal to one mole of non-useable DOC. It was

assumed that the only organic compound that may not be utilized by heterotrophic

bacteria witiiin the feed was urea. Due to the lack of a complete understanding on the

68

Page 83: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

hydrolysis of otiier major compounds in urine (mainly creatinine and hippuric acid),

further research should be conducted to understand the fate of urine-compounds in

biological freatment systems of tiiis type. It was assumed that the calculated organic

nifrogen value for each tank was accurate because this value depends only on the NH4

and NOx data, which were accurate for each feed tank.

The "DOC Method" refers to the calculation of urea concentration by the methods

outiined in Section 4.1.2.b. This method is not accurate for the clean feed tanks due to

the lack of enzymatic activity; the hydrolysis in the clean feed tanks was assumed to be

"incomplete" due to the large presence of organic nitrogen (230 mg-N/L) following the

140 hour test. Thus, the DOC Method should not be utilized to estimate the useable DOC

for the clean feed tanks. The "70% fraction of organic nitrogen as urea (fu-N) Method"

was based on the fact that the average fraction of organic nitrogen as urea reported by

Putnam et al , (1988) was approximately 0.70. The initial urea concentration was then

determined by multiplying the initial calculated organic nitrogen concentration (mg-N/L)

by the fraction of organic nitrogen as urea (0.70). The "LC/MS Method" is based on urea

values measured at JSC by LC/MS analysis. The LC/MS resuhs for the first feed tank

were not as accurate as the other feed tanks. This may have been due to errors in sample

collection. The samples were frozen and shipped in a cooler to limit enzymatic activity

during the shipping process. The samples arrived at JSC two days late and were no

longer frozen, but it was assumed that the samples remained cold enough to limit

substantial enzymatic activity. Duplicate samples were analyzed following to tiie

publication of this paper to ensure tiie data from each feed tank was accurate. The three

69

Page 84: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

one metiiods are based on different sets of measured values and are independent of

anotiier. The LC/MS metiiod is a fimction of tiie measured urea value, the 70% method

a fimction of ammonia and NOx measured values and the DOC method is a fiinction of

tiie measured DOC. It was expected that the DOC method would overestimate the

concenfration due to combustion of other non-useable DOC compounds to CO2. A

comparison of tiie three fraction of organic nifrogen as urea methods is presented i

Figure 4.12.

IS

urea

m

o o o en

O O Q J j J2 eg (U u>

3

275

250

225

200

175 -

150 -

125

100

75

50

25

O

T

• LCMS Method O 70% fu-N Method • DOC Method

Tank No,

Figure 4.12. Determination ofUseable DOC Methods

It can be seen in Figure 4.12 that further research is required to accurately

determine the initial urea concentration, and therefore useable DOC, within the feed tanks

at TTU. Quantification of the wastestream is necessary in analyzing the biological

system and will aid in overall system optimization.

70

Page 85: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

4.1.3 Bioreactor System Comparison

At tiie time of tiiis submittal, tiie PB-AMR system had been in fiill operation for

280 days; tiie first 52 days were to allow reactor startup. The system was operated at

RRIO for 125 days and RR20 for 105 days. The fraction of alkalinity removed across the

AMR witiiin the PB-AMR system for recycle ratios of 10 and 20 was 0.93 ± 0.10 and

0.87 ±0.08, respectively. The alkalinity concerifrations in the infiuent and effluent of the

AMR were 465.0 ± 9.0 and 10.0 ± 15.0 mg-CaCOs/L, respectively.

The pH at each sampling point for RRIO and RR20 are presented in Figure 4.13.

The influent AMR pH was within the optimum pH range (7.3 - 8.0) reported for

nitrification (Metcalf and Eddy, 2002). The decrease in pH across the AMR for RRIO

and RR20 was 0.91 ± 0.30 and 0.66 ± 0.22, respectively. The decrease in pH is an

indication of nitrification as alkalinity is consuined by autofrophic microorganisms. The

bulk liquid pH in the AMR (6.57 + 0.61) may have been low enough to significantly

decrease the nifrification efficiency, but was above 6.66 for 135 of the days during

operation. Henze et al. (2000) stated that the pH within the biofilm may be lower than

the pH within the bulk liquid due to tiie deprotonating nature of the nitrification process,

so it is possible that pH could have reduced nittification efficiency within the system.

71

Page 86: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

RBcyde Ratio 10 RecydeRaiio20 RecydeRaOolO

'A

fiJm/^M^ INF EFF

AIVR AA/R INF EFF

Figure 4.13. PB-AMR pH Data

The AMR has been in operation for 430 days, the first 150 days were to allow

reactor moculation. During tiiis extended period of time, it is hypotiiesized that the

bioaugmentation of the microbial populations occurred. The bacteria acclimated to pH

and subsfrate levels considered to be "extreme" when compared to common literature

values. This is indicated by the extended duration of time the microbes within the PB

and AMR were able to freat the wastestream. For example, typical literature values

indicate pH inhibition below a value of 6.0, but the microbes within the AMR were able

to maintain acceptable treatment levels in the 5.0-8.23 range.

The variation of DOC in the influent is due to the high urine concentration in the

feed solution. The DOC concenfration in the influent of the AMR (31.4 mg-DOC/L) may

be low enough to hinder substantial heterofrophic growth within the AMR, assuming that

72

Page 87: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

the DOC entering tiie AMR consists of carbon species not easily degradable. To verify

tills assumption, influent and effluent samples were analyzed for biochemical oxygen

demand (BOD). The average influent and effluent BOD, COD and DOC values for the

AMR system are presented below. Samples were analyzed for BOD in the last month of

the experiment to quantify the biodegradability of tiie influent and effluent, while COD

and DOC values represent average values over the 280 days of operation.

Table 4.6. AMR BOD, COD and DOC Influent and Effluent Values

Sample

PB-AMR

Influent

PB-AMR

Effluent

BOD

[mg/L]

361

14

COD

[mg/L]

600

110

DOC

[mg/L]

315

20

BOD/COD

[-]

0.60

0.12

BOD/DOC

[-]

1.15

0.70

Typical untreated wastewater has a BOD/COD ratio of 0.45 and a BOD/TOC

ratio of 1.38, while the effluent of the PB-AMR system is similar to wastewater following

primary sedimentation (Metcalf and Eddy, 2002); therefore the wastesfream in the PB-

AMR system can be considered a high-sfrength wastestream. The RR20 and RRIO DOC

data for all sampling points is presented in Figure 4.14.

73

Page 88: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

100

•-r7o

D>SO

o *>

20

Recycle Ratio 20 Recycle Ratio 10

PB PB INF EFF

PB PB INF EFF

AMR AMR INF EFF

AMR AMR INF EFF

Figure 4.14. PB-AMR DOC Data

The TN in the feed tank is composed of organic nitrogen and any ammonium

hydrolyzed; NOx within the feed tank is negligible. The total nitrogen in the influent tank

varies from 320 to 830 mg-N/L. The TN removal efficiency was assumed to equal the

denifrification efficiency following the verification that ammonia stripping was

negligible. The TN data for all points within the system are presented in Figure 4.15.

74

Page 89: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

600

350

ffsoo

150

Recvple Ratio 20 Recycle Ratio 10 Recyi^le Ratio 20 Recycle Ratio 10

. &

PB PB INF EFF

PB PB INF EFF

Ah/R AIUR INF EFF

AIUR AIVR INF EFF

Figure 4.15. PB-AMR TN Data

The NOx-N concentration in the effluent of the AMR affects the denitrification

rate, and therefore, the overall system performance. The NOx-N in the system is 12.5% ±

22% nifrite (N02"-N) and 87.5% ± 22% nitrate (NO3-N). The graph indicating NOx-N

concenfration at each point within the system may be seen below (Figure 4.16). A t-test

(a factor=0.05) indicated there was no significant difference between the treatment

efficiency for the two recycle ratios.

75

Page 90: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

260

240

220

200

180

_J 160

z '140 O) ^ 1 2 0 X

O 100

80

60

40

20

0

R9cyc/e/feto20 Recycle Ratio 10 Recycle Ratio 20 Recycle Ratio 10

A£.

PB PB INF EFF

PB PB INF EFF

AIVR AIVR INF EFF

AIVR AIVR INF EFF

Figure 4.16. PB-AMR NOx-N Data

The nitrogen disfribution of the various species of inorganic nifrogen in the

effluent tank for RRIO and RR20 is presented in Figure 4.17. The bars represent the

relative concenfration of inorganic nifrogen in the effluent tank of the system, while the

dots represent the available TN in a fresh solution of feed for a given day. The average

concenfrations of NOx-N and NH4-N in the effluent tank were 175 and 188 mg-N/L,

respectively. The graph indicates that significant organic nitrogen does not exist within

the effluent tank. As witii the TTU-WRS, statistical analysis indicated that recycle ratio

had no significant effect on treatment performance.

76

Page 91: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

O FEEDTN ^ EFFN02

800 -| H M EFF N03 ^ EFFNH4

Z 600 I

O) £ 5 0 0

start Up Period

20 40 60 [ 80 ' 100

4.17. PB-AMR Effiuent

120 140 160 180 200 220 240

Timje [days]

Nitrogen Distribution

The pH, NH4, NOx-N, alkalinity, and EO data for the PB-AMR system indicate

the presence of a highly efficient biological sy;5tem. The overall efficiency of the system ! i;

is a function of available carbon and nitrogen in the feed and varies with the feed

concentration on a given day. The average feed C:N ratio during the experiment was

1.5:1. Typical high strength and low strength]wastesfreams contain C:N ratios of 4:1 and

3.5:1, respectively (Metcalf and Eddy, 2002); Implying that carbon typically dominates

untreated wastestreams. Thus, the early plane ;ary wastestream to be treated is very high

in nitrogen while deficient in carbon. This isja clear indication that removing all of the

nifrogen and carbon from the system by biological means would be a difficuh task given 1 !, I I '

the wastestream characteristics. H(j)lding kine ;ic rates constant, an approximate C:N ratio

77

Page 92: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

of 3.0:1 would be required to hypothetic^lly dehitrify all of the NOx within the system.

Altiiough 100% d<=nifrification is not the goal of the WRS design, this is a direct

indication of tiie fiictor limiting denifrification. Experimental values of alkalinity

consumption (7.2] g-CaCOs required/g-NH4-N oxidized) were comparable to common

values in tiie literature (7.14 g-CaCOs required/g-NH4-N oxidized) throughout the

experiment (Metcidf and Eddy, 2003). Therefore, the assumption can be made that

nifrification is carljon limited as 1.5 g-C^COa of additional alkalinity are required to

oxidize the 210 m J NH4-N/L remaining in the effluent.

To verify that tiie AMR is a highly robust gravity-independent nitrifying reactor,

results from the P3-AMR were compared to results from the TTU-WRS for RR20 and

RRIO. The per-pass HRT for the TR is 4 minutes, while the HRT for the AMR is 54

hours. This large difference in HRT makes direct comparison difficult. As mentioned

above, all freatineat data in the discussion is normalized to HRT to account for this large

variation. The decrease in pH across the nitrifying reactor within each system for recycle

ratios of 10 and 20 may be seen in Table 4.7.

Table 4.7. Nitrifying Reactor pH Decrease

System

AMR RRIO

AMRRR20

TRRRIO

TRRR20

Nifrifying Reactor

pH Decrease

0.98 + 0.31

0.62 ± 0.22

0.95 ± 0.56

0.62 ± 0.34

78

Page 93: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

The values in Table 4.8 represent the feed tank and effluent tank values for the

biblogical systems at TTU are all carbon limited. The

the organic carbon concentration in the waste stream,

limited by the alkalinity concentration in the waste

NH4-N concenfration in the effluent and relatively

concenfration. The TR and the AMR at TTU are both

concenfration =10.0 ± 08.0 mg-CaCOa/L).

two water recovery systems. The

denitrification process is limited by

while the nifrification process is

sfream. This is supported by the

low DOC/alkalinity effluent

alkalinity limited (effluent

high

Table 4.8. Average Influent and Effluent Values

System

PB-AMR RRIO

PB-AMR RR20

TTU-WRS RRIO

TTU-WRS RR20

(DOC)

[mg-DO(

331

311

415

465

nf

:/L]

(

[m

DOOefF

g-DOC/L]

20

26

1 54

93

(TN)i„f

[mg-N/L]

412

551

425

520

(TN)eif

[mg-N/L]

268

424

208

302

The percent nifrification, denifrification and DOC decrease across each of the

biological systems at TTU may be seen m Figure 4.18. The percent DOC removal for the

anaerobic packed bed within each system has been corrected for aerobic organic carbon

oxidation in the nitrifying reactor. :rhe averag^ amount of aerobic carbon oxidation i

within the TR and AMR (3.7% ± 0.8% and 1.5% ± 0.2%, respectively) was subfracted

from the total carbon oxidation to describe values accurately. The PB-AMR percent

nitrification for RR's 10 and 20 were (61% ± 15%) and (55% ± 20%). The maximum

79

Page 94: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

nifrification (61% ± 15%) achieved at TTl|

t-test statistical analysis indicated tbat the

score=0.66) is statistically significant, whi

critical t-value for the test was 2.68). The

would relieve the inorganic carbon-limitation

design of a WRS for applications in long-i

addition of excess chemicals. Research is I

reduce the carbon-limitation problem in I tiie

was accomplished by the AMR at RRIO. A

>B-AMR vs. TTU-WRS data for RR20 (z-

e the data for RRIO (z-score=4.64) is not (the

addition of external alkalinity into the system

problem, but one of NASA's goals in the

duration space missions is to minimize the

continuing to aid in understanding how to

WRS waste stream.

Percent Nitrification

• PB-AMR a TTU-WRS

Figure 4.18. PB-Al|lRys.

The high standard deviatiori in the

waste and the various factors affec^ng ni

Percent Denitrification

Percent TOC Removal

TTU-WRS System Performance

graphs above is due to the nature of the raw

nitrification and denitrification. The percent

80

Page 95: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

nifrification (aerobic) is affected by tiie urea concenfration, ammonia concentration, DO

concenfration, alkalinity and pH witiiin tiie AMR. The percent denifrification (anoxic) is

affected by tiie NOx concentration, organic carJDon concenfration, DO and pH. The PB-

AMR system was operated at RR20 for 125 days with a 55-day operation at steady state.

The TTU-WRS was operated at steady state for 200 days and was allowed to form a

much more active biofilm layer than the AMR. Following the formation of a mature

nifrifying biofilm in tiie AMR during the last 5,5 days of the RR20 test point, the

nifrification efficiency was 58% ± 13%. When the RR was decreased from 20 to 10 the

AMR achieved a nifrification efficiency 9% higher than the TR within the TTU-WRS

system.

Although the TR in the TTU-WRS system successfully nitrified the waste stream

to meet NASA's 50% nitrification requirement, the TR is drastically affected by

fiuctuations in loading rates and requires constant operator maintenance to avoid biomass

shedding events. Operation of the TTU-WRS at low recycle ratios requires forced

shedding events daily to avoid excessive buildup of biomass in the TR, which risks a

considerable loss of biofilm. Operation of the PB-AMR operation at RR5 did not

significantly affect the effluent suspende4 solids (ESS) concentration. The reduction in

nitrification efficiency in the TR system due to shedding events caused reductions in

system effluent quality and was tiiereforeinot considered to be a viable nifrifying reactor

for NASA's water recovery system.

81

Page 96: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

4.1.4 Equivalent System Mass

An ESM analysis was conducted to compare the TR and AMR pre-flight mass,

power requirements and stowage requirenients to quantify the system performance. The

pumps, pressure gages and gas-liquid sep^ators were neglected in the ESM analysis

because tiiey were identical for each of the two systems. The results of the ESM analysis

are presented below.

Table 4.9. ESM Analysis

System

AMR Reactor Vessel

(including water) Stainless steel pressure taps

Silicon membranes

Rubber mats

System

Tubular Reactor

Tubing

Mass-flow Confroller (2)

traps

Number of components

[No.]

1

150

150

2

Number of components

[Np.]

1

1

5

Dimensions

[L]

10 cm X 54.7 cm

4 inch X 1.5mm OD

0.17 cm ODX 125 cm

10 cm ODX 2 cm Total

Dimensions

[L]

3.16 mm ODX 15.5 m

Total

Total Working Mass

[g]

9270 1

25

640

160 10.3 kg

Total Working Mass

[g]

705

906.48

62 2.8 kg

82

Page 97: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Accurate records were not kept at TIU on estimated crew time requirements, but

researchers have indicated that the TR requited much more maintenance than the AMR I

(personal communication-Collins, 2004; Jackson, 2004; Morse, 2004). Although the

ESM analysis indicates that tiie TR is more ]'mass-ESM efficienf than the AMR, the TR

experienced frequent shedding events and required continual maintenance in order to i

sustain acceptable freatment efficiency levelis (Jackson et al., 2004; McLamore et al.,

2004; Morse et al., 2004). The AMR requir^ little to no maintenance and did not

experience any excessive sloughing; although some suspended cells will always escape

an attached growtii bioreactor, the TSS in the effiuent of the AMR (20 mg-TSS/L)

verifies that the amount of sloughing in the K M R was negligible. The specific surface

'' • 2 1

area available for biofilm grov^h in the AMR (0.83 m /m ) was higher than the specific

surface area available in the TR (0.41 m^/m^). Preliminary resuhs from loading studies

conducted at TTU indicated tiiat the AMR ii5 oyerdesigned by an approximate factor of

two. Thus, it can be stated that the volume of the AMR required to treat the given

wastesfream is only 1930 mL, reducihg tiie j^MR ESM to 5.2 kg.

1183'

Page 98: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

CHAPTER V

CONCLUSIONS

An ECLSS designed for long

require little to no in-flight maintenan|;e

freatment systems into current

capability of being a simple, robust

ready water recovery systems. The

required fransportation of potable water

incorporating biological systems into

reduce nifrogen and carbon species in

efficiency of the PPS.

Current research to develop

generated wastewater is ongoing at

compatible membrane-aerated bioreatttor

reactor within the biological portion

and Thermal Systems Division Water

original nitrifying reactor was highly

unpredictable and required constant

Although the TR is more mas^

indicated that tiie TR requfred much

not provide as much specific surface

(juration space exploration should be reliable and

The incorporation of biological wastewater

physio/chemical water recovery systems in space has the

system that meets NASA's requirements for flight-

potential reduction in cost due to the decrease in

from earth could be immense. The purpose of

he current physio/chemical treatment system is to

an attempt to prolong the life and improve the

robust bioreactors capable of treating spacecraft-

Tech University and other facilities. A gravity

was designed to replace the current nitrifying

o|f the water recovery system designed by the Crew

Team at NASA. ESM analysis indicated that the

;fficient in terms of payload weight (mass), but was

inaintenance.

efficient than the AMR, research at TTU has

rkore continued maintenance than the AMR and did

area for biofilm growtii as the AMR. The AMR

Texas

84

Page 99: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

required little to no maintenance, was

excessive sloughing. Research at TTU

given wastesfream and loading studies;

AMR. Results from tiie MABR at TTU

not subject to shock loading and did not experience

indicated tiiat the AMR was overdesigned for the

at TTU Will quantify the appropriate sizing of the

indicate that the MABR is a highly robust and

reactor with little to no required crew versatile gravity-compatible nitrifying

maintenance

The removal of carbon and nit|:ogen within the biological system is a function of

the wastesfream characteristics. Resekch has indicated that the wastestream does not

contain enough carbon for the nitroge i

within the system require both nifroge}n

of the biological system will require

concentrations of carbon compounds

complete removal of the nitrogenous

addition of other carbon-containing

Quantification of the transport

TTU indicated that tiie MABR is a

reactor. Although ESM analysis mdi

detailed analysis implied that the

The MABR was not subject to shock

efficiency at any point during the exi

to be completely removed, as microorganisms

and carbon for cell growth. Future optimization

djCtailed analysis of the types and relative

within a typical spacecraft wastestream. Near

^pecies within the biological system may require

sources of Waste onboard the spacecraft,

and transformation processes within the MABR at

candidate to replace the current nitrifying

that the TR is more efficient than the MABR,

[ was a much more versatile reactor than the TR.

loads or significant failure to maintain freatment

likely'

mdicated i

MABR

penment.

85

Page 100: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

REFERENCES

Bitton, Gabriel (1999). "Wastewater Microbiology, 2"'' Edition." Wiley-Liss Publishing

Co. (pp. 34-90). New York, NY.

Campbell, M., B. Finger, C. Verostico, K.R. Wines, G. Pariani and K.D. Pickering

(2003). Integrated Water Recovery System Test. Submitted to the International

Confemece on Environmental Systems. Society of Automotive Engineers.

#2003-01-2555.

Casey, E., B. Glennon, and G. Hamer (1999). f'Oxygen Mass Transfer Characteristics in

a Membrane-Aerated Biofilrti Reactdr." Chemical Engineering Department,

University College Dublin 4, Ireland. John Wiley & Sons, Inc.

Characklis, William G. and Kevin C. Marshall (1990). "Biofilms" Wiley Pubhshing Co.

New York, NY.

CoUms, 2004-personal communication.

Cussler, E.L. (1997). "Diffiision-Mass Transfer in Fluid Systems, 2""* Edition."

Cambridge University Press, (pp. 12-8$). New York, NY.

Edeen M.A., K.D. Pickering (1998). "Biological and Physical-Chemical Life Support

Systems Integration-Resuhs of the Lunar Mars Life Support Phase III Test."

Society of Automotive Engineers, Paper #9811708. I

i

Fidaleo, M. and R. Lavecchia (2003). Kinetic Stiidy of Enzymatic Urea Hydrolysis in tiie

pH Range 4-9." Chemistry arid Biocheinical Engineering. 17(4). 311-318.

86i;

Page 101: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Finger, B. L.N. Supra, L. DallBauman and K.D. Pickering (1999). "Development and

Testing of Membrane Biologickl Wastewater Processors." Submitted to the

International Confemece on Erivironmental Systems. Society of Automotive

Engineers. Paper #1999-01-1947.

Ho, CM., S.K. Tseng and Y.J. Chang (2002). "Simultaneous nitrification and

denifrification using an autotrophic membrane-immobilized biofilm reactor". The

Society for Applied Microbiology, Letiers in Applied Microbiology, vol. 35. pgs

481-485.

Jackson, A., K. Rainwater, A. Morse, D. Muiriead, T. Rector (2002). "Evaluation of

NASA's Advanced Life Support Integrated Water Recovery System for Non-

Optunal Conditions and Terrestrial Applications." NASA. j

Jackson, A. A. Morse, K. Rainwater, T. Anderson, T. Wiesner, (2004). "Evaluation of

NASA's Advanced Life Support Integrated Water Recovery System for Non-

Optimal Conditions and Terrestrial Applications." NASA.

McLamore, E., A. Morse, A. Jackson, K. Rainwater and D. Muirhead (2004).

"Development of a nitrifying bibreactbr for the treatment of wastewater in long

term space applications." Engineering, Construction, and Operations in

Challenging Environments. American Society of Civil Engineers. 9"' Earth &

Space. March 7-10, 2004. League City/Houston Texas.

McLamore, E., A. Morse, A. Jackson, A., and K. Rainwater (2003). "Incorporation of a

Membrane-Aerated Bioreactor in a Water Recovery System." Submitted to 34 ^

International Conference on Environmental Systems (ICES)." Doublefree Hotel,

Colorado Springs, Co. July 17-22,2004.

87

Page 102: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Metcalf & Eddy (2002). "Wastewater Engineering: Treatment and Reuse, (pp. 35-112).

McGraw Hill Higher Education.

Morse, A., A. Jackson, K. Rainwater and K.D. Pickering (2002). "Membrane Aerated

Reactors for tiie Treatinent of Simulated Wastewater." WEFTEC 2002. Chicago,

Illinois. September 28-October 03,2002.

: i

Morse, A., A. Jackson, A., K. Rainwater, an|i K. Pickering (2003). "Nitrification using a

Membrane-Aerated Biological R6actor." Submitted to 33''' International

Conference on Environmental Systems (ICES)." Bayshore Resort & Marina,

Vancouver, B.C., Canada. July 7-10, 2003.

Morse, A. and A., Jackson (2004). "Fate of Amoxicillin in two Water Reclamation

Systems". Submitted to Water, Air and Soil Pollution. In press.

Muirhead, D., T. Rector, A. Jackson, H. Keister, A. Morse, K. Rainwater and K.D.

Pickering (2003). "Performance of a small scale biological water recovery

system." Submitted to International Conference on Environmental Systems

(ICES)." Paper #2003-01-2557.

Rector, D., W.A. Jackson, K. Rainwater and K.D. Pickering (2003). "Determination of

the Fate and Behavior of a Coriimercial Surfactant in a Water Recycle System

(WRS). Submitted to Intematiohal Conference on Environmental Systems

(ICES)." Paper #2003-01-2558.

Rittman, Bruce E. and P.L. McCarty. (1994). "Environmental Biotechnology-Principles • • , , !

and Applications." McGraw Hill Publishing Co. Boston, MA.

Ungar, E.K., I. Chen and S.H. Chan (1998). "Selection of a gravity insensitive ground

88

Page 103: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

test fluid and test configuratioii to allow simulation of two-phase fiow in

microgravity." AIAA/ASME Joint Thermophysics and Heat Transfer

Conference. Albuquerque, NM; June 15-18.

Verostico, C. B. Finger, and B. Duffield (^000). "Design of a Post-Processor for a.

Biological Water Recovery System." Submitted to International Conference on

Envfronmental Systems (ICES)." Paper # OOICES-244.

Weisner, 2004-personal communication.

89

Page 104: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

APPENDIX A

PB-AMR PHYSIOLOGICAL DATA

90

Page 105: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table A. 1. Mass Transfer Experiment #1 Test Parameters

Volume^ Flowrate=F Flowrate=i=

Operating Pressure= Operating Pressure=f=

Henry's constant for 024= Surface Area per HF=

Total Membrane Surface Area= CL (0)=

Membrane Thickness= Membrane Thicknessr

3.865 2

3.6 0.2449^46116

41100 55.33333333

8300 1.12 0.09

0.0009

L cm'^3/min cm^3/min psi atm atm cm^2 cm''2 mg-DO/L cm m

(Metcalf & Eddy)

Table A.2. Mass Transfer Experinient #1 Test Resuhs

Time

[min] 0 60 120 180 480

CL

[mg-DO/L] 1.12 6.04 7.19 7.46 7.49

Change in Cone

[mmol-DO] -

0.594 0.138 0.032 0.003

Change in Time [min]

-60

i 60 60 300

Flux (J)

[riig-DO/min*m'^2] -

0.3818 0.0892 0.0209 0.0004

Change in Cone

[mg-DO/m^3] -

4920 1150 270 30

liO

[m/min]

7.76104E-05 7.76104E-05 7.76104E-05 1.55221E-05

Table A.3. Mass Transfer E fperiment #2 Test Parameters

Volun Flowra

ie=

te= Flowraite=

Operating Pressure= Operating Pressure=

Henry's constant for 02= Surface Area per HF=

Total Membrane Surface Areap CL (0)=

Membrane Thickneis= Membrane Thickness=

3;865

24

2.6 0.176918889

41100 55.33333333

8300 0.92

0.09 0.t)009

L cm'^3/min cm'^S/min psi atm atm cm'^l cm'^1 mg-DO/L cm m

(Metcalf & Eddy)

91

Page 106: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table A.4. Mass Transfer Experinient #2 Test Results

Time

[min] 0

30 60 90 120 150 180 240 300

CL

[mg-DO/L] 0.92 5.45 6.18 6.69 6.97 7.14 7.17 7.38 7.56

Change in Cone

[mmol-DO] -

0.547 0.088 0.061 0.033 0.020 0.003 0.025 0.021

Change in Tipiei [mm]

-30

io 30 30 30 30 60 60

Flux (J)

[mg-DO/min*m'^2] -

0.703 0.113 0.079 0.043 0.026 0.004 0.016 0.013

Change in Cone

[mg-DO/m^3] .

4530 730 510 280 170 30

210 180

Table A.5. Mass Transfer Experiment #3 Test Parameters

Volum Flowrai Flowrai

e= e= e=

Operating Pressufe= Operating Pressuire=

Henry's constant for 02= Surface Area per H!F=

Total Membrane Surface Area= CL (i))=

Membrane Thickness= Membrane Thickness=

3.865 24

2.6 0.17691$889

4il0& 55.33333333

^300 0.84 0.09

0.0009

L cm'^3/min cm^3/min psi atm atm cm^2 cm 2 mg-DO/L cm m

(Metcalf & Eddy)

ko

[m/mi

0.000 0.000 0.000 0.000 0.000 0.000 7.76E-7.76E-

Table A.6. Mass Trans

Time

[min] 0

30 60

210 300 420

CL

[mmol-DO/L] 0.84 5.04 6.56 7.12 7.22 7.32

fer Experin

Change Cone.

[mg-DO -

0.507 0.183 0.067 0.0120 0.0120

lent #3 Test Results

° ^

Change in Time

[min] -

30 30 150 90: 120

Flux (J)

[mg-DO/min*m'^2] -

0.65192 0.23593 0.01738 0.00517 0.00388

Change in Cone.

[mg-DO/m''3] -

4200 1520 560 100 100

I

[m/

0.0( 0.0( 3.i: 5.i: 3.8

92

Page 107: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table A.7. Mass Transfer Reactor Characteristics

Mean Hydraulic Diameter= Diffusivity of 0 2 in water (20 C)= Diffusivity of 0 2 in water (20 C)=

Henry's Constant (02)= Membrane Thickness=

0.00751 0.0000197 1.97E-09 3123600 0.0009

[m] |cm^2/sec] [m'^2/sec] cm-Hg m

Table A. 8. Mass Transfer !lembfane Resistances

Material

Polymer Dimethyl silicon rubber

Fluorosilicone Nitrile silicone Natural Rubber

Permeability [m'^3-m/m'^2-mi^-cmHgl

3.6E-10 6.6E-11 5UE-11 1.44E-11 1.26E-11

kM [m/min] 1.24944

0.229064 0.177004

0.0499776 0.0437304

1/kM [min/m]

0.800358561 4.365592149 5.64958984

20.00896402 22.86738745

Taken from Cote et al. (1989)

Table A.9. Mass Transfer Dimensionless Nimibers

Fiowrate

[mL/min] 2

24 24

Air Pressure

[psi] 3.6 2.6 2.6

ko :

[m/min] 7.761E-0.0001 0.0001

05 5 5

l/ko (overall) [min/m] 12884.86 6442.43 6442.43

1/kL (liquid) [sec/m]

12884.06 6441.63 6441.63

1/kM (membrane)

[sec/m] 0.80 0.80 0.80

Sh

[-1 2.96E+02 5.92E+02 5.92E+02

93

Page 108: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table A. 10, PB-AMR RRO Tracer Study Experimental Results

Time

[hours]

0 0

0.266667

0.716667

2.05

3.76

5.91

7.89

8.066667

9.383333

9.98 11.74

16 20

22.45 22.96667

23.9

24.93333

25.96667

26.61667

28.16667

28.48333 30.21667

30.45 31.06667

31.5

37 38

C/Co

[d-less]

0 0 0 0 0 0 0 0

0.123346

0.153309

0.1236

0.198

d.370988

0.509278 Q.631881

0.604513 Q.664127

0.622537

0.641857

0.671465

0.643496

0.689496 0.706677

0.697646

0.677467

0.713195

0.860087

0.87441

Time

[hours]

40 42 44 46

46.06667

46.85

48 48.05

49 49.8

51.16667

52.2

52.73333

53.41667

53.93333 61 62 63 64.5

65 66 67 67.5

68 68.5

69 69.5

C/Co

[d-less]

0.956907

0.921366

0.936741

0.926082

0.816452

0.799856

0.915436

0.81948

0.839112

0.835561

0.84862 0.856082

0.855169

0.827521 0.841485 0.870152

0.864569

0.87264

0.875128

0.880229

0.855606

0.857191 0.862798

0.867713

0.872393

0.876205

0.852078

94

Page 109: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table A. l l . PB-AMR Port Stiidy Bromjde Data

Time [hours]

0 7

26 31 61

Table A. 1

Time [hours]

0 7

26 31 61

Abe Feed Tank

Bromide [mg-Br/L] 123.8524 121.4659 118.5262 123.0005 119.2901

Abe Port 1 Bromide

[mg-Br/L] 32.4919 63.2405 87.2459 103.3539 121.2417

2. PB-AMR Port Study" Abe Feed

Tank Nitrite

[mg-N/L] 0

0

Abe Port 1 Nitrite

[mg-N/L] 8.3899 12.8561 7.307

10.3102 7.227

Abe Port 2 Bromide

[mg-Br/L] 4C 60 75 96

.6967

.9276

.8529

.9252 122.246

Nfitri

I

Abe Port 3 Bromide

]mg-Br/Ll 38.1336 28.3983 66.4392 91.6729 119.7022

Abe Eff Tank

Bromide [mg-Br/L]

54.0927 52.7639 60.5014 89.0378 105.5734

:e Data

Abe Port 2 ^ litrite

[liig-N/L] I 3.0089 15.6059 13.7911

1 5.6181 0

Abe Port 3 Nitrite

[mg-N/L] 20.4373 13.3699 17.6912 18.6652 4.1076

Abe Eff Tank

Nitrite ]mg-N/Ll 27.3447 20.6151 18.7843 17.8584 14.2596

Table A. 13. PB-AMR Port Stiidy Nitrate Data Abe Feed

Tank Abe Port 1 Abe Port 2 Abe Port 3 Abe Eff

Tank Time Nitrate Nitrate Nitrate Nitrate Nitrate

[hours] [mg-N/L] [mg-N/L] hrig-N/L] [mg-N/L] [mg-N/L] 2.0764 76.4182 120.8404 117.187 129.3026

146.66 166.0791 82.8398 176.5535 26 131.0411 149.7479 139.8491

31 151.4371 163.5029 173.4441 153.4162 174.9908

61 177.8698 254.7194 207.8023 203.7377 182.811

Table A. 14. PB-AMR Port Stiidy NO;

Time [hours]

0

26 31 61

Abe Feed Tank NOx

[mg-N/L] 2.0764

0

0 177.8698

Abe Port 1 NOx

fmg-N/L[ 84.8081 159.5161 138.3481 161.7473 261.9464

Data

Atie Port 2 NOx

[qig-N/L] 136.8493 179.685 163.539 179.121

207.8023

Abe Port 3

NOx [mg-N/L] 137.6243 96.2097 157.5403 192.1093 207.8453

Abe Eff Tank NOx

[mg-N/L] 156.6473 197.1686 172.2005 192.8492 197.0706

95

Page 110: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table A. 15.

Time [hours]

0 7 26 31 61

PB-AMR Porl Abe Feed

Tank TN

(mg-N/L] 245.6 280.1 250 280

290.2

Study TN I

Abe Port 1 TN

[mg-N/L] 247.8 278.55 251.45 280.75 284.6

Ab

^

)a ta

e Port 2 TN g-N/L] J34.7 78.95 :48.55 271.5 283.9

Abe Port 3 TN

[mg-N/L[ 219.75

293 233.9 276.45 284.6

Abe Eff ^_ Tank

TN [mg-N/L]

249.85 279.9

256.85 215.1 278.25

Table A. 16. PB-AMR Port Study N ifrification Data

Time [hours]

0 7

26 31 61

Abe Port 1 Nitrification

[%1 0.327897801 0.575030703

0.5475924 0.574990357 0.30901654

Abe Port 2 Nitrificatioi

[%] 0.5931307

0.64560871 0.659956 0.670075

0.12485354!

I

)

Abe Port 3 Nitrification

[%1 0.657157573 0.297428418

0.6945612 0.698783214 0.122589593

Abe Eff Tank

Nitrification

[%] 0.612055782 0.704636201

0.661402 0.704104286 0.107342522

Table A. 17. PB-AMR Port Study Demfrification Data

Time jhours]

0

26 31 61

Abe Port 1 Denitrification

J%L -0.008957655

0.005533738

-0.0058

-0.002678571 0.019297037

Abe Port 2 Denitrification

J%1 0.044381107

0.004105677

0.0058

0.030357143 0.021709166

Abe Port 3 Denitrification

_[%; 0.105252443 -0.04605498

0.0644 0.012678571 0.019297037

Abe Eff Tank

Denitrification

J%] -0.01730456 0.000714031

-0.0274

0.015357143

0.041178498

96

Page 111: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table A. 18. P B - A M R H y d r o d y n a m

time

0.000

0.267

0.717

2.050

3.760

5.910

7.890

12.000

16.000

20.000

22.450

23.900

24.933

25.967

26.617

28.167

30.217

31.500

37.000

38.000

40,000

42.000

44.000

46.000

48.000

49.000

49.800

51.167

52.200

52.733

53.417

53.933

61.000

62.000

63.000

64.500

65.000

66.000

67.000

67.500

68.000

t/T

0.000

0.005

0.013

0.038

0.070

0.109

0.146

0.222

0.296

0.370

0.416

0.443

0.462

0.481

0.493

0.522

0.560

0.583

0.685

0.704

0.741

0.778

0.815

0.852

0.889

0.907

0.922

0.948

0.967

0.977

0.989

0.999

1.130

1.148

1.167

1.194

1.204

1.222

1.241;

1.250

1.259

;(C/Co)exp

0.000

0.000

0.000

0.000

0.000

0.000

0.000

0.000

0.371

0.509

0.632

0.664

0.623

0.642

0.671

0.643

0.707

0.713

0.860

0.874

0.957

0.921

0.937

0.926

0.915

0.839

0.836

0.849

0.856

0.855

0.828

0.841

0.870

0.865

0.873

0.875

0.880

0.856

0.857

0.863

0.868

(C/cJ 1

1

u 1

1.

ill i |

iJ i |

ll 1

M 1' 1

1

i \ 1

i 1

i (

1 (

K 1(

1(

i( i<

)'( 1 (

i (

r( ];(

; :(

;i(

\M i: ; i

[i

: '.>

; J

.'

1

1

j

c Analy 1 :

!

itheoii i:,3' '

i:i3,,|:

i l 3 ' : M3 ) 1 3 ' : I, ) 3 : i ' !

)l3!i .1

)13| ii )13

)13

)13

)|13

)|l3i

):i3:'

)il3'

13' .

j i3:: : i i3ii :

in m | l3| .

)13 ,

)13 li

H: Hi: i i i ir 1 W : : •

\lt' \\i\ )13

Hjii ; )l3!ii i \u: )U li

1 • 1 ,

)13 )1^

)13

)13

313

)13

m \ •'

i P 9

3is

(C/Co)theo-2

0.040

0.041

: i 0.043

0.051

0.061

0.078

0.095

0.142

, 0.203

i 0.279

1 i 0.333

0.367

1 0.393

0.419

0.437

1 i 0.478

0.535

: 0.571

: 0.727

; 0.754

: i 0.805

0.853

. ; 0.895

i 0.932

0.961

i 0.973

0.981

, 0.991

0.996

0.998

j 1.000

1.000

0.947

0.932

i 0.914

0.885

1

7

0.875

0.853

0.830

0.818

0.805

(C/Co)theo

0.040

0.042

0.044

0.051

0.062

0.079

0.097

0.144

0.205

0.282

0.337

0.372

0.398

0.425

0.442

0.485

0.542

0.579

0.736

0.763

0.816

0.864

0.907

0.944

0.974

0.986

0.994

1.004

1.010

1.011

1.013

1.013

0.960

0.944

0.926

0.897

0.886

0.864

0.841

0.828

0.816

Mean Square Error

0,002

0.002

0,002

0,003

0,004

0,006

0,009

0,021

0,027

0,052

0,087

0,085

0,050

0,047

0,053

0,025

0,027

0,018

0,015

0,012

0,020

0,003

0,001

0,000

0,003

0,021

0,025

0,024

0,024

0.024

0.034

0,029

0,008

0,006

0.003

0,000

0.000

0.000

0.000

0,001

0,003

Sum of Error

1,00

Page 112: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table A. 19. PB-AlJlR

Q= A= v= L= D= d=

Pe=

0.ii;i67 78

34 ci6

i^droldynamic Dimensionles^ Numbers

500d h

0. )002 7Q0Q

Em

t?2|8§4r

cm'^3/sec cm' 2 cm/sec

cm cm'^2/sec

98

Page 113: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

WpEriDilxB

PB-AHl B|OLpG|CAL DATA

^9

Page 114: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table B.l

Average

St. Dev.

Maximum

Minimum

. PB-AMl

Date

7/28/2003

7/29/2003

7/30/2003

7/31/2003

8/1/2003

8/2/2003

8/3/2003

8/4/2003

8/5/2003

8/6/2003

8/7/2003

8/8/2003

8/9/2003

8/10/2003

8/11/2003

8/12/2003

8/13/2003

8/14/2003

8/15/2003

8/16/2003

8/17/2003

8/18/2003

8/19/2003

8/20/2003

8/21/2003

8/22/2003

8/23/2003

8/24/2003

8/25/2003

8/26/2003

8/27/2003

8/28/2003

8/29/2003

8/30/2003

8/31/2003

9/1/2003

9/2/2003

9/3/2003

9/4/2003

9/5/2003

9/6/2003

9/7/2003

IpHData

Day No, [

1

2

3

4 1 5 i

6 !

7

8

9 10

11 .1 12 i

13 1

14

15 i

16

17

18 1

19

20

21

22 i

23

24

25

26

27

28

29

30

31 ;l

32 I 33

3" 1 35

36 ,

37 1

38 ll 39 1 40

41 '

42 1

:i

ATJOL

ledTink!

pr -7.168

0.i7i

9.^!

S.^' '.

7,82

8J5(

8,3(1

8,6i

7!2[

1

8 si; , 7 98

8 14

7 14

8i81

1 1

1 i 1 i

1 1 1

^ 1 ^ 5 '••

• 1

j

1

1

• 1 j

^ , 5 3

8.H

i.U il7 8.i7, 8,b ' 8,(19 '•

8,io

ih \!h: i7,|7

^,^2

' •

6^9

i '

6 66 ;

'i 1 0 ii

!

!PB

Ir fluent

1 ]

1

1

1

i 1

~] "n

1 [

i

1

1" i

0

pH

16.61

0.85

8.23

0.37

16.84

7,07

6.49

6,87

6.65

7.04

7,34

7,32

6,73

6,85

6,79

5,90

6,80

6.93

6,70

6,55

6,01

6,37

6,19

6,69

6,65

6,08

6,14

6.53

5.71

PB Effluent/

AMR Influent

pH

7.19

0.70

8.91

4.25

8,43

8,35

7.58

8,43

8.67

8,54

8,46

8,41

8,56

8,85

8,86

8.57

8.68

871

7,86

8,71

7,81

7.82

7.84

7,93

7,73

7,66

7,88

8,23

8.39

A I U R

Effluent

|H 6^61

m : 8.27'

dioo 6*79

too 6.40

^:78

^62

| , 9 5

131 | . 2 8

iii lis ll f i'

^,69

1: 1 P 1,: |i

i

c 1 5,87

fc,70 16-91 fe.60 II5.43 :5,88

6.^5

6.Q7

6.59

16.60

6.62

6.10

16.52

5.66

[

1

AMR Effluent

Tank

pH 6.57

0.61

8.83

5.03

6.93

6.67

6.31

6.76

6.62

6.61

7,19

6,52

7,82

6.77

7.31

6.40

6,38

6,01

6.12

5.93

5.78

6,12

5,38

5,89

5,86

5.65

5.87

6.03

5.98

Page 115: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

. continue

9/9/2003

9/10/2003

9/11/2003

9/12/2003

9/13/2003

9/14/2003

9/15/2003

9/16/2003

9/17/2003

9/18/2003

9/19/2003

9/20/2003

9/21/2003

9/22/2003

9/23/2003

9/24/2003

9/25/2003

9/26/2003

9/27/2003

9/28/2003

9/29/2003

9/30/2003

10/1/2003

10/2/2003

10/3/2003

10/4/2003

10/5/2003

10/6/2003

10/7/2003

10/8/2003

10/9/2003

10/10/2003

10/11/2003

10/12/2003

10/13/2003

10/14/2003

10/15/2003

10/16/2003

10/17/2003

10/18/2003

10/19/2003

10/20/2003

10/21/2003

10/22/2003

10/23/2003

10/24/2003

10/25/2003

10/26/2003

10/27/2003

10/28/2003

d

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66 1 67

68 1 69

70

71

72

73 III 74

75

76

77

78 1 79 1 80 1 81

82

83

84 li 85 {

86 T 87 ,1

88

89

90

91 92

^3

ilf jij ff'iP

1 7.^9

1 ^-T

1 < + 'f !| •.:io

1 - \\« ll :ii 't 1 0 An

'f T

j.ls f-F r r

1 1 p|i

K 4

Kfo 1 7.?2

f ' f 11 11!

P f

fp i slU 1 7|:80 1 7|!29 1 '71162

6|49

650

1 1 •fi57

7177

•e|93

1 6[99 491 1 i

7l,42 1.73

101

6,19

i 0.37 '

7.36

6,34

6.59

6.28

7.33

6.40

6.96

7,39

6,24

1 6,29 1

6,53

6,25

6,17

6.03

6,24

6,35

6,26

6,25

; 6,75

6,30

6,34

6.26

6.62

6.50

6.44

7,05

6,77

6,72

6,88

6.99

7,39

6,09

' 7,83

6.84

7,42

7,06

7.08

6.99

7.74

7,12

7,49 8,32

7,48

6,92

7,08

7,10

6,80

6.61

6,88

6.93

6,95

6.97

7,13

6,84

6,99

6,81

7,20

7,42

7,18

7.93

7.46

7,13

7,49

6,98

8,00

6.68

6.78

,'

613 ;

7.38 j r

6,i4 6.4 6.24 7.34 6.i4 6.^ 7,34

6,^b 6.24

6,

6

6.

6.

6.

6

6

6,

6

6

6

6

6

6

6.

7,

6

t

50 r6 i:i

02

io i& 2il 25

67 24

24

18

59

45 44

98

78

67

6.88

1 $.99

7-41 I

h: 6:03 7,79 1 1

j

5.97

6.55

6.12

6.96

6.57

6.30

7,32

8.30

6,80

7,42

6,13

6,11

6.31

6.20

6.02

6,15

6,09

6,22

6,18

6.21

7.13

6.14

6.20

6,12

6.26

6.52

6.46

6,96

6,78

6,62

6,72

6,97

7,65

5,77

6,53

Page 116: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

. continuec

10/29/2003

10/30/2003

10/31/2003

11/1/2003

11/2/2003

11/3/2003

11/4/2003

11/5/2003

11/6/2003

11/7/2003

11/8/2003

11/9/2003

11/10/2003

11/11/2003

11/12/2003

11/13/2003

11/14/2003

11/15/2003

11/16/2003

11/17/2003

11/18/2003

11/19/2003

11/20/2003

11/21/2003

11/22/2003

11/23/2003

11/24/2003

11/25/2003

11/26/2003

11/27/2003

11/28/2003

11/29/2003

11/30/2003

12/1/2003

12/2/2003

12/3/2003

12/4/2003

12/5/2003

12/6/2003

12/7/2003

12/8/2003

12/9/2003

12/10/2003

12/11/2003

12/12/2003

12/13/2003

12/14/2003

12/15/2003

12/16/2003

12/17/2003

j

94 '

95 ;

96

97

98

99

100

101 '

102

103

104

105

106 i

107 i

108 !

109

110

111

112 !

113

114 !,

115 '•

116 '•;

117 l|i|

118 jii 119 ii

120 1 i1 121 h 122 11 1 123 1!1 124 1 f i 125 I'll 126 ll 127 T 128 i :

129 ill 130 [i 131 :

132 T' r;

133 ir 134 Tji

135 M

136 Til i 137 "Pi 138 |l :

139 11; 140 ll ^ 141 1 i

142 1 143 i i

j

l[

• • • '

sit •

8 95" 1

1 7 0^

6 8^

7ii 7,si 8.47

_tL 6r96 7.06

6^8^ 6.48

7 ^

8,36

7.817

• 1 %\

m i l l i [iji

It ' m •I III • 1

ilin jiiii III i ::'.|

lis 1 !•!

7.24 J :ii<: 7,lt Ji II

iiic I ' l

55(.

5 2!'

JlS'' •'\

I . J • l i !

'•Mi\

i i i i i ill ! i : i l ^

1 ' 10 •

15.72

7,37

6,48

6,25

6.49

6.65

16,57

1 6.17

6.44

5,80

1 6,09

1

6,48

7.03

6.44

6.96

6.30

6.52

j

1 5,69

6,65

7,49

7,69

1 7,11

6,68

6,55

7,24

6,75

1

1

1

2!

5.97

6.48

6,04

6,92

6,96

7,19

7.07

6,38

7,11

6,30

6,68

4,25

7.87

7.07

7.93

5,60

6.98

5.86

7,08

7,76

8.11

6,73

6,99

7,13

7,95

7,29

5.57

7.29

6.45

6,22

6,43

6,61

6.48

6.13

6.41

5,75

6.07

6.44

6.97

6.37

6,87

6.26

6.46

5.61

6.62

7.57

7.70

7,03

6,59

6,47

7.18

6,67

6,51

6,54

5,65

6,11

6.41

6,43

6.27

6,59

6,30

6.72

5,99

6.27

6.86

6.56

6.81

6.20

6.52

6.30

7.51

8.80

6.34

7,14

6,21

6.83

6.60

Page 117: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

. continued

12/20/2003

12/21/2003

12/22/2003

12/23/2003

12/24/2003

12/25/2003

12/26/2003

12/27/2003

12/28/2003

12/29/2003

12/30/2003

12/31/2003

1/1/2004

1/2/2004

1/3/2004

1/4/2004

1/5/2004

1/6/2004

1/7/2004

1/8/2004

1/9/2004

1/10/2004

1/11/2004

1/12/2004

1/13/2004

1/14/2004

1/15/2004

1/16/2004

1/17/2004

1/18/2004

1/19/2004

1/20/2004

1/21/2004

1/22/2004

1/23/2004

1/24/2004

1/25/2004

1/26/2004

1/27/2004

1/28/2004

1/29/2004

1/30/2004

1/31/2004

2/1/2004

2/2/2004

2/3/2004

2/4/2004

2/5/2004

2/6/2004

2/7/2004

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

Pi 1; , ::

,

' 1

1

1 •

., 1

'. 8,C

8.'!

f-. 1 :• 7 . f li ;,

:

ll 6,ii

'i k' ; 1

il ,8-'^

i i ' iJ i "in '.'••'i M

1 i

" !' 7:1

1

l,i 7 : '

i'i 8 i ' i' 1 !• '

i '&:.

: kl :

ll [7 ; |

1' % ",: si:

ir 7i' i i . 7I '1 ! l

ii 7i.

ii 7I !;

1

!

j .

i '

6

1

i 1

21 li

6 Ci

C'i

ill

.1

Sll

9 7

7i

i6 1

.h hi

!| •'

i'i •

57

1(

1

1

6,39

6.85

7,70

6.73

5.69

6.50

6,96

7.58

6.84

6,25

5,86

7,85

6,31

6,55

6,15 j

;

)3

8,03

6,31

6,98

7,33

6,79

6,46

6,68

7,20

8,10

7,27

6.11

6.98

7,81

8,25

7,58

6.77

7,18

8,70

6,96

7,49

6,95

6,81

7,09

7,97

8,35

7.80

7.94

6,31

6,76

7.66

6,69

5,67

6,49

6,87

7,52

6.79

6.17

5.67

7.79

6,11

6.38

5.97

7:99

6:12

6:88

7:28

6,69

6.35

6,75

6,54

7,68

7,18

6.53

6.36

6.76

7.21

8.83

5.81

6,01

7,28

5.87

6.07

6.26

6.49

6,50

6.43

6.80

6,99

5.95

Page 118: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

. continued

2/8/2004

2/9/2004

2/10/2004

2/11/2004

2/12/2004

2/13/2004

2/14/2004

2/15/2004

2/16/2004

2/17/2004

2/18/2004

2/19/2004

2/20/2004

2/21/2004

2/22/2004

2/23/2004

2/24/2004

2/25/2004

2/26/2004

2/27/2004

2/28/2004

2/29/2004

3/1/2004

3/2/2004

3/3/2004

3/4/2004

3/5/2004

3/6/2004

3/7/2004

3/8/2004

3/9/2004

3/10/2004

3/11/2004

3/12/2004

3/13/2004

3/14/2004

3/15/2004

3/16/2004

3/17/2004

3/18/2004

3/19/2004

3/20/2004

3/21/2004

3/22/2004

3/23/2004

3/24/2004

3/25/2004

3/26/2004

3/27/2004

3/28/2004

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

7.5

1

8.0

8.7

7.6

^4

7.8

7,6

i 7,3

1 8.7

1 7.7

6.5

1 l.t

i.(

:.i

i.: '; i I ,:',; •

1 j ;

1 [ • ,

'"' i 1 '

'

i

i i I 1 1

i\

5

1 '!

) i! 3

1 :l s i i ll } T 8

1

1 8' :[ 1

5 [ [

2i ' : 2I ' :

, i 1

7 1 11. l ! 1'

I 1 i 1:

|i I '1;

1 ! \' 1 1

• ' i : 1

, 1

1 1

:

1

'• t

1

i 1 5,70

6.23

6.95

7.33

6,59

6,15

6,52

6.69

6,91

8,23

1 6,75

6,49 t

8.07

^ 5,26

j 6,91

!

" 7,19

8,21

!

1

t

i

6,79

6,58

7,92

8,01

7,10

6,58

7.86 7,94

8.10

6.89

7.62

7,39

8,91

5.89

7.36

7,81

8,57

5,52

6,05

6,77

7,29

6,40

5,99

6,4o 6.62

6.73

8.27

6.73

6.37

7,91

s.Ho 6,78

7.15

8.15

5.03

6,50

6,21

6,47

6,97

6,76

6,17

6.38

6.44

6,64

6,38

5.96

8.01

5.64

6,54

6,73

7.81

Page 119: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table B.2

Average

St. Dev.

Maximum

Minimum

P5-AM]

Date

7/28/2003

7/^9/2003

7/^0/2003

7/31/2003

8/1/2003

8/2/2003

8/3/2003

8/4/2003

8/5/2003

8/6/2003

8/7/2003

8/8/2003

8/9/2003

8/10/2003

8/11/2003

8/12/2003

8/13/2003

8/14/2003

8/15/2003

8/16/2003

8/17/2003

8/18/2003

8/19/2003

8/20/2003

8tal/2003

8^22/2003

8/23/2003

8/24/2003

8/25/2003

8/26/2003

8/27/2003

8/28/2003

8/29/2003

8/30/2003

8/31/2003

9/1/2003

9/2/2003

9/3/2003

9/4/2003

9/5/2003

9/6/2003

R. TN Data

Day No.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

/

Fie

fm '. ^

1

s

1

.

I

i : . 1

! ; '

j

• •

l i <

; (

;

i

v l i

LMR

d|ran)c

Tl , ,

5-N/L]

98.5

6^.5

54.0 )3J.4 '•

, 1 2).0 1

90.0

: 30.0 i

'

': i i6p!o 1

' '. 1 '

r ' i

' . 1;

'. '•'••. 't

:'i

l i ' 1 '••'•

i

ilO.O: ii

:. . ,il iso.o| |i sso.o, il i<0,0 1

j('d,o' i! 580,0, i J •0,0, ii

"^0,0' 1 !-0,0 1 356.0i ii 590.0 'i

• ^ j

. ' i .' i ll 1;:'

'•i 1

: i f 5

1

PB

Influent

TN

|mg-N/L]

388.8

140.1

650.0

29.6

250.5

274.7

1 1 ( 1 i

PB Effluent/

AMR Influent

TN

[mg-N/L]

365.2

132.1

590.0

106.7

180,0

270,0

AMR

Effluent

TN

[mg-N/L]

38i7.0

138.7

660.0

108.8

250,0

280.0

AMR Effluent

Tank

TN

[mg-N/Ll

367.2

146.5

750.0

108.7

170.0

160.0

450.0

440.0

490.0

360,0

390.0

430.0

390,0

300,0

270,0

250.0

Page 120: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

. continue

9/8/2003

9/9/2003

9/10/2003

9/11/2003

9/12/2003

9/13/2003

9/14/2003

9/15/2003

9/16/2003

9/17/2003

9/18/2003

9/19/2003

9/20/2003

9/21/2003

9/22/2003

9/23/2003

9/24/2003

9/25/2003

9/26/2003

9/27/2003

9/28/2003

9/29/2003

9/30/2003

10/1/2003

10/2/2003

10/3/2003

10/4/2003

10/5/2003

10/6/2003

10/7/2003

10/8/2003

10/9/2003

10/10/2003

10/11/2003

10/12/2003

10/13/2003

10/14/2003

10/15/2003

10/16/2003

10/17/2003

10/18/2003

10/19/2003

10/20/2003

10/21/2003

10/22/2003

10/23/2003

10/24/2003

10/25/2003

10/26/2003

10/27/2003

d

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

1

( :

'

i

•'

4

1

60,0

90,0

lj),0

90,0

2j).0

8?.0

j

45,0

1 6i|).o :! 5

5 5

. 4

5

4

5

4

7

6

6

4

8b,0

ojo.o

f 1

ijo.o 20,0

20,0

60,0

;

25,0

60.0

65,0

io.o ! •

Io.o ^0,0

1' 1 1 io.o

,1

1

i

1

583,7

256,5

529,1

437.5

470,7

650.0

629.1

566.7

424.2

574,2

i

1 1

378,9

426.9

i

483.6

416,6

560,0

240,0

540.0

430.0

540.0

540.0

410,0

580.0

345,0

405,0

460,0

1

5J0.O

250.0

51 0.0

430.0

41 0.0

ZJ \\

6^0.0

( 6|o,0

t 5|j'0,0

1 4h ,0

1 1

5|o.O

^po.o

4I25.0

1 4^5.0 1 ll

410.0 1 ^15,0

610.0

230,0

530.0

400,0

520.0

750.0

680.0

340.0

640.0

365.0

400.0

390.0

460.0

320,0

410.0

455.0

430.0

550.0

480.0

410.0

10^

Page 121: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

. continued

10/29/2003

10/30/2003

10/31/2003

11/1/2003

11/2/2003

11/3/2003

11/4/2003

11/5/2003

11/6/2003

11/7/2003

11/8/2003

11/9/2003

11/10/2003

11/11/2003

11/12/2003

11/13/2003

11/14/2003

11/15/2003

11/16/2003

11/17/2003

11/18/2003

11/19/2003

11/20/2003

11/21/2003

11/22/2003

11/23/2003

11/24/2003

11/25/2003

11/26/2003

11/27/2003

11/28/2003

11/29/2003

11/30/2003

12/1/2003

12/2/2003

12/3/2003

12/4/2003

12/5/2003

12/6/2003

12/7/2003

12/8/2003

12/9/2003

12/10/2003

12/11/2003

12/12/2003

12/13/2003

12/14/2003

12/15/2003

12/16/2003

12/17/2003

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

' . :' il

''

1, 1,1

il!

:

'

'.! 1

1

i.

, r

740

780

320

580

450

580

57C

52(

72(

67(

515

49C

56(

36(

83(

75(

64

38

69

51

0

0

0

0

0

0

.0

,0

,0

,0

,0

,0

1,0

|l-0

).o ),0

',4

3.0

1,0

r

1( )7

541,7

494,2

637,2

476,7

415,1

460,3

515,0

512,3

235,7

239,2

419,4

500,0

490.0

420.0

470,0

420,0

490.0

590.0

470,0

222,9

210.7

187.1

530.0

490.0

640,0

500.0

410.0

450,0

515.0

510,0

210,5

219.2

415.0

730.0

240.0

570.0

430,0

500,0

480.0

220.0

170.0

400.0

245.1

470,0

520.0

520.0

400.0

690.0

313.5

230.4

440.0

183.0

168.0

Page 122: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table B.2. continued

12/19/2003

12/20/2003

12/21/2003

12/22/2003

12/23/2003

12/24/2003

12/25/2003

12/26/2003

12/27/2003

12/28/2003

12/29/2003

12/30/2003

12/31/2003

1/1/2004

1/2/2004

1/3/2004

1/4/2004

1/5/2004

1/6/2004

1/7/2004

1/8/2004

1/9/2004

1/10/2004

1/11/2004

1/12/2004

1/13/2004

1/14/2004

1/15/2004

1/16/2004

1/17/2004

1/18/2004

1/19/2004

1/20/2004

1/21/2004

1/22/2004

1/23/2004

1/24/2004

1/25/2004

1/26/2004

1/27/2004

1/28/2004

1/29/2004

1/30/2004

1/31/2004

2/1/2004

2/2/2004

2/3/2004

2/4/2004

2/5/2004

2/6/2004

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

790 0

565 0

580 0

59;

55;

45(

38C

80C

37C

53C ,

551

501

44:

406

4i:.

247

):o

i

|.o.

.0

,0

.0

.0

,0

.8

,4

,6

,5

,6

0 j

38^,7

34^.4 ,

426.7

441.3

361

420

0

4

34^.0 (

j

1 \0i

451,6

11455.4

499,0

1

i II 504,4

1

i

i i 1483,5

469,1

i 303,7

331,9

1:473,8 !j

1;

1

279.6

326,0

232,1

}!

203,8

445,0

490,0

490.0

470,0

450,0

310,0

350,0

560,0

288.3

318,7

218,7

435,0

450 0

495.0

500.0

480.0

470.0

300,0

330,0

470,0

271,4

316,6

220,4

198 9

465 0

505 0

510.0

475,0

460,0

310,0

440,0

400,0

335.0

466.6

406.6

356.6

299.1

325.8

213.2

286.3

269,3

309.0

321,2

261,5

301.3

213.1

Page 123: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

. continue(

2/7/2004

2/8/2004

2/9/2004

2/10/2004

2/11/2004

2/12/2004

2/13/2004

2/14/2004

2/15/2004

2/16/2004

2/17/2004

2/18/2004

2/19/2004

2/20/2004

2/21/2004

2/22/2004

2/23/2004

2/24/2004

2/25/2004

2/26/2004

2/27/2004

2/28/2004

2/29/2004

3/1/2004

3/2/2004

3/3/2004

3/4/2004

3/5/2004

3/6/2004

3/7/2004

3/8/2004

3/9/2004

3/10/2004

3/11/2004

3/12/2004

3/13/2004

3/14/2004

3/15/2004

3/16/2004

3/17/2004

3/18/2004

3/19/2004

3/20/2004

3/21/2004

3/22/2004

3/23/2004

3/24/2004

3/25/2004

3/26/2004

3/27/2004

1

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

!, 1

3

, 3

1

1 «

1 3 •3

3

j <

'' (

il 'li

l i •

'I: •

i.

;

^ [

ill 1

1

,

'

'

i I I

i

24 2

38 1

69 4

33 0,

8815

4312

4815

881:6

92|,5

09,5

87,8

li.i

Ml

i 1 r i r i : l ; . i l l 1

1,1

;i

10 9

214,4

287,0

232.6

350.6

!310.3

256.4

364.3

403,3

1131,1

[

203,3

288,5

224,6

323,9

301,3

249,2

330,5

367.8

117,7

203,5

284.9

219.0

332.5

302,6

247,8

331.6

372.8

116.5

208,8

288.6

219.1

214.0

290.4

254.2

279.6

253.0

275.4

372.6

305.6

136.0

Page 124: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table B.3

Average

St. Dev.

Maximum

Minimum

PB-AMl

Date

7/28/2003

7/29/2003

7/30/2003

7/31/2003

8/1/2003

8/2/2003

8/3/2003

8/4/2003

8/5/2003

8/6/2003

8/7/2003

8/8/2003

8/9/2003

8/10/2003

8/11/2003

8/12/2003

8/13/2003

8/14/2003

8/15/2003

8/16/2003

8/17/2003

8/18/2003

8/19/2003

8/20/2003

8/21/2003

8/22/2003

8/23/2003

8/24/2003

8/25/2003

8/26/2003

8/27/2003

8/28/2003

8/29/2003

8/30/2003

8/31/2003

9/1/2003

9/2/2003

9/3/2003

9/4/2003

9/5/2003

9/6/2003

9/7/2003

I Alkalinity Data

Day No.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

AMR

Feed Tai

1

ni

AlkalitiiW [mgJ

CaC03/L]

464.23

219.72

930.0C

50.00

; , 1 ',

1

, i ' i 1

i!

i

, 1 :

,!

1

1

i

:

: '• •'. •]

i

• . i 1 |. ; '1 1

?i Influent

Alkalinity [mg-

CaC03/Ll

63.32

7 i ^8

326l40

2.33

j

1

i

il ; 1

i

:

i ' i

''

1 ,1

1 :i : \

: i

110

1

PB Effluent/

AMR Influent

Alkalinity [mg-

CaC03/L]

107.19

92.40

350.00

35.00

AMR

Effluent

Alkalinity [mg-

CaC03/Ll

55.28

83.52

325.00

5.00

AMR

Effluent Tank

Alkalinity [mg-

CaC03/L]

48.70

75.60

275.00

7.50

Page 125: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table B.3. continued 9/9/2003

9/10/2003

9/11/2003

9/12/2003

9/13/2003

9/14/2003

9/15/2003

9/16/2003

9/17/2003

9/18/2003

9/19/2003

9/20/2003

9/21/2003

9/22/2003

9/23/2003

9/24/2003

9/25/2003

9/26/2003

9/27/2003

9/28/2003

9/29/2003

9/30/2003

10/1/2003

10/2/2003

10/3/2003

10/4/2003

10/5/2003

10/6/2003

10/7/2003

10/8/2003

10/9/2003

10/10/2003

10/11/2003

10/12/2003

10/13/2003

10/14/2003

10/15/2003

10/16/2003

10/17/2003

10/18/2003

10/19/2003

10/20/2003

10/21/2003

10/22/2003

10/23/2003

10/24/2003

10/25/2003

10/26/2003

10/27/2003

10/28/2003

44

45

46

47 48

49

50

51

52

53 54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73 74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

930.001 67|23 80.00

530.1 ,00

647 5o:

450 30| 260 )0 245

845

420,

520.

290.30

•9 .03 60,00

;9I,75 65,00

1815 50,00

30 ii.i3 50.00

30 68.03 85.00

30 24.36 35.00

00 :i8,56 50,00

355 ,00

370 00

715

523

448

449

:!0.68 57.50

:!3.25 70.00

1)0.63 120,00

00

21 '?2,95

24,40

105,00

00 20,90

o6

25,00

15.00

10,00

7,50

15.00

30.00

5.00

15.00

7.50

17.50

35,00

62,50

140:12 242,00 125.00

25.00

20,00

17,50

7.50

25.00

10.00

70.00

15.00

15,00

10.00

10.00

25.00

275,00

45.00

202.50

225.00

111

Page 126: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table B.3 . continue 10/30/2003

10/31/2003

11/1/2003

11/2/2003

11/3/2003

11/4/2003

11/5/2003

11/6/2003

11/7/2003

11/8/2003

11/9/2003

11/10/2003

11/11/2003

11/12/2003

11/13/2003

11/14/2003

11/15/2003

11/16/2003

11/17/2003

11/18/2003

11/19/2003

11/20/2003

11/21/2003

11/22/2003

11/23/2003

11/24/2003

11/25/2003

11/26/2003

11^7/2003

11/28/2003

11/29/2003

11/30/2003

12/1/2003

12/2/2003

12/3/2003

12/4/2003

12/5/2003

12/6/2003

12/7/2003

12/8/2003

12/9/2003

12/10/2003

12/11/2003

12/12/2003

12/13/2003

12/14/2003

12/15/2003

12/16/2003

12/17/2003

12/18/2003

d 95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

843.00 650.0(|

168,0(i

i 395,00

423.0(1)

355.00

50.od 260.00

1 i

i

!

i

i

39

87

7;

42

34

•33 .33

84

.^6

,C4

325,}j0

2

2d

I

112

3P

..50

110.00

50.00

50.00

350.00

300.00

60.00

25.00

15.00

325.00

200.00

17 50

17 50

7 50

10.00

10,00

25,00

35.00

Page 127: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table B .3. continu< 12/19/2003

12/20/2003

12/21/2003

12/22/2003

12/23/2003

12/24/2003

12/25/2003

12/26/2003

12/27/2003

12/28/2003

12/29/2003

12/30/2003

12/31/2003

1/1/2004

1/2/2004

1/3/2004

1/4/2004

1/5/2004

1/6/2004

1/7/2004

1/8/2004

1/9/2004

1/10/2004

1/11/2004

1/12/2004

1/13/2004

1/14/2004

1/15/2004

1/16/2004

1/17/2004

1/18/2004

1/19/2004

1/20/2004

1/21/2004

1/22/2004

1/23/2004

1/24/2004

1/25/2004

1/26/2004

1/27/2004

1/28/2004

1/29/2004

1/30/2004

1/31/2004

2/1/2004

2/2/2004

2/3/2004

2/4/2004

2/5/2004

id 145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

II

:

1

1

1

1

i 1

1

1

1 i

\ 1

i i

' 1

i 1 :' i

1

i i ' 1

i . ' '

i •

i 1

1

1 j

. i

' .

J

ll

1 I

1'

• '

j

1

j

113

Page 128: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

continued 2/7/2004

2/8/2004

2/9/2004

2/10/2004

2/11/2004

2/12/2004

2/13/2004

2/14/2004

2/15/2004

2/16/2004

2/17/2004

2/18/2004

2/19/2004

2/20/2004

2/21/2004

2/22/2004

2/23/2004

2/24/2004

2/25/2004

2/26/2004

2/27/2004

2/28/2004

2/29/2004

3/1/2004

3/2/2004

3/3/2004

3/4/2004

3/5/2004

3/6/2004

3/7/2004

3/8/2004

3/9/2004

3/10/2004

3/11/2004

3/12/2004

3/13/2004

3/14/2004

3/15/2004

3/16/2004

3/17/2004

3/18/2004

3/19/2004

3/20/2004

3/21/2004

3/22/2004

3/23/2004

3/24/2004

3/25/2004

3/26/2004

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

ii t

••<

_J il i

i 1

1

i ! !

i

ii |l

1

i

'

1 1

1

1 i

1 1 1 i 1 l i

• 1

1

il

! i

i

1 1 1 :i

i, Ii I

: 1

ii i ' ••

i

j

—1 1

|i

)

-

i

i

11 [

Page 129: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table B.4.

Average

St. Dev.

Minimum

PB-AMR

Date

Maximum

7/28/2003

7/29/2003

7/30/2003

7/31/2003

8/1/2003

8/2/2003

8/3/2003

8/4/2003

8/5/2003

8/6/2003

8/7/2003

8/8/2003

8/9/2003

8/10/2003

8/11/2003

8/12/2003

8/13/2003

8/14/2003

8/15/2003

8/16/2003

8/17/2003

8/18/2003

8/19/2003

8/20/2003

8/21/2003

8/22/2003

8/23/2003

8/24/2003

8/25/2003

8/26/2003

8/27/2003

8/28/2003

8/29/2003

8/30/2003

8/31/2003

9/1/2003

9/2/2003

9/3/2003

9/4/2003

9/5/2003

9/6/2003

TOC Data

Day No.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

i ANjIR

Feed jTank

Tqc [mg-TpC/L]

316157 1 125[,02

8051.00

86.75

J

:

263;:30

255.30

: l'

t •

!

538.30

677.70

43');. 10

251,80

531.00

211.60

26;,50

147,00

179,00

401.90

714,00

351,40

|.

11

I

i i

1 i f

PB

jjifluent

ITGC

lfiii;-TOC/L]

, i

, ;

II

ll

j '

'

li i:

1,

j

'

i'

;

5;

41.53

18.41

[21.56

9.84

PB Effluent/

AMR Influent

TOC

[mg-TOC/L]

30.32

15.43

86.30

4.65

59.90

AMR

Effluent

TOC

[mg-TOC/L]

23.35

11.18

55.00

0.60

AMR

Effluent Tank

TOC

[mg-TOC/L]

21.62

13.93

77.40

1.00

9.80

9.95

14.85

6.35

7.45

0.00

2.45

2.25

13.90

2.55

0.00

3.80

9,75

Page 130: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table B.4. continued 9/8/2003

9/9/2003

9/10/2003

9/11/2003

9/12/2003

9/13/2003

9/14/2003

9/15/2003

9/16/2003

9/17/2003

9/18/2003

9/19/2003

9/20/2003

9/21/2003

9/22/2003

9/23/2003

9/24/2003

9/25/2003

9/26/2003

9/27/2003

9/28/2003

9/29/2003

9/30/2003

10/1/2003

10/2/2003

10/3/2003

10/4/2003

10/5/2003

10/6/2003

10/7/2003

10/8/2003

10/9/2003

10/10/2003

10/11/2003

10/12/2003

10/13/2003

10/14/2003

10/15/2003

10/16/2003

10/17/2003

10/18/2003

10/19/2003

10/20/2003

10/21/2003

10/22/2003

10/23/2003

10/24/2003

10/25/2003

10/26/2003

10/27/2003

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

275.20

284.170

290,40

298:50

50dj60

39(|i60

533:10

34i;70

368:80

386;90

1

169l70

I, 356i,00

1 228:00

348.50

153:40

275.60

137,03

1'

313,70

31030

397.20 1'

432,70

380,14

45b,29

767,80

40^,30

316.80

11.50

35.47

70.66

68.59

41,02

46,14 i

, 55.23

53,01

37,68

26,08

23,13

30.51

41.94

16,55

25,95

38,66

22,73

50,32

58.28

1

is.is u - - L

9,60

4,65

37,50

65,45

39,85

32,65

44,20

51,23

28.05

24.98

21,00

28,90

38.60

13,95

17,25

34.29

21.85

34.30

45.30

23.40

12.70

i55.00

45,85

,26,30

30.35

,39.00

47.30

22.10

16.20

7,20

24.50

30.50

10.65

11.87

25.36

4.40

31.60

41.10

21.40

1

22.35

10.75

20.20

22,70

2,85

34.15

26.20

29,60

39,70

77,40

27,70

17,86

34.10

12.55

9.55

10.70

4.55

10.35

3.07

4.90

27.00

15.59

29.55

27.25

54.10

12.35

116

Page 131: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table B.4. continued 10/29/2003

10/30/2003

10/31/2003

11/1/2003

11/2/2003

11/3/2003

11/4/2003

11/5/2003

11/6/2003

11/7/2003

11/8/2003

11/9/2003

11/10/2003

11/11/2003

11/12/2003

11/13/2003

11/14/2003

11/15/2003

11/16/2003

11/17/2003

11/18/2003

11/19/2003

11/20/2003

11/21/2003

11/22/2003

11/23/2003

11/24/2003

11/25/2003

11/26/2003

11/27/2003

11/28/2003

11/29/2003

11/30/2003

12/1/2003

12/2/2003

12/3/2003

12/4/2003

12/5/2003

12/6/2003

12/7/2003

12/8/2003

12/9/2003

12/10/2003

12/11/2003

12/12/2003

12/13/2003

12/14/2003

12/15/2003

12/16/2003

12/17/2003

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

306,66

313.00

1

28^.00

305.20

217,10

>19.00

50d.50

1

^2.60

192.56

:

222.00

186.00

396,50

15^,50

285,59

2- 9,30 '

i • ,

86,75

196,90 1

140,95

535,50

'

369,90

273.70 ;

19.56

23.02

i 59.25

36,37

10,93

34,70

i6.9l

32,77

j

29,48

47,48

37.15

30,50

9,84

22,49

13,20

12.50

47,00

31,45

4,70

31,80

21.56

27,05

20,80

46.59

16.65

13.22

10.49

5.20

10.00

36.75

13.65

0.60

27,30

20.76

20,40

17,25

45,56

12.76

13.89

10.32

10.20

28 65

28.20

10.00

9.75

13,20

41.10

40,55

4,24

1.68

7.52

3.94

12.93

24.10

30,70

13.80

34,80

1.00

11.94

10,32

27,66

22.46

30.80

14.07

11.80

117

Page 132: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

1 continued 12/18/2003 144

12/19/2003

12/20/2003

12/21/2003

12/22/2003

12/23/2003

12/24/2003

12/25/2003

12/26/2003

12/27/2003

12/28/2003

12/29/2003

12/30/2003

12/31/2003

1/1/2004

1/2/2004

1/3/2004

1/4/2004

1/5/2004

1/6/2004

1/7/2004

1/8/2004

1/9/2004

1/10/2004

1/11/2004

1/12/2004

1/13/2004

1/14/2004

1/15/2004

1/16/2004

1/17/2004

1/18/2004

1/19/2004

1/20/2004

1/21/2004

1/22/2004

1/23/2004

1/24/2004

1/25/2004

1/26/2004

1/27/2004

1/28/2004

1/29/2004

1/30/2004

1/31/2004

2/1/2004

2/2/2004

2/3/2004

2/4/2004

2/5/2004

145

146

147

148

149

150

151

152

153 154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

260,54

288.50

348,50

275.40

379,60

354,20

390,40

305.60 1

336.00

347,00

346,35

372,60

367.80

313,20

338.50

324.60

308,19

124,50

244,85

152,50

308,00

3^2.40

323.12

322.78

—1

,35,99 1 ,|

1

3i7.73 '

4il.28 1

314.31 ,! 3'8.29

36.50

ii 4d,72

i ii'ii 1 .

1147.90

i i i

39,51

i 43.45

37,70 [

50,36 i

39,27

40,40

45,35

]

1

i 1

1

i. . i I i ; 1

' 1 : i

11 ;

r i

1

6,49

30.10

41,60

30,82

31,40

30,60

28.73

31.12

26.72

41,33

30,42

30,50

24,90

38,97

24,19

28,08

36,94

65,80

i

121.20

|25.00 1

\

75,46

126,24

'22.51

121,59

i20,95

123,60

135,29

! 25,00 1 ' •

128.59

1 122,59

34.59

23,19

1 27.05

31.00

18.92

9.77 9 77

24 95

24 26

21 29

20 16

19 97

27.29

34.80

23.90

25,80

22,64

23,90

21,89

26.30

29.27

19.40

17,55

18.21

17,24

15,29

12,80

18,60

16.81

17.37

118

Page 133: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

. continued 2/6/2004

2/7/2004

2/8/2004

2/9/2004

2/10/2004

2/11/2004

2/12/2004

2/13/2004

2/14/2004

2/15/2004

2/16/2004

2/17/2004

2/18/2004

2/19/2004

2/20/2004

2/21/2004

2/22/2004

2/23/2004

2/24/2004

2/25/2004

2/26/2004

2/27/2004

2/28/2004

2/29/2004

3/1/2004

3/2/2004

3/3/2004

3/4/2004

3/5/2004

3/6/2004

3/7/2004

3/8/2004

3/9/2004

3/10/2004

3/11/2004

3/12/2004

3/13/2004

3/14/2004

3/15/2004

3/16/2004

3/17/2004

3/18/2004

3/19/2004

3/20/2004

3/21/2004

3/22/2004

3/23/2004

3/24/2004

3/25/2004

3/26/2004

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

1 218

219

1 220

221

1 222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

3

3

ll

3

5

1

2

1

2

5

i

•;

17,46

, 82,66 ii

1 • 1 44,85 • : ll

08,00

57,20

57.00

88.20

98.50

32.50

05,00

80,77 i

i

~ i

1

1 [

'f

>

1

- . 1

4 4 . 2 3

i ,1 1

1 ,1 i .

1 48.93 i! 1 ;

i ' •

66,76

30,98

39,17

,36.88

46.06

72.13

121.56

66,72

9

33,91

86.30

29.40

25.40

23.12

26.10

22.40

28.10

82.66

41,26

17,03

19,4^

22.78 I8.4I3

17.46

21.80

20.9b !

26.24 1

53.44

35.42 j

i

1

18.49

14.00

18,29

12.81

17,37

18,49

24,00

18.29

19,86

18.63

48.38

34.71

Page 134: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table 8.5.

Average

St. Dev.

Maximum

Minimum

PB-AMI

Date

7/28/2003 7/29/2003

7/30/2003

7/31/2003

8/1/2003

8/2/2003

8/3/2003

8/4/2003

8/5/2003

8/6/2003

8/7/2003

8/8/2003

8/9/2003

8/10/2003

8/11/2003

8/12/2003

8/13/2003

8/14/2003

8/15/2003

8/16/2003

8/17/2003

8/18/2003

8/19/2003

8/20/2003

8/21/2003

8/22/2003

8/23/2003

8/24/2003

8/25/2003

8/26/2003

8/27/2003

8/28/2003

8/29/2003

8/30/2003

8/31/2003

9/1/2003

9/2/2003

9/3/2003

9/4/2003

I TA Data

|Day No,

1

2

3

4

5

6

7

8

9

10

11 12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

, 36

37

38

39

I

i

:W Fe^dTank

[rt

iTA

5-N/L]

ilt7.10 I

: i

;

: 4 i: 3

:

2^71 S9.20 1.28

si.60

1 1 i h

94.20

I

1 1

I 1

; 1

! "!— ; ;

11 ' ,

1

1

46.00 ^ .78

50.84

08.49

d!6.35

59,26

|!i22,48

,:

1719,34 fel7,63 ^3,76

il.91

sis ,28 1

12

i

i ;

f<i !l

li

if

II

;

J

1 • 1

0

PB

fluent

TA

g-N/Ll

08.42

)7.16 37.88 57.97

72.46

PB Effluent/

AMR Influent

TA

[mg-N/L]

203.84

100.90 460.44 50.70

60.90

!

AMR 7

Effluint

1^

[mg-N/L] — ^ - ^ 1 '

202.51

102.43 569.47 46.' 6

1

1

161.30

1

'\

1

i

1

AMR Effluent

Tank

TA

fmg-N/L]

188.72

80.35 362.29 52.64

119,80

103,80

253.03

274.09

294.86

236.85

269.37

172,61

198.37

152.30

141,58

164.41

120.23

142.57

Page 135: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table B.S. continued 9/8/2003

9/9/2003

9/10/2003

9/11/2003

9/12/2003

9/13/2003

9/14/2003

9/15/2003

9/16/2003

9/17/2003

9/18/2003

9/19/2003

9/20/2003

9/21/2003

9/22/2003

9/23/2003

9/24/2003

9/25/2003

9/26/2003

9/27/2003

9/28/2003

9/29/2003

9/30/2003

10/1/2003

10/2/2003

10/3/2003

10/4/2003

10/5/2003

10/6/2003

10/7/2003

10/8/2003

10/9/2003

10/10/2003

10/11/2003

10/12/2003

10/13/2003

10/14/2003

10/15/2003

10/16/2003

10/17/2003

10/18/2003

10/19/2003

10/20/2003

10/21/2003

10/22/2003

10/23/2003

10/24/2003

10/25/2003

10/26/2003

1 10/27/2003

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

i

:.li

i 4: ''i

i i

i 1

4

I li

'il 1 1 1

4 II h 1

•il

i' i

11

i

ji ' 1

i

1 1

., 1 ii

— 1 r j

' i I

1 i

1

i

)i,02

16.80

id, 10

V».20

i io i:),98

1 )k.n

i

1 13,18

^5,80

i

!5,04

si.04

i i

J6.32

17,45

^9.16

26.8I 1

31,75

t5,25

12

'

1

'li

1

1 !

i

1

73,23

29,26

88.54

10.07

23.96

34,46

1

31,18

07,81

72,53

l4,81

56,18

1

42,76

i3,66

1

;60.58

i

179,81

;64,09

.74,31

160,46

240,80

287,10

446,00

234,10

131,80

153,17

159,95

250,56

155.09

139,79

253,09

313,88

303.27

199.08

173.82

228.40

282.10

391,51

329,44

,124,11

232.50

196,29

172.37

229.20

247.62

143.08

123,96

261,14

282,40

267.63

175,68

105,72

264.80

290.20

334.10

222.10

125,88

242,80

362.29

316.09

156.83

228.87

160.81

137.49

361.38

293.68

254.57

176.41

Page 136: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

. continued 10/29/2003

10/30/2003

10/31^003

11/1/2003

11/2/2003

11/3/2003

11/4^003

11/5/2003

11/6/2003

11/7/2003

11/8/2003

11/9/2003

11/10/2003

11/11/2003

11/12/2003

11/13/2003

11/14/2003

11/15/2003

11/16/2003

11/17/2003

11/18/2003

11/19/2003

1 l/2d/2003

11/21/2003

11/22/2003

11/23/2003

11/24/2003

11/25/2003

11/26/2003

11/27/2003

11/28/2003

11/29/2003

11/30/2003

12/1/2003

12/2/2003

12/3/2003

12/4/2003

12/5/2003

12/6/2003

12/7/2003

12/8/2003

12/9/2003

12/10/2003

12/11/2003

12/12/2003

12/13/2003

12/14/2003

12/1^/2003

12/16/2003

12/17/2003

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

419,30

220,94

1250.24

278,26

i

1130,46 1 1

226.40

^34.60 j

i 350,81 1

\ I i

1187,88

1233,25

,217,03

' 213,93

II i

\: 11

;!04.71

,77,72

116,12 ,

129,04

102,58

94,46

, 222,69

294,42

176.00

274.01

212,11

m.n

220.05

183.56

119.20

106.38

119.01

125.42

226.99

286.86

176,21

224,99

202,74

151.59

194,21

175,60

109.56

121.74

101.22

88.00

207.42

291.66

175,42

276,00

211,87

233.17

199.77

175.60

97.37

117.70

110.48

99.46

177.50

199.99

125.90

127.71

132.23

126.61

Page 137: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table B.!5

j

1 1 1

1

. continue( 12/18/2003

12/19/2003

12/20/2003

12/21/2003

12/22/2003

12/23/2003

12/24/2003

12/25/2003

12/26/2003

12/27/2003

12/28/2003

12/29/2003

12/30/2003

12/31/2003

1/1/2004

1/2/2004

1/3/2004

1/4/2004

1/5/2004

1/6/2004

1/7/2004

1/8/2004

1/9/2004

1/10/2004

1/11/2004

1/12/2004

1/13/2004

1/14/2004

1/15/2004

1/16/2004

1/17/2004

1/18/2004

1/19/2004

1/20/2004

1/21/2004

1/22/2004

1/23/2004

1/24/2004

1/25/2004

1/26/2004

1/27/2004

1/28/2004

1/29/2004

1/30/2004

1/31/2004

2/1/2004

2/2/2004

2/3/2004

2/4/2004

2/5/2004

1 144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

i

i2(

?

i< .;,

'1

!3

2

2

'? 2

,4

•2

1

13

16

1,

3

! i

1 i

2

i

1

., J9ib7

1

ilob f

5i56

\ •

,! .1 t il

0.26

001

8;90

i5i30

;o,90

1,44

14,88

!5U4

15,40

Ul.70

04,59

1128

20,95

12

224,54

1 ll 362,69

1 322,78 ii

1

1

371,52

ij

302,98

278,60 •;

1 314,33

311,93

111,24

: 146,30

212,96

t 291.65

i ' 188,53

1

r

1 101,89

' :l

i 537,88

.3

215,21

381,56

334,10

405,26

329,44

305.26

345,98

325,88

136.22

154.79

240.12

299.69

157,34

96.94

169,27

225,25

365.26

324.11

372,56

304.10

279,56

315,26

313.45

104,21

147,32

207.46

257.76

176.96

103.94

569.47

214,32

324.49

299.46

361.43

282.00

264.80

302.57

303.95

127.31

334.56

134.00

206.50

184.38

146,86

77,38

118.02

Page 138: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

. continue( 2/6/2004

2/7/2004

2/8/2004

2/9/2004

2/10/2004

2/11/2004

2/12/2004

2/13/2004

2/14/2004

2/15/2004

2/16/2004

2/17/2004

2/18/2004

2/19/2004

2/20/2004

2/21/2004

2/22/2004

2/23/2004

2/24/2004

2/25/2004

2/26/2004

2/27/2004

2/28/2004

2/29/2004

3/1/2004

3/2/2004

3/3/2004

3/4/2004

3/5/2004

3/6/2004

3/7/2004

3/8/2004

3/9/2004

3/10/2004

3/11/2004

3/12/2004

3/13/2004

3/14/2004

3/15/2004

3/16/2004

3/17/2004

3/18/2004

3/19/2004

3/20/2004

3/21/2004

3/22/2004

3/23/2004

3/24/2004

3/25/2004

3/26/2004

i 194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

3

3

3

2

3

2

,4

2

X

•1

• •

47,10

03,42

55,00

53,52

, 1

07.62

Q4.15

34.01

63.44 [

58.79

1

93,50

80,81

.05:27

92:66

.55,83

12 4

181,80

156,27

215,74

201.11

155.38

291.23

320.04

85,10

78.29

88.40

67.97

88.18

99.69

96.53

177.90

176.46

229.98

156.95

195.11

460.44

233.94

55,17

55,87

50.70

96,54

67.65

86.93

64.02

165.32

141,60

201,86

195,89

140,21

299,91

298.71

67,32

60.30

67.96

46.76

76.51

90.42

80.65

165,99

177.18

181,56

136,31

148.94

105.98

207,51

155.40

150.04

165.82

152.17

167.65

86.93

154,74

Page 139: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table B.

Averagei

St. Dev.\

Maximum

Minimum

•'

i

1

1

j

1

. PB-AM

Date

7/28/2003

7/29/2003

7/30/2003

7/31/2003

8/1/2003

8/2/2003

8/3/2003

8/4/2003

8/5/2003

8/6/2003

8/7/2003

8/8/2003

8/9/2003

8/10/2003

8/11/2003

8/12/2003

8/13/2003

8/14/2003

8/15/2003

8/16/2003

8/17/2003

8/18/2003

8/19/2003

8/20/2003

8/21/2003

8/22/2003

8/23/2003

8/24/2003

8/25/2003

8/26/2003

8/27/2003

8/28/2003

8/29/2003

8/30/2003

8/31/2003

9/1/2003

9/2/2003

9/3/2003

9/4/2003

9/5/2003

9/6/2003

RNOz'-NDat

Day No.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

'c\

^WlR

Fee 1 Tank

fn-

N02

,;-N/L]

:i.26

1.07

}2.20

1.00

),00

),00

),00

0,00

0,19

0.00

0.00

0.00

0,00

0.00

0.00

0.00

o.oo 0,25

4.64

12 5

PB

Influent

N02

ing-N/L]

11.91

27.06

199.44

0.02

102.81

0.01

0.01

0.22

PB Effluent/

AMR Influent

N02

[mg-N/L]

7.96

24.73

186.37

0.00

122,79

AMR

Effluent

N02

[mg-N/L]

10.34

27.21

219.32

0.00

107,84

AMR Effluent

N02

[mg-N/Ll

10.67

26.86

189.11

0.00

145.34

105.95

73.57

0.00

0.00

0.00

0.00

0.00

0,00

0.00

0.00

0.00

0.00

0.00

0.00

Page 140: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

. continued 9/8/2003

9/9/2003

9/10/2003

9/11/2003

9/12/2003

9/13/2003

9/14/2003

9/15/2003

9/16/2003

9/17/2003

9/18/2003

9/19/2003

9/20/2003

9/21/2003

9/22/2003

9/23/2003

9/24/2003

9/25/2003

9/26/2003

9/27/2003

9/28/2003

9/29/2003

9/30/2003

10/1/2003

10/2/2003

10/3/2003

10/4/2003

10/5/2003

10/6/2003

10/7/2003

10/8/2003

10/9/2003

10/10/2003

10/11/2003

10/12/2003

10/13/2003

10/14/2003

10/15/2003

10/16/2003

10/17/2003

10/18/2003

10/19/2003

10/20/2003

10/21/2003

10/22/2003

10/23/2003

10/24/2003

10/25/2003

10/26/2003

10/27/2003

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

),00

).00

),79

),00

).71

).00

3.37

0.00

0.00

0.00

0.00

0.00

0.82

12

!

i 1

6

2,87

0.04

8.32

0.39

0.39

2,15

1,35

4.07

28.75

40.08

0,60

0,00

1.37

0,00

0,00

1.32

0.00

0.00

1.24

0.00

15,10

31.32

0.00

3.01

0.00

0.00

0.00

8.69

0.41

0.39

2,25

1,42

4,27

30.16

42.04

0.59

0,00

1.73

2.92

0.00

4.96

0 00

0,00

3.08

1.68

4.24

22.85

45.83

0.51

Page 141: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

. continuec 10/29/2003

10/30/2003

10/31/2003

11/1/2003

11/2/2003

11/3/2003

11/4/2003

11/5/2003

11/6/2003

11/7/2003

11/8/2003

11/9/2003

11/10/2003

11/11/2003

11/12/2003

11/13/2003

11/14/2003

11/15/2003

11/16/2003

11/17/2003

11/18/2003

11/19/2003

11/20/2003

11/21/2003

11/22/2003

11/23/2003

11/24/2003

11/25/2003

11/26/2003

11/27/2003

11/28/2003

11/29/2003

11/30/2003

12/1/2003

12/2/2003

12/3/2003

12/4/2003

12/5/2003

12/6/2003

12/7/2003

12/8/2003

12/9/2003

12/10/2003

12/11/2003

12/12/2003

12/13/2003

12/14/2003

12/15/2003

12/16/2003

12/17/2003

1 94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

0.00

0.00

0.83

3.50

0.95

0.00

1,71

0.00

0,00

0,00

2,25

3,41

o,do 0,00

8.50

25.97

0,00

0,l8

13.08

2,97

\: 7

0,04

0,16

0,95

1.15

0,81

0,45

0,42

1,12

12,86

2,48

15,41

1,59

1.20

25.80

4.99

1,46

1,45

1,63

9,32

0,88

0,53

0,00

0,24

0.00

0,00

0.00

1.18

1,54

0.86

0,78

0,97

0.43

6,99

10,11

3.06

0.82

0.00

0.00

22.12

13.17

0.00

0.47

0.00

1.46

0.00

0.00

0.00

0.00

0.95

1,21

0,00

0,77

0,48

0,00

0,44

1,17

13.49

2.61

16.06

0.00

1.50

1.26

26.65

3.96

1.53

1.51

1.07

9.63

1.59

1.04

0.00

0.00

0.00

1.11

1.26

0,66

0.00

5,74

0.41

0,00

0,95

9,07

5.59

5.06

1.21

12.25

0.00

24.51

0.00

22.07

1.06

0.00

0 89

Page 142: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table B.6 . continue* 12/19/2003

12/20/2003

12/21/2003

12/22/2003

12/23/2003

12/24/2003

12/25/2003

12/26/2003

12/27/2003

12/28/2003

12/29/2003

12/30/2003

12/31/2003

1/1/2004

1/2/2004

1/3/2004

1/4/2004

1/5/2004

1/6/2004

1/7/2004

1/8/2004

1/9/2004

1/10/2004

1/11/2004

1/12/2004

1/13/2004

1/14/2004

1/15/2004

1/16/2004

1/17/2004

1/18/2004

1/19/2004

1/20/2004

1/21/2004

1/22/2004

1/23/2004

1/24/2004

1/25/2004

1/26/2004

1/27/2004

1/28/2004

1/29/2004

1/30/2004

1/31/2004

2/1/2004

2/2/2004

2/3/2004

2/4/2004

2/5/2004

2/6/2004

i 145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

3,47

2,05

0,00

0.00

3.56

5.77

1.85

1,83

3,30

0,00

0.00

1,82

29,91

0,62

0,00

3,11

1,72

0,39

0,00

0,00

12

1, i 18.27

1

5.43

38,31

31.85

1.83

2.52

,0.55

,21.56

17.00

15.24

43.85

2.23

4,52

2,57

0,28

1,20

7,79

21.08

8

8.85

10,76

20.42

38.66

5.26

0,87

0.00

7.15

8.14

6.63

16.24

1.29

0.01

0.00

0.00

18.35

8.07

0.00

4.08

0.00

18.99

5.60

40.18

33.41

1.75

2.36

0.49

22.52

17.67

15,99

48,22

2,27

1,98

2,76

0,00

0,00

1.15

8.52

23.19

0,00

7.43

6.56

40.11

63.15

6.29

1.73

1.37

18.42

0.00

11.80

3.48

29.03

5.30

3.29

1.73

0.00

5,21

3.16

3.31

16,78

0.00

Page 143: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table B.6 . continue* 2/7/2004

2/8/2004

2/9/2004

2/10/2004

2/11/2004

2/12/2004

2/13/2004

2/14/2004

2/15/2004

2/16/2004

2/17/2004

2/18/2004

2/19/2004

2/20/2004

2/21/2004

2/22/2004

2/23/2004

2/24/2004

2/25/2004

2/26/2004

2/27/2004

2/28/2004

2/29/2004

3/1/2004

3/2/2004

3/3/2004

3/4/2004

3/5/2004

3/6/2004

3/7/2004

3/8/2004

3/9/2004

3/10/2004

3/11/2004

3/12/2004

3/13/2004

3/14/2004

3/15/2004

3/16/2004

3/17/2004

3/18/2004

3/19/2004

3/20/2004

3/21/2004

3/22/2004

3/23/2004

3/24/2004

3/25/2004

3/26/2004

3/27/2004

d 195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

1

1

0.00

0.00

0,00

0,00

0.00

0.00

0.00

0,00

0,00

0,00

0,41 1

1.99

I

0.00

0,00 i

0.00

1

3.58

0.87 1

5.15

0,00 ^

0,26

0,00

0.00

1

0.00

0.00 !

0.00 i

'•

1

II

199.44

82.40

0.04

1.05

1,05

7,53

10.60

0.57

1.48

0.47

7.99

0.02

1.69

0.22

4.32

8.24

3.58

9

0,00

0,00

0.00

0,00

0.00

0.00

0,00

0.00

186.37

113,31

2.13

0.00

0.32

3.13

5.18

1.38

0.00

0,00

0.00

0.00

0,00

0,00

0,00

0.00

219.32

90.62

0.00

0.96

1.15

8.28

11.66

0.27

1.54

0.00

8.79

0.00

1.86

0.25

4.75

9.06

3.94

0.00

0.00

0.00

0.00

0.00

0,00

0.00

0.00

189.11

81.94

17.73

0.00

0.61

15.25

12.81

0.00

0.71

0.00

6.37

2.56

1.95

1.74

4,34

4.57

Page 144: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

ible B.7

Average

St. Dev

Maximum

Minimum

PB-AM]

Date

7/28/2003

7/29/2003

7/30/2003

7/31/2003

8/1/2003

8/2/2003

8/3/2003

8/4/2003

8/5/2003

8/6/2003

8/7/2003

8/8/2003

8/9/2003

8/10/2003

8/11/2003

8/12/2003

8/13/2003

8/14/2003

8/15/2003

8/16/2003

8/17/2003

8/18/2003

8/19/2003

8/20/2003

8/21/2003

8/22/2003

8/23/2003

8/24/2003

8/25/2003

8/26/2003

8/27/2003

8/28/2003

8/29/2003

8/30/2003

8/31/2003

9/1/2003

9/2/2003

9/3/2003

9/4/2003

9/5/2003

9/6/2003

[INO3-N]

Day No.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

Data

AMR

Feed Tank

N03

[mg-N/Ll

5.73

20.57

151.19 0.00

0.00

0.00

0.12

0.00

0.00

0.00

0.00

0.00

0,00

0.00

0.28

0,00

0,00

0.00

0,00

PB

Influent

N03

[mg-N/L]

148.56

78.29

428.93 0.01

PB Effluent/

AMR Influent

N03

[mg-N/L]

148.84

72.92

444.70 0.00

3.65

AMR

Effluent

N03

[mg-N/L]

158.02

82.83

449.93 0.00

1,77

AMR Effluent

Tank

N03

[mg-N/L]

164.86

85.04

469.49 0.00

5,39

8.06

13.17

118.85

101.05

56,64

80.58

119.20

127.20

60.05

130.19

76.92

34.15

71 97

56,54

130

Page 145: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table B.7 . continue 9/8/2003

9/9/2003

9/10/2003

9/11/2003

9/12/2003

9/13/2003

9/14/2003

9/15/2003

9/16/2003

9/17/2003

9/18/2003

9/19/2003

9/20/2003

9/21/2003

9/22/2003

9/23/2003

9/24/2003

9/25/2003

9/26/2003

9/27/2003

9/28/2003

9/29/2003

,9/30/2003

10/1/2003

10/2/2003

10/3/2003

10/4/2003

10/5/2003

10/6/2003

10/7/2003

10/8/2003

10/9/2003

10/10/2003

110/11/2003

10/12/2003

ilO/13/2003

10/14/2003

10/15/2003

10/16/2003

10/17/2003

10/18/2003

10/19/2003

10/20/2003

10/21/2003

10/22/2003

10/23/2003

10/24/2003

10/25/2003

10/26/2003

10/27/2003

d 43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

0,00

1.19

i,53

f[),26 2.39

d,65

1,39

;

1 i 1

3.00

3.00

3.23

1 0.00

0.00

i

3,88

108,38

91,57

145,65

177,32

228,79

233,09

226.57

184,97

211.77

216,73

143.85

162.13

208.38

127.88

108,98

171,43

136,35

204,77

224.32

221,46

169.65

197.01

185.27

121.43

146.28

203.42

113.63

96.00

152,71

185,99

239,88

244.46

237.60

194.03

222,14

227,33

150.89

170.07

218.54

127.97

110.46

144.19

176.42

211.02

252.03

99.95

208.95

235 55

219.96

184.51

158.03

23455

131

Page 146: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table B.7. continued 10/29/2003

10/30/2003

10/31/2003

11/1/2003

11/2/2003

11/3/2003

11/4/2003

11/5/2003

11/6/2003

11/7/2003

11/8/2003

11/9/2003

11/10/2003

11/11/2003

11/12/2003

11/13/2003

11/14/2003

11/15/2003

11/16/2003

11/17/2003

11/18/2003

11/19/2003

11/20/2003

11/21/2003

11/22/2003

11/23/2003

11/24/2003

11/25/2003

11/26/2003

11/27/2003

11/28/2003

11/29/2003

11/30/2003

12/1/2003

12/2/2003

12/3/2003

12/4/2003

12/5/2003

12/6/2003

12/7/2003

12/8/2003

12/9/2003

12/10/2003

12/11/2003

12/12/2003

12/13/2003

12/14/2003

12/15/2003

12/16/2003

12/17/2003

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131 132

133

134

135

136

137

138

139

140

141

142

143

1,94

0,00

0,00

20,95

0,00

0.00

0.00

4,82

0.25

0,00

0.00

0,00

0,00

0.00

4.31

0,00

7.22

0,00

0,00

0.28

0,00

1,61

1.41

0,18

7,16

2.97

216,19

188.22

78,70

147,87

122.93

90.39

167,84

111,17

88,02

129,17

111,60

107,19

132,86

178,85

203,07

428,93

294,81

1

154.69

306.46

221,63

209.34

207.15

260.42

221,40

218.15

218,29

215,86

168,10

80,37

145.48

111,53

84,27

150,29

110,23

100,80

113.13

198.71

147.23

118.33

167.40

228,50

444,70

287.17

119.80

285.98

203.34

196,03

236.25

253.98

223.40

219.44

205,44

226.68

197.44

82,55

154,08

128,94

94,82

176,05

116.37

92.32

135.49

117.07

112,43

139,37

187,60

212,80

449,93

308.89

162.27

321.46

232.47

219.59

217.21

273.10

232.23

228.48

228.83

199,18

210.26

82.31

169,58

100,64

53.65

106,08

178.33

81.72

134.66

112.25

132.29

171.69

198.74

252.15

314.06

165.27

469.49

243.36

212.26

271.19

357.06

262.17

230.93

246.30

132

Page 147: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

. continue( 12/18/2003

12/19/2003

12/20/2003

12/21/2003

12/22/2003

12/23/2003

12/24/2003

12/25/2003

12/26/2003

12/27/2003

12/28/2003

12/29/2003

12/30/2003

12/31/2003

1/1/2004

1/2/2004

1/3/2004

1/4/2004

1/5/2004

1/6/2004

1/7/2004

1/8/2004

1/9/2004

1/10/2004

1/11/2004

1/12/2004

1/13/2004

1/14/2004

1/15/2004

1/16/2004

1/17/2004

1/18/2004

1/19/2004

1/20/2004

1/21/2004

1/22/2004

1/23/2004

1/24/2004

1/25/2004

1/26/2004

1/27/2004

1/28/2004

1/29/2004

1/30/2004

1/31/2004

2/1/2004

2/2/2004

2/3/2004

2/4/2004

2/5/2004

i 144

145

146

147

148

149

150

151

152

153 154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

0,00

0,00

0,00

0,00

0,50

0.00

151,19

2,22

0,74

0.00

0.00

0.00

0.00

83.30

7.97

0.18

99.34

7.28

0.46

0.22

6.41

!34,18

142.31

45,84

110,28

118.61

172.83

105.17

117,75

91.41

116.88

134.14

95.30

173,50

175.38

103.61

0.02

163.86

117.49

140.69

105.24

193.60

234.32

253.04

127.60

89.31

130.72

150.27

123.69

90.36

84.72

105.56

152.06

76,04

154.57

165.45

141.60

144.25

152.43

131.70

85.73

154.78

245.64

254.17

152.98

115.67

124.39

181.29

102.91

123.41

95.84

122.60

140.70

104,80

190.80

184.55

113.14

170.30

128.47

154.67

115.71

212.26

323.43

261.21

170.82

100.00

126.28

176.56

151.96

112.80

99.80

1.88

173.04

137.20

188.26

170,27

186,11

169,60

166 53

194.36

131.01

214.00

133

Page 148: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table B.7. continued 2/6/2004

2/7/2004

2/8/2004

2/9/2004

2/10/2004

2/11/2004

2/12/2004

2/13/2004

2/14/2004

2/15/2004

2/16/2004

2/17/2004

2/18/2004

2/19/2004

2/20/2004

2/21/2004

2/22/2004

2/23/2004

2/24/2004

2/25/2004

2/26/2004

2/27/2004

2/28/2004

2/29/2004

3/1/2004

3/2/2004

3/3/2004

3/4/2004

3/5/2004

3/6/2004

3/7/2004

3/8/2004

3/9/2004

3/10/2004

3/11/2004

3/12/2004

3/13/2004

3/14/2004

3/15/2004

3/16/2004

3/17/2004

3/18/2004

3/19/2004

3/20/2004

3/21/2004

3/22/2004

3/23/2004

3/24/2004

3/25/2004

3/26/2004

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

1 8,69

9,25

12.00

9,15

9,93

J

1

1

(29,851 i i

18,8211 i '

io,ooh '\ I

0,3 Ij

0.00

1 1

0,16i

i0,28i '

0.97

0.04

0.44

0,00

0.461

i

5,97

0,17 i

1 1.80 0.00

0.36 '

1

0.20

0.66

1

256,74

215.90

247.91

234.20

250.06

173.44

187,76

i 278.25

110.29

0.01

54.22

41,73

35.46

63,56

68.87

68.00 '

32.54

49.63

32.63

58.19

17,63

245.84

120.03

119.43

117,46

186,24

153,44

205,20

227,10

179,80

165.20

290.40

87.37

0.00

0.00

55.24

43,27

60,80

66.98

131.81

281.46

236,50

271.42

256.63

274.00

187,75

205,60

305.99

121,26

0.00

0.00

59.60

45,79

38,99

69.85

75.73

74.74

35.19

54,56

35.71

63,99

19.35

270,32

131,93

131.33

290 40

254 20

279.60

253.00

175.40

188.60

248.50

243.15

96.39

63.57

0.00

142.71

61.45

40,04

74.49

78.58

77.58

40.08

82.13

37.21

84 14

29.60

191.89

136 52

58.54

134

Page 149: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

.^pi'ENpiX C

FEED TANK; A]S[ALYSIS DATA

135

Page 150: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Tabled. ^ Sample

No. 100 101 102 103 104 105 106 107 108 109

Total Change

Sample

No. 100 101 102 103 104 105 106 107 108 109

Total Change

ia. HRT

[hoursi] 0.0 10.5 17.51 22.51 24.5 41.5 45.01 57.5 70.5! 139.5

TA [mg-N/L] 50.4 151.7 231.9 207.0 200.7 266.7 310.^ 427.^ 441.0 402.4

352.0

ture Feed Tank #1 Dati pH

6.7 7.1 1.1 7.9 8.0 8.6 8.7 8.9 8.8 8.8

2.1

COD [mg-

COD/Ll 674.0 740.0

980.0

930.0

782.0 460.0

214.0

Temp

fq 23.8 23.7 23.2 24.1 24.3 23.3 23.4 23.5 22.9 23.9

0.1

NOx [mg-N/L] 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

0.0

T [r

TD

1

DS ng-S/L]

3019.0 28^9.0 2720.0 2680.0 3061.0

i 3563.0 32ii6.0 33^.0

1 366.0 GAS

TRAP

ImgJN/LI

i' h 1.6 1.4 1.4

1-1 6.8

0.4

i

11

i

1 1 j

DO [mg-

1 DO/L] 5.4 3.6 2.0 2.0 2.0 1.9 1.8 2.0 1.7 1.9

3.5 UREA (JSC)

[mg-N/L] 138.9 110.1 83.0 75.9 77.9 9.2 0.0 0.0 0.0 0.0

-138.9

i

i

1

OrgN [mg-N/L] 386.7 280.7 194.8 216.9 229.7 140.9 100.4 0.9

-53.3 10.1

376.6 %

NH3

[%] 0.0 0.0 0.0 0.0 0.1 0.2 0.2 0.3 0.3 0.3

TOC

[mg-TOC/L] 314.0 364.7 314.4 318.1 331.8 276.9 267.6 235.5 223.7 205.9

108.1 NH3

(dissolved)

[mg-N/Ll 0.1 1.0 6.4 9.3 10.2 50.7 64.8 127.9 119.5 105,4

TN

[mg-N/L 437.1 432.4 426.7 423.9 430.4 407.6 411.3 428.7 387.7 412.5

24,6 NH4

(dissolved

[mg-N/Ll 50,2 150,7 225,5 197,7 190,5 216,1 246.1 299,9 321.5 297.0

136

Page 151: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table Sample

No. 200 201 202 203 204 205 206 207 208 209 Total

Change

Sample

No. 200 201 202 203 204 205 206 207 208 209 Total

Change

C.2. ^ ia HRT

[hours] 0.0 10.5 17.51 22.5, 24.5 41.5 45.0 57.5: 70.5' 139.5

TA [mg-N/L]!

23.4, 28.21 31.6 36.1 35.6i 54.3 56.7 95.2

499.4 385.2

-361.7

ture Feed Tank #2 Data pH

6.4 6.7 6.7 6.8 6.9 7.4 7.4 8.0 8.5 9.0

2.5

COD [mg-

COD/L] 556.0 840.0

892.0

1012.0 900.0 808.0 620.0

-64.0

Temp

[Cl 22.9 23.8 22,.A 24.0 24.1 23.1 23.5 23.7 23.3 23.8

0.9

NOx [mg-N/L] 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

0.0

TDS [mg-

TDS/L]

1114.0 1163.0 1169.0

1 1324.0 1 1352.0

1483.0 1621.0 2713.0

1599.0 GAS

TRAP

[mg^N/LJ

0.7 0.7 0.8

1.0

1.1 0.8

0.4

DO [mg-

DO/L] 5.4

1 2.4 2.1 1.9 1.7 1.5 1.4 1.5 1.2 1.2

4.2 UREA (JSC)

[mg-N/L] 220.2 218.7 202.7 207.6 203.1 150.2 117.0 134.1

-220.2

OrgN [mg-N/L] 375.6 383.3 375.3 397.5 352.6 379.3 370.5 383.7 376.6 403.1

-27.5 %

NH3

[%] 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.3

TOC

[mg-TOC/L] 339.2 390.2 359.7 378.3 367.4 363.2 353.6 342.6 318.1 167.8

171.4 NH3

(dissolved)

[mg-N/L[ 0.0 0.1 0.1 0.1 0.1 0.7 0.9 5,4

74,0 128,6

TN

[mg-N/L 375.6 383.3 375.3 397.5 352.6 379.3 370.5 383.7 376.6 403.1

-27.5 NH4

(dissolved

[mg-N/L] 23,4 28,1 31.6 36.0 35.4 53,7 55.9 89.8

425,5 256.6

137

Page 152: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table C.3. Ma Sample

No. 300 301 302 303 304 305 306 307 308 309 Total

Change

Sample

No. 300 301 302 303 304 305 306 307 308 309 Total

Change

HRT

[hours] 0.0 10.5 17.5 22.5 24.5 41.5 45.0 57.5 70.5 139.5

TA [mg-N/L] 15.3 39.2 89.1 147.7 204.1 251.8 262.8 296.5 303.5 386.9

-371.6

ure Feed Tank #3 Dat pH

6.5 7.3 8.4 8.7 8.7 8.9 8.8 9.0 8.9 8.8

2.3

COD [mg-

COD/L] 496.0 1140.0

952.0

820.0 770.0 800.0 766.0 700.0

-204.0

Temp

[C] 22.5 23.8 23.4 24.1 24.3 23.2 23.6 23.8 23.3 24.0

1.5

NOx [mg-N/L] 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

0.0

I

TDS [mg-

tDS/L[

1 (

•••

15^1.0 M29.0 l8l5.0 2209.0 2183.0 i236l.O ^50.0 2862.0

\1271.0 iGlAS TRAP

[mg-N/L]

1.1 1.0 1.1

1.2

1.2 0.8

0.1

DO [mg-

DO/L] 5.3 2.7 1.6 1.4 1.3 1.3 1.0 1.0 1.8 0.7

4.7 UREA (JSQ

[mg-N/L| 202.7 184.2 133.9 96.4

2.5 20.8 19.1

-202.7

OrgN [mg-N/L] 391.1 411.4 385.6 390.1 379.6 393.3 383.7 378.1 368.1 399.6

-8.5 %

NHS

[%1 0.0 0.0 0.1 0.2 0.2 0.3 0.3 0.4 0.3 0.3

TOC

[mg-TOC/L] 318.1 389.5 347.3 327.2 321.0 277.0 276.0 255.4 246.4 168.8

149.3 NH3

(dissolved)

[mg-N/L] 0.0 0.5 10.8 31.3 41.7 72.9 73.6 113.1 92.2 103.1

TN

[mg-N/L] 391.1 411.4 385.6 390.1 379.6 393.3 383,7 378,1 368,1 399.6

-8.5 NH4

(dissolved

[mg-N/L] 15.3 38.7 78.3 116.4 162.3 178.9 189.2 183.4 211,3 283.8

138

Page 153: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table C.4. Clean Feed Tank #1 Dal Sample

No. 400 401 402 403 404 405 406 407 408 409 Total

Change

Sample

No. 400 401 402 403 404 405 406 407 408 409 Total

Change

HRT

[hours[ 0.0 10.5 17.5 22.5 24.5 41.5 45.0 57.5 70.5 139.5

TA [mg-N/L] 25.1 25.0 26.4 28.5 25.6 49.7 41.9 60.6 57.6 173.0

-147.9

pH

6.0 6.2 6.0 5.9 6.0 6.7 6.2 6.9 6.5 7.6

1.6

COD [mg-

COD/L] 584.0 1060.0

1074.0

896.0 800.0 846.0 640.0

-56.0

Temp

[C[ 21.5 23.7 23.3 24.0 24.3 23.4 23.5 23.6 22.3 23.9

2.4

NOx [mg-N/L] 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

0.0

^

1

ll ii '

j

1 1 '''

1

i

TDS [n^g-

TDS/L]

1379.0 1402.0 1387.0 1922.0 1514.0 1686.0 1613.0 2156.0

777.0 GAS

TRAP

mg-N/L]

1.2 0.9 0.6

0.9

1.0 0.8

-03

DO [mg-

DO/L] 5.4 4.6

1 3.6 2.1

i 1.8 1.8 1.5 1.4 1.2 1.1

43 UREA (JSC)

[mg-N/L[ 232.8 235.5 231.1 232.3

230.1 159.1 280.3 112.2

-232.8

OrgN [mg-N/Ll 393.5 397.4 387.1 398.7 399.4 405.2 391.0 415.4 385.9 417.6

-24.1 %

NH3

[%] 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

TOC

[mg-TOC/L[ 347.7 409.7 400.1 408.9 408.5 389.2 395.3 401.2 386.5 277.0

70.7 NH3

(dissolved)

[mg-N/L[ 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3 0.1 4.0

TN

[mg-N/Ll 393.5 397.4 387.1 398.7 399.4 405,2 391,0 415.4 385.9 417.6

-241 NH4

(dissolved

[mg-N/Ll 25,0 24.9 26.3 28.5 25.6 49.6 41.8 60.3 57.5 169.0

139

Page 154: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table C.5. Cle Sample

No. 500 501 502 503 504 505 506 507 508 509

Total Change

Sample

No. 500 501 502 503 504 505 506 507 508 509

Total Change

HRT

[hours] 0.0 10.5 17.5 22.5 24.5 41.5 45.0 57.5 70.5 139.5

TA [mg-N/L] 24.3 26.9 25.0 24.4 25.0 36.7 34.9 45.1 24.1 149.1

-124.8

an Feed Tank #2 Dati pH

6.3 6.5 6.3 6.3 6.3 6.7 6.7 7.0 7.1 8.2

2.0

COD [mg-

COD/L] 566.0 880.0

984.0

760.0 766.0 720.0 684.0 580.0

-14.0

Temp

[Cl 21.3 22.6 23.3 24.0 24.1 23.4 23.3 23.4 22.8 24.0

2.7

NOx [mg-N/L] 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

0.0

1

1 TDS i [mg-TDS/L]

1 1

1 1454.0 1083.0 1067.0

1 1170.0 ' I 1166.0 : 1232.0 ^1237.0 i 1727.0

273.0 GAS

TRAP

[mg-N/L]

1.0

i 1.2 1.3

1 1.3

i 1.1 ' 0.8

0.1

\

'

DO 1 [mg-1 DO/L]

5.5 4.0 2.9 1.5

I 1.0 0.8 0.8 0.5 0.4 0.6

4.9 UREA (JSC)

[mg-N/L[ 233.4 232.9 321.3 229.3 226.1 184.7 158.8 213.9 190.1 108.4

-125.0

OrgN [mg-N/L] 396.6 388.1 392.5 382.6 393.9 373.9 398.5 392.4 384.0 388.2

8.4 %

NH3

f%] 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0,0 0,1

TOC

[mg-TOC/L] 327.0 390.0 380.2 390.8 384.1 354.2 364.4 363.9 337.5 204.6

122.4 NH3

(dissolved)

[mg-N/L] 0.0 0.0 0.0 0.0 0.0 0.1 0,1 0,2 0,2 13,3

TN

[mg-N/L 396.6 388,1 392,5 382.6 393.9 373.9 398.5 392.4 384.0 388.2

8.4 NH4

(dissolvec

[mg-N/L 24,3 26,8 24,9 24,4 24,9 36.6 34.8 44,8 23,9 135.8

140

Page 155: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table Sample

No. 600 601 602 603 604 605 606 607 608 609 Total

Change

Sample

No. 600 601 602 603 604 605 606 607 608 609 Total

Change

C.6. Cle HRT

[hours[ 0.0 10.5 17.5 22.5 24.5 41.5 45.0 57.5 70.5 139.5

TA [mg-N/L[ 25.0 147.2 36.1 30.1 27.1 37.7 40.4 60.8 66.8 174.5

-149.5

an Feed Tank #3 Data pH

6.3 6.4 7.3 6.4 6.3 6.8 6.9 7.2 7.4 8.6

2.3

COD [mg-

COD/L[ 624.0 1000.0

1008.0

1140.0 886.0 800.0 772.0 660.0

-36.0

Temp

1 [Cl _

21.1 23.7 23.4 22.7 24.0 23.4 23.3 23.5 23.0 24.1

3.0

NOx [mg-N/L] 0.0 0.0 0.0 0.0 0.0 1 0.0 ^ 0.0 0.0 0.0 0.0

0.0

1 WDS

l:i^s?Li n, ri ;

Ilil05.0 ,1182.0 : 1369.0 1213.0 1210.0 ii328.0 J300.0 1847.0

742.0 GAS

TRAP

[jng-N/L]

1.0 0.9 1,0

1

I 1.0 ^ 1 1

1.0 0:9

0.1

1

• 1

1

1

DO [mg-

DO/L] 5.3 4.3 3.0 1.5 1.5 1.2 1.0 0.9 0.9 0.8

45 UREA (JSQ

[mg-N/L[ 228.2 231.2 229.1 229.5 221.4 157.9 163.0 211.7 205.8 83.6

-144.6

OrgN [mg-N/L[ 375.6 383.7 381.4 375.6 311.1 401.9 403.7 406.1 382.0 401.9

-263 %

NH3

f%] 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2

TOC

[mg-TOC/LI 334.5 408,1 389,3 394.5 391.8 378.8 372.8 369.0 352.4 228.9

105.6 NH3

(dissolved)

[mg-N/L] 0,0 0.2 0,4 0.0 0.0 0.1 0.2 0.6 1.0

33.1

TN

[mg-N/L 375.6 383,7 381,4 375,6 377.7 401,9 403,7 406,1 382.0 401,9

-263 NH4

(dissolvec

[mg-N/L 25.0 146.9 35,7 30.0 27,0 37.6 40,3 60,3 65,8 141.4

141

Page 156: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

^ENDIK

^ M DMA

D

142

Page 157: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table D.]

, !'! 1 • 1

' ' • '•••' ' I I

I. A M R ReactorliiEi^3<;riptioi!i Length of Ftea^fU Length of l^eaititblr

1

1 1

Diameter of Redctpt Diameter of Reacf or

Total Reactor Volilimp :, , ' !

(Tube/Reactor) l^engtli Ratio

Length of Single Hollo^ Length of Single HoUbW

Fiber fiber

Number of Hoilow Fibers Total Length of Hollov\^ |= Total Length of Hollow F

•'. • • \ ' \ \

Membrane Thickn^s Hollow Fiber DiameteH

Single Hollow Fiber ^ Total Hollow Fiber Ar

Single Hollow Fibei* Vp Total Hollow Fiber Vo(

Table D.2. AMR|Iftiii( (T/R) Lengtii H

,0.0i vli 1.6 ill 2.0 i 2.5 3.0 3.5 3.6 i; 3.7 : 3.8 3,^ 4,0 4.1 4.2 4.3 4.4 4,5 4,6 4,7 4,8 4.9 5.0

' bers 'bers

!S

(OD) rea ea ume Lime

;isity Dk jitio

21.5 54.7 3.9 10

4293.95

2.3

49.53149606 125.81

150 7429,724409 619.1437008

0.09 0.17

0.0226865 3.402975

2,854188565 428.1282848

sign

1

Porosity 1,000 0,957 0.913

inches cm

inches cm

cm*3

inches cm

inches feet

cm cm

cm*2 cm'^2 cm*3 cm*3

0.892 0.870 0.848 0.844 0,840 0,835 0,831 0.827 0.822 0.818 0.813 0.809 0,805 0,800 0,796 0,792 0,787 0,783

143

Page 158: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table D.3. AMR Volumes

AMR Total Volume

[mL]

AMR Length

[cm] 4293.95

Table D.4. AMR Reynold's Numbers Recycle R&tio 20

(RR20)

AMR Diameter

[m]

AMR Flow

[mL/min]

AhflR Vel c iy

Density l a t p c

Viscosity at20C

[N*s/m^2]

AMR Rey. No.

[-1 0.1 21 3.50ETI 0.001002 0,034867265

Page 159: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table D.5. AMR Reynold's Numbep Recycle Ratio 10

AMR Diameter

[ml

AMR Flow

[mL/min] 0.1 11 1.83 B07'

Table D.6. PB Reynold's Numbers Recycle Ratio 20 '

PB Diameter

[m]

PB Flow

[mL/min] 8.5 21

Table D.7. PB Reynold's Numbers Recycle Ratio 10

6m [mm

Density at^OC

tkg/m*3] 998.2

Viscosity at20C

[N*s/m*2]

0.001002

AMR Rey. No.

[-] 0.018263806

00000035 998.2

Density at20C

[kg/m^3]

Viscosity at20C

[N*s/m^2]

PB Rey. No.

t] 0.001002 2,963717565

m.\o) PB

Diameter [m]

PB Flow

[mL/min]

Density at 20 C

[kg/m*3]

Viscosity at20C

[N*s/m^2]

PB Rey. No.

__t] 1.82

8.5 11

Table D.8. PB-AMR

System

TR TR

AMR AMR

Recycle Ratio

20

10 20

10

17

998.2

TU-WRS HRT

571

0.001002 1.552423486

HRT

[hours] 2.880952 2.880952

64.41667 64.41667

[mL/min] 0.7 0.7

[mL] 121 121

3865 3865

145

Page 160: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

Table D.9. AMR ESM

Membrane mass

[mg] 693.0

membrane length

[in] 8.0

Vessel length Vessel thickness [cm] 54.7

membrane lengtii

[cm] 20.3

[cm] 0.6

Pressure Tap mass

[msl 172.0

Total ring mass

JsL 298.2

No. of taps

J± 150.0

Total plate mass

[g1 5108.4

Total membrane m^s!

Membriane m£ss/le

639,5

Table D. TR mass

[mg] 4321.0

0. TRESM TR length

[in] 8.0

TR empty mass

[gl 648.2

TR length

[cm] 20.3

TR water mass

[gJ 56.0

njisg/lt!

Icffi 51 !0.

mg/c 34.1

Totsil tap mass

tiigA:m

W

volume Vessel mass

25.8

ngth

1?,6

air mass

Total membrane length

JcmJ 18750.0

[mg] 2039079.3

Tc( al tap lass

Total membrane mass

JgL 639.5

Rubber mat mass

isL 319.1

AMR water mass

isL 3866.0

otal TR length

cm 3048.0

TR empty mass [g]

648.2 TR m-f controllers

(2) [Rl

1813.0

TR traps (5)

[gl 310.0

146

Page 161: MEMBRANE-AERATED BIOREACTORS FOR TREATMENT A …

PERMISSION TO COPY

In presenting this thesis in partial fiilfilhnent of the requirements for a master's

degree at Texas Tech University or Texas Tech University Healdi Sciences Center, I

agree that the Library and my major department shall make it freely available for

research purposes. Permission to copy this thesis for scholarly purposes may be

granted by the Director of the Library or my major professor. It is understood that any

copying or publication of this thesis for financial gam shall not be allowed without my

further written permission and that any user may be liable for copyright infringement.

Agree (Permission is granted.)

Student Signamre Date